

**(12) STANDARD PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. **AU 2018282127 B2**

(54) Title  
**Therapeutic apoptotic cells for cancer therapy**

(51) International Patent Classification(s)  
**A61K 35/15** (2015.01) **A61P 35/00** (2006.01)  
**A61K 35/17** (2015.01) **C12N 5/078** (2010.01)

(21) Application No: **2018282127** (22) Date of Filing: **2018.06.07**

(87) WIPO No: **WO18/225072**

(30) Priority Data

(31) Number	(32) Date	(33) Country
<b>62/549,465</b>	<b>2017.08.24</b>	<b>US</b>
<b>62/516,714</b>	<b>2017.06.08</b>	<b>US</b>

(43) Publication Date: **2018.12.13**

(44) Accepted Journal Date: **2023.11.16**

(71) Applicant(s)  
**Enlivex Therapeutics RDO Ltd**

(72) Inventor(s)  
**Novik, Shai;Mevorach, Dror**

(74) Agent / Attorney  
**Griffith Hack, Level 10 161 Collins St, MELBOURNE, VIC, 3000, AU**

(56) Related Art  
**WO 2016/170541 A1**  
**WO 2017/141243 A1**  
**WO 2016/132366 A1**  
**WO 2014/087408 A1**



(51) International Patent Classification:

A61K 35/15 (2015.01) C12N 5/078 (2006.01)

A61K 35/17 (2015.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IL2018/050621

(22) International Filing Date:

07 June 2018 (07.06.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/516,714 08 June 2017 (08.06.2017) US

62/549,465 24 August 2017 (24.08.2017) US

(71) Applicant: ENLIVEX THERAPEUTICS LTD. [IL/IL];

POB 12167, Hadassah Ein Kerem, 91120 Jerusalem (IL).

(72) Inventors: NOVIK, Shai; 30 Anni Maamin Street,

4721249 Ramat Hasharon (IL). MEVORACH, Dror; 7

Ma'agal Hanikba, Ein-Karem, 9574630 Jerusalem (IL).

(74) Agent: COHEN, Mark S. et al.; Pearl Cohen Zedek Latzer

Baratz, P.O. Box 7198, 6107121 Tel Aviv (IL).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: THERAPEUTIC APOPTOTIC CELLS FOR CANCER THERAPY

(57) Abstract: Methods of use of early apoptotic cell populations and compositions thereof disclosed herein, including methods of treating a cancer or a tumor, extending survival times of a subject suffering from a cancer or a tumor, and reducing the size or reducing the growth rate of a cancer or a tumor, wherein subjects are administered apoptotic cells or compositions thereof. Cancers may include solid tumors or diffuse cancers, for example leukemia. In certain instances compositions may include additional chemotherapeutic agent. Further, inactivated early apoptotic cell populations are disclosed and methods of making the same.



WO 2018/225072 A1

## THERAPEUTIC APOPTOTIC CELLS FOR CANCER THERAPY

### CROSS-REFERENCE TO RELATED APPLICATIONS

[001] This Application claims benefit of U.S. Provisional Application No. 62/516,714, filed June 8, 2017 and U.S. Provisional Application No. 62/549,465, filed August 24, 2016, which are incorporated by reference herein in their entirety.

### FIELD OF INTEREST

[002] Disclosed herein are compositions comprising early apoptotic cell populations and methods thereof for cancer therapy. Compositions disclosed herein may be used for treating, preventing, inhibiting the growth of, or reducing the incidence of, a cancer or a tumor in a subject. Further, composition may be used for increasing survival of a subject suffering from a cancer or a tumor. Compositions used may be administered alone or in combination with other chemotherapies.

### BACKGROUND

[003] Cancer is an abnormal state in which uncontrolled proliferation of one or more cell populations interferes with normal biological functioning. The proliferative changes are usually accompanied by other changes in cellular properties, including reversion to a less differentiated, more developmentally primitive state. The *in vitro* correlate of cancer is called cellular transformation. Transformed cells generally display several or all of the following properties: spherical morphology, expression of fetal antigens, growth-factor independence, lack of contact inhibition, anchorage-independence, and growth to high density.

[004] The primary cause of lethality of malignant diseases such as lung and skin cancer arises from metastatic spread. In many cases, it is not possible to prevent the onset of metastatic disease since cancers are often metastatic by the time of diagnosis, and even in cases where cancers are diagnosed prior to this stage, complete surgical removal or destruction of primary lesion tissues which are capable of eventually generating metastases may not be feasible. Metastatic disease may be impossible to diagnose at early stages due to the small size of metastatic lesions, and/or the absence of reliable markers in primary lesions upon which to reliably predict their existence. Such lesions may be difficult or impossible to treat via ablative methods due to their being inaccessible, disseminated, and/or poorly localized. Chemotherapy/radiotherapy, the current methods of choice for treatment of certain metastatic malignancies are often ineffective or suboptimally effective, and have the significant disadvantage of being associated with particularly harmful and/or potentially lethal

side-effects.

[005] Immunotherapeutic cancer treatment methods, such as those involving antigen presenting cell (APC) vaccinations, have the potential to be optimally effective for treatment of inaccessible, disseminated, microscopic, recurrent and/or poorly localized cancer lesions. One promising immunotherapy avenue involves the use of professional APCs, such as dendritic cells (DCs), to elicit systemic anti-cancer immunity.

[006] Dendritic cells are antigen-producing and presenting cells of the mammalian immune system that process antigen material and present it on the cell surface to the T-cells of the immune system and are thereby capable of sensitizing T-cells to both new and recall antigens. DCs are the most potent antigen-producing cells, acting as messengers between the innate and the adaptive immune systems. DC cells may be used, to prime specific antitumor immunity through the generation of effector cells that attack and lyse tumors.

[007] Apoptotic cells present one pathway of physiological cell death, most commonly occurring via apoptosis, which elicits a series of molecular homeostatic mechanisms comprising recognition, an immune response and a removal processes. Moreover, apoptotic cells are immunomodulatory cells capable of directly and indirectly inducing immune tolerance to dendritic cells and macrophages. Apoptotic cells have been shown to modulate dendritic cells and macrophages and to render them tolerogenic and inhibit proinflammatory activities such as secretion of proinflammatory cytokines and expression of costimulatory molecules.

[008] There remains an unmet need for compositions and methods for treating, preventing, inhibiting the growth of, or reducing the incidence of, a cancer or a tumor in a subject. Advantageously, the apoptotic cell preparations, compositions and uses thereof, described herein below, may address this need by providing a population of early apoptotic cells that may be used to treat, prevent, inhibit the growth or, or reduce the incidence of a cancer or tumor in a subject. Further, the methods of use described herein may address the need to increasing survival of a subject suffering from a cancer and tumor, including increasing remission of the cancer or tumor.

## SUMMARY

[009] In one aspect disclosed herein is a method of treating, preventing, inhibiting the growth of, delaying disease progression, reducing the tumor load, or reducing the incidence of a cancer or a tumor in a subject, or any combination thereof, comprising a step of administering a composition comprising an early apoptotic cell population to said subject, wherein said method treats, prevents, inhibits the growth of, delays the disease progression, reduces the tumor load, or reduces the

incidence of the cancer or a tumor in said subject, or any combination thereof, compared with a subject not administered the early apoptotic cell population.

[009a] In one aspect, there is provided a method of treating, preventing, inhibiting the growth of, delaying disease progression, reducing the tumor load of a solid tumor, or reducing the incidence of a solid cancer or a solid tumor in a subject, or any combination thereof, consisting essentially of a step of administering a composition comprising an early apoptotic mononuclear enriched cell population to said subject, wherein said method treats, prevents, inhibits the growth of, delays the disease progression, reduces the tumor load of a solid tumor, or reduces the incidence of the solid cancer or solid tumor in said subject, or reduces the minimal residual disease, increases remission, increases remission duration, reduces tumor relapse rate, prevents metastasis of said solid tumor or said solid cancer, or reduces the rate of metastasis of said solid tumor or said solid cancer, or any combination thereof, compared with a subject not administered the early apoptotic cell population.

[009b] In another aspect, there is provided use of a composition consisting essentially of an early apoptotic mononuclear enriched cell population in the manufacture of a medicament for treating, preventing, inhibiting the growth of, delaying disease progression, reducing the tumor load, or reducing the incidence of a solid cancer or a solid tumor in a subject, or any combination thereof, wherein administering said medicament treats, prevents, inhibits the growth of, delays the disease progression, reduces the tumor load, or reduces the incidence of the solid cancer or solid tumor in said subject, or reduces the minimal residual disease, increases remission, increases remission duration, reduces tumor relapse rate, prevents metastasis of said solid tumor or said solid cancer, or reduces the rate of metastasis of said solid tumor or said solid cancer, or any combination thereof, compared with a subject not administered with said medicament.

[0010] In a related aspect, the size or the growth rate, or a combination thereof, of said cancer or tumor is reduced. In another related aspect, the survival of said subject is increased.

[0011] In a related aspect, the early apoptotic cell population comprises a mononuclear enriched cell population, or an apoptotic population stable for greater than 24 hours, or an apoptotic population devoid of cell aggregates, or an apoptotic population irradiated following apoptotic induction, or any combination thereof. In another related aspect, the early apoptotic cell population comprises a pooled population of early apoptotic cells.

[0012] In a related aspect, the subject is a human subject.

[0013] In a related aspect, the cancer or tumor comprises a solid tumor or non-solid tumor. In another related aspect, the non-solid cancer or tumor comprises a hematopoietic malignancy, a blood cell cancer, a leukemia, a myelodysplastic syndrome, a lymphoma, a multiple myeloma (a plasma cell

myeloma), an acute lymphoblastic leukemia, an acute myelogenous leukemia, a chronic myelogenous leukemia, a Hodgkin lymphoma, a non-Hodgkin lymphoma, or plasma cell leukemia. In another related aspect, the solid tumor comprises a sarcoma or a carcinoma, a fibrosarcoma, a myxosarcoma, a liposarcoma, a chondrosarcoma, an osteogenic sarcoma, a chordoma, an angiosarcoma, an endotheliosarcoma, a lymphangiosarcoma, a lymphangioendotheliosarcoma, a synovium, a mesothelioma, an Ewing's tumor, a leiomyosarcoma, a rhabdomyosarcoma, a colon carcinoma, a pancreatic cancer or tumor, a breast cancer or tumor, an ovarian cancer or tumor, a prostate cancer or tumor, a squamous cell carcinoma, a basal cell carcinoma, an adenocarcinoma, a sweat gland carcinoma, a sebaceous gland carcinoma, a papillary carcinoma, a papillary adenocarcinomas, a cystadenocarcinoma, a medullary carcinoma, a bronchogenic carcinoma, a renal cell carcinoma, a hepatoma, a bile duct carcinoma, a choriocarcinoma, a seminoma, an embryonal carcinoma, a Wilm's tumor, a cervical cancer or tumor, a uterine cancer or tumor, a testicular cancer or tumor, a lung carcinoma, a small cell lung carcinoma, a bladder carcinoma, an epithelial carcinoma, a glioma, an astrocytoma, a medulloblastoma, a craniopharyngioma, an ependymoma, a pinealoma, a hemangioblastoma, an acoustic neuroma, an oligodendroglioma, a schwannoma, a meningioma, a melanoma, a neuroblastoma, or a retinoblastoma. In another related aspect, the tumor or cancer comprises a metastasis of a tumor or cancer.

[0014] In a related aspect, the administering comprises a single infusion of said early apoptotic cell population. In another related aspect, the administering comprises multiple infusions of said apoptotic cell population. In another related aspect, the method further comprises administering an additional

immune therapy, a chemotherapeutic agent, or an immune modulator to said subject, or any combination thereof. In another related aspect, the additional immune therapy, a chemotherapeutic agent, or an immune modulator is administered prior to, concurrent with, or following administration of said early apoptotic cells. In another related aspect, the immune therapy comprises administration of CAR T-cells. In another related aspect, the immune modulator comprises an antibody or a functional fragment thereof. In another related aspect, the antibody or functional fragment thereof comprises a rituximab (RtX) antibody or functional fragment thereof.

[0015] In a related aspect, the method increases the efficacy of said CAR T-cells, compared with a subject administered CAR T-cells and not administered early apoptotic cells

[0016] In a related aspect, the method comprises a first-line therapy.

[0017] In a related aspect, the method comprises an adjuvant therapy.

[0018] In a related aspect, the method reduces the minimal residual disease, increases remission, increases remission duration, reduces tumor relapse rate, prevents metastasis of said tumor or said cancer, or reduces the rate of metastasis of said tumor or said cancer, or any combination thereof.

[0019] In one aspect, disclosed herein is a population of mononuclear apoptotic cell comprising mononuclear cells in an early-apoptotic state, wherein said mononuclear apoptotic cell population comprises: a decreased percent of non-quiescent non-apoptotic viable cells; a suppressed cellular activation of any living non-apoptotic cells; or a reduced proliferation of any living non-apoptotic cells; or any combination thereof.

[0020] In a related aspect, the decreased percent of non-quiescent non-apoptotic viable cells is less than 10%. In another related aspect, the mononuclear apoptotic cell population comprises no viable non-apoptotic cells.

[0021] In a related aspect, the mononuclear cell population is selected from the group consisting of: lymphocytes, monocytes, dendritic cells, and natural killer cells.

[0022] In a related aspect, the population of mononuclear apoptotic cells is irradiated after production of early apoptotic cells. In another related aspect, irradiation comprises gamma irradiation, X-ray irradiation, or UV irradiation. In another related aspect, the irradiated cell population comprises a decreased percent of non-quiescent non-apoptotic cells per population compared with a non-irradiated apoptotic cell population.

[0023] In one aspect, disclosed herein is a pharmaceutical composition, comprising a population of mononuclear apoptotic cell comprising mononuclear cells in an early-apoptotic state, wherein said mononuclear apoptotic cell population comprises: a decreased percent of non-quiescent non-apoptotic viable cells; a suppressed cellular activation of any living non-apoptotic cells; or a reduced

proliferation of any living non-apoptotic cells; or any combination thereof. and a pharmaceutically acceptable excipient.

[0024] In one aspect, disclosed herein is a method for producing a population of mononuclear apoptotic cell comprising a decreased percent of non-quiescent non-apoptotic viable cells; a suppressed cellular activation of any living non-apoptotic cells; or a reduced proliferation of any living non-apoptotic cells; or any combination thereof, said method comprising the following steps,

obtaining a mononuclear-enriched cell population of peripheral blood;

freezing said mononuclear-enriched cell population in a freezing medium comprising an anticoagulant;

thawing said mononuclear-enriched cell population;

incubating said mononuclear-enriched cell population in an apoptosis inducing incubation medium comprising methylprednisolone at a final concentration of about 10-100 µg/mL and an anticoagulant;

resuspending said apoptotic cell population in an administration medium; and

inactivating said mononuclear-enriched population, wherein said inactivation occurs following induction,

wherein said method produces a population of mononuclear apoptotic cell comprising a decreased percent of non-quiescent non-apoptotic cells; a suppressed cellular activation of any living non-apoptotic cells; or a reduced proliferation of any living non-apoptotic cells; or any combination thereof.

[0025] In a related aspect, the inactivating step comprises decreasing the percent of non-quiescent non-apoptotic cells, suppressing cellular activation of any living non-apoptotic cells, or reducing the proliferation of any living non-apoptotic cells, or any combination thereof within said mononuclear apoptotic cell preparation. In another related aspect, the percent of non-quiescent non-apoptotic cells is decreased to about 10%. In another related aspect, the percent of non-quiescent non-apoptotic cells is decreased to about 0%.

[0026] In a related aspect, mononuclear-enriched cell population is selected from the group consisting of lymphocytes, monocytes, dendritic cells, and natural killer cells.

[0027] In a related aspect, the incubating is for about 2-12 hours.

[0028] In a related aspect, the step (f) inactivating of said mononuclear-enriched population comprises suppressing or eliminating an immune response, suppressing or eliminating cross-reactivity of cells, or reducing or eliminating T-cell receptor activity, and wherein said population comprises a decreased the percent of living non-apoptotic cells, a suppress cellular activation of any



living non-apoptotic cells, or a reduced proliferation of any living non-apoptotic cells, or any combination thereof. In another related aspect, the said ep (f) inactivating comprises irradiating a mononuclear-enriched apoptotic cell population produced in step (e). In another related aspect, the irradiation comprises gamma irradiation, X-ray irradiation, or UV irradiation. In another related aspect, the irradiation comprises about 10-80 Grey units (Gy). In another related aspect, the irradiation comprises about 25-50 Grey units (Gy).

### BRIEF DESCRIPTION OF THE DRAWINGS

[0029] The subject matter disclosed herein is particularly pointed out and distinctly claimed in the concluding portion of the specification. The compositions and methods disclosed herein, however, both as to organization and method of operation, together with objects, features, and advantages thereof, may best be understood by reference to the following detailed description when read with the accompanying drawings.

[0030] **Figure 1.** Flow chart presenting the steps during one embodiment of a manufacturing process of an early apoptotic cell populations, wherein anti-coagulants were included in the process.

[0031] **Figure 2.** Survival curves for *in vivo* diffuse tumor SCID mouse model. The curves show that administration of early apoptotic cells (APO; broad dashed lines ----) extended survival compared with mice not administered apoptotic cells (NO APO; dotted line ····), wherein control SCID mice showed 100% survival (solid line \_\_\_\_\_).

[0032] **Figures 3A-3D.** Apoptotic cell infusions increased the lifespan of leukemic mice and increased the number of mice attaining complete remission. Cohorts: No leukemia (Control-striped pattern); Leukemia + early apoptotic cells (spotted); Leukemia only (solid grey). n=51 in total (p<0.001) **Figure 3A.** Apoptotic cell infusions increased the percentage of mice surviving through the expected life-span post leukemia induction. **Figure 3B.** Apoptotic cell infusions increased the percentage of mice surviving up to 12% of the expected life-span post leukemia induction. **Figure 3C.** Apoptotic cell infusions increased the percentage of mice surviving up to 30% of the expected life-span post leukemia induction. **Figure 3D.** Apoptotic cell infusions increased the percentage of mice surviving up to 100% of the expected life-span post leukemia induction and attaining complete remission.

[0033] **Figures 4A-4E.** Apoptotic cell infusions increased the life-span of leukemic mice, increased the number of mice attaining complete remission, and enhanced the anti-CD20 monoclonal antibody (mAb) therapeutic effect. Cohorts: Leukemia only (solid grey); Leukemia + early apoptotic cells (striped pattern); Leukemia + anti-CD20 mAb (checkered); Leukemia + anti-CD20 + early apoptotic

cells (spotted). n=28 in total (p<0.002) **Figure 4A**. Shows the percent (%) survival through the expected lifespan of mice following induction of leukemia with Raji cells. **Figure 4B**. Apoptotic cell infusions increased the percentage of mice surviving up to 24% longer than the expected life-span post leukemia induction. **Figure 4C**. Apoptotic cell infusions increased the percentage of mice surviving up to 59% longer than the expected life-span post leukemia induction and enhanced the anti-CD20 mAb effect on the life-span of leukemic mice. **Figure 4D**. Apoptotic cell infusions increased the percentage of mice surviving up to 76% longer than the expected life-span post leukemia induction and enhanced the anti-CD20 mAb effect on the life-span of leukemic mice. **Figure 4E**. Apoptotic cell infusions increased the percentage of mice attaining complete remission.

[0034] **Figures 5A and 5B. Testing the efficacy of CD19-CAR-T cells in an IP model of HeLaCD19 (Leukemia), in the presence or absence of ApoCell.** HeLa-CD19 - Blue; HeLaCD19+Mock - Green; HeLaCD19 + CAR-T - Purple; and HeLaCD19 + CAR-T + ApoCell - orange. **Figure 5A** was with  $0.5 \times 10^6$  CAR-T positive cells. **Figure 5B** was with  $2.2 \times 10^6$  CAR-T positive cells.

[0035] **Figure 6. Kaplan-Meier survival plot of SCID-Bg mice with Raji leukemia/lymphoma, receiving ApoCell.** (RPMI group, n = 15; Raji group, n = 23; Raji + ApoCell group, n = 24) RPMI (control) - Black; Raji only - Orange; Raji + ApoCell - Blue.

[0036] **Figures 7A-7C. Kaplan-Meier survival plots.** **Figure 7A** presents data from a study wherein female SCID-Bg mice, 7-weeks-old (ENVIGO, Jerusalem, Israel), were injected IV with  $0.1 \times 10^6$  Raji cells per mouse (n = 10 per group, three groups). Mice received three IV doses (days 5, 8, 11) of  $30 \times 10^6$  ApoCell. (RPMI-light blue; Raji-orange; and Raji + ApoCell - dark blue) **Figure 7B** presents data from a study wherein female SCID-Bg mice, 7-weeks-old (ENVIGO, Jerusalem, Israel), were injected IV with  $0.1 \times 10^6$  Raji cells per mouse (n = 10 per group, three groups). Mice received three IV doses (days 5, 8, 11) of  $30 \times 10^6$  ApoCell. (RPMI-black; Raji-orange; and Raji + ApoCell - dark blue) **Figure 7C** presents data from a study wherein female SCID-Bg mice, 8-9-weeks-old (ENVIGO, Jerusalem, Israel), were injected IV with  $0.1 \times 10^6$  Raji cells per mouse (n=10 per group, 2 groups). Mice received three IV doses (days 5, 8, 12) of  $30 \times 10^6$  ApoCell. (Raji-orange; and Raji + ApoCell - dark blue)

[0037] **Figure 8. Kaplan-Meier survival plot of SCID-Bg mice with Raji leukemia/lymphoma, receiving RtX and ApoCell.** (Raji alone - orange; Raji + ApoCell - blue; Raji + RtX 2mg - green; Raji + RtX 2mg + ApoCell - yellow; Raji + RtX 5mg - purple; Raji + RtX 5mg + ApoCell - grey.)

[0038] **Figure 9. Kaplan-Meier survival plot of SCID-Bg mice with Raji leukemia/lymphoma, receiving rtx and ApoCell.** (Raji alone - orange; Raji + ApoCell - blue; Raji + RtX 2mg - green; Raji

+ RtX 2mg + ApoCell – yellow.)

[0039] **Figures 10A-10B.** Schematic showing standard CAR T-cell therapy (**Figure 10A**) and embodiments of a method of safe and efficacious CAR T-cell cancer therapy in a patient using patients' own cells (autologous) (**Figure 10B**) to produce apoptotic cells or an apoptotic cell supernatant.

[0040] **Figure 11.** Schematic showing embodiment of a method of safe and efficacious CAR T-cell cancer therapy in a patient, using donor cells to produce apoptotic cells or an apoptotic supernatant.

[0041] **Figures 12A-12B.** Survival following CAR T-cell therapy alone or with co-administration of apoptotic cells. **Figure 12A** is representative of 5 separate experiments, as described in Example 6 and shows survival curves of peritoneal solid tumor Hela-CD19, treated by CAR T-cell therapy alone or CAR T-cell therapy plus co-administration of apoptotic cells. (HeLa-CD19: control no treatment; HeLa-CD19+ CAR-T: includes treatment with CAR T-cells; HeLa-CD19+Mock-T: control addition of Mock T-cells; HeLa-CD19+CAR-T + OTS-ALC-4K: treatment was with CAR T-cells and "off the shelf" apoptotic cells irradiated with 4000rad). **Figure 12B** (Luciferase *in vivo* imaging system (IVIS) results) shows progression of tumor as visualized by IVIS representing the development leading to the survival curve results presented in **Figure 12A**. Spread of the tumor can already be visualized on day 15 (Hela-CD19-Luc; control no treatment) whereas mice treated with CAR T-cells did not show any tumor spread until day 43. When mice receive apoptotic cells in conjunction with CAR T-cell treatment, unexpectedly most mice did not show tumor spread until day 50 and tumor size (see scale for correlation) was clearly smaller.

### DETAILED DESCRIPTION

[0042] In the following detailed description, numerous specific details are set forth in order to provide a thorough understanding of the methods disclosed herein. However, it will be understood by those skilled in the art that these methods may be practiced without these specific details. In other instances, well-known methods, procedures, and components have not been described in detail so as not to obscure the methods disclosed herein.

[0043] In some embodiments, disclosed herein is a method of treating, preventing, inhibiting the growth of, reducing the incidence of, or any combination thereof, a cancer or a tumor in a subject, comprising a step of administering an early apoptotic cell population to said subject, wherein said method treats, prevents, inhibits the growth of, reduces the incidence of, or any combination thereof, a cancer or a tumor in said subject.

[0044] In some embodiments, disclosed herein is a method of increasing survival of a subject

suffering from a cancer or a tumor, comprising a step of administering an early apoptotic cell population to said subject, wherein said method increases survival of said subject.

[0045] In some embodiments, disclosed herein is a method of reducing the size or reducing the growth rate of a cancer or a tumor, or a combination thereof, in a subject, comprising a step of administering an early apoptotic cell population to said subject, wherein said method reduces the size or reduces the growth rate of said cancer or said tumor.

[0046] In some embodiments, compositions of early apoptotic cells comprising a population of mononuclear cells in an early-apoptotic state, wherein said mononuclear apoptotic cell population comprises: a decreased percent of non-quiescent non-apoptotic viable cells; a suppressed cellular activation of any living non-apoptotic cells; or a reduced proliferation of any living non-apoptotic cells; or any combination thereof. In some embodiments, disclosed herein are populations of inactivated early apoptotic cells comprising a population of mononuclear cells in an early-apoptotic state, wherein said mononuclear apoptotic cell population comprises: a decreased percent of non-quiescent non-apoptotic viable cells; a suppressed cellular activation of any living non-apoptotic cells; or a reduced proliferation of any living non-apoptotic cells; or any combination thereof.

[0047] In some embodiments, a cell population disclosed herein is inactivated. In another embodiment, inactivation comprises irradiation. In another embodiment, inactivation comprises suppressing or eliminating an immune response in the population. In another embodiment, inactivation comprises suppressing or eliminating cross-reactivity between an early apoptotic cell population and any other cell population. In other embodiment, inactivation comprises reducing or eliminating T-cell receptor activity in an early apoptotic cell population. In another embodiment, an inactivated cell preparation comprises a decreased percent of living non-apoptotic cells, suppressed cellular activation of any living non-apoptotic cells, or a reduce proliferation of any living non-apoptotic cells, or any combination thereof.

[0048] In another embodiment, an inactivated cell population comprises a reduced number of non-quiescent non-apoptotic cells compared with a non-radiated cell preparation. In some embodiments, an inactivated cell population comprises 50 percent (%) of living non-apoptotic cells. In some embodiments, an inactivated cell population comprises 40% of living non-apoptotic cells. In some embodiments, an inactivated cell population comprises 30% of living non-apoptotic cells. In some embodiments, an inactivated cell population comprises 20% of living non-apoptotic cells. In some embodiments, an inactivated cell population comprises 100% of living non-apoptotic cells. In some embodiments, an inactivated cell population comprises 0% of living non-apoptotic cells.

[0049] In some embodiments, disclosed herein is a method of preparing an inactivated early

apoptotic cell population. In some embodiments, disclosed herein is a method for producing a population of mononuclear apoptotic cell comprising a decreased percent of non-quiescent non-apoptotic viable cells; a suppressed cellular activation of any living non-apoptotic cells; or a reduced proliferation of any living non-apoptotic cells; or any combination thereof, said method comprising the following steps, obtaining a mononuclear-enriched cell population of peripheral blood; freezing said mononuclear-enriched cell population in a freezing medium comprising an anticoagulant; thawing said mononuclear-enriched cell population; incubating said mononuclear-enriched cell population in an apoptosis inducing incubation medium comprising methylprednisolone at a final concentration of about 10-100 µg/mL and an anticoagulant; resuspending said apoptotic cell population in an administration medium; and inactivating said mononuclear-enriched population, wherein said inactivation occurs following induction, wherein said method produces a population of mononuclear apoptotic cell comprising a decreased percent of non-quiescent non-apoptotic cells; a suppressed cellular activation of any living non-apoptotic cells; or a reduced proliferation of any living non-apoptotic cells; or any combination thereof.

[0050] In another embodiment, the irradiation comprises gamma irradiation, X-ray irradiation, or UV irradiation. In yet another embodiment, the irradiated preparation has a reduced number of non-quiescent non-apoptotic cells compared with a non-irradiated cell preparation.

[0051] *Apoptotic Cells and Methods of Production thereof*

[0052] In some embodiments, production of apoptotic cells ("ApoCells") for use in compositions and methods as disclosed herein, has been described in WO 2014/087408, which is incorporated by reference herein in its entirety, and is described in brief in Example 1 below. In another embodiment, apoptotic cells for use in compositions and methods as disclosed herein are produced in any way that is known in the art. In another embodiment, apoptotic cells for use in compositions and methods disclosed herein are autologous with a subject undergoing therapy. In another embodiment, apoptotic cells for use in compositions and methods disclosed herein are allogeneic with a subject undergoing therapy. In another embodiment, a composition comprising apoptotic cells comprises apoptotic cells as disclosed herein or as is known in art.

[0053] A skilled artisan would appreciate that the term "autologous" may encompass a tissue, cell, nucleic acid molecule or polypeptide in which the donor and recipient is the same person.

[0054] A skilled artisan would appreciate that the term "allogeneic" may encompass a tissue, cell, nucleic acid molecule or polypeptide that is derived from separate individuals of the same species. In some embodiments, allogeneic donor cells are genetically distinct from the recipient.

[0055] In some embodiments, obtaining a mononuclear-enriched cell composition according to the

production method disclosed herein is effected by leukapheresis. A skilled artisan would appreciate that the term “leukapheresis” may encompass an apheresis procedure in which leukocytes are separated from the blood of a donor. In some embodiments, the blood of a donor undergoes leukapheresis and thus a mononuclear-enriched cell composition is obtained according to the  
5 production method disclosed herein. It is to be noted, that the use of at least one anticoagulant during leukapheresis is required, as is known in the art, in order to prevent clotting of the collected cells.

[0056] In some embodiments, the leukapheresis procedure is configured to allow collection of mononuclear-enriched cell composition according to the production method disclosed herein. In some embodiments, cell collections obtained by leukapheresis comprise at least 65%. In other  
10 embodiments, at least 70%, or at least 80% mononuclear cells. as disclosed herein. In some embodiments, blood plasma from the cell-donor is collected in parallel to obtaining of the mononuclear-enriched cell composition In the production method disclosed herein. In some embodiments, about 300-600ml of blood plasma from the cell-donor are collected in parallel to obtaining the mononuclear-enriched cell composition according to the production method disclosed  
15 herein. In some embodiments, blood plasma collected in parallel to obtaining the mononuclear-enriched cell composition according to the production method disclosed herein is used as part of the freezing and/or incubation medium. Additional detailed methods of obtaining an enriched population of apoptotic cells for use in the compositions and methods as disclosed herein may be found in WO 2014/087408, which is incorporated herein by reference in its entirety.

[0057] In some embodiments, the early apoptotic cells for use in the methods disclosed herein comprise at least 85% mononuclear cells. In further embodiments, the early apoptotic cells for use in the methods disclosed herein contains at least 85% mononuclear cells, 90% mononuclear cells or alternatively over 90% mononuclear cells. In some embodiments, the early apoptotic cells for use in the methods disclosed herein comprise at least 90% mononuclear cells. In some embodiments, the  
25 early apoptotic cells for use in the methods disclosed herein comprise at least 95% mononuclear cells.

[0058] It is to be noted that, in some embodiments, while the mononuclear-enriched cell preparation at cell collection comprises at least 65%, preferably at least 70%, most preferably at least 80% mononuclear cells, the final pharmaceutical population, following the production method of the early apoptotic cells for use in the methods disclosed herein, comprises at least 85%, preferably at  
30 least 90%, most preferably at least 95% mononuclear cells.

[0059] In certain embodiments, the mononuclear-enriched cell preparation used for production of the composition of the early apoptotic cells for use in the methods disclosed herein comprises at least 50% mononuclear cells at cell collection. In certain embodiments, disclosed herein is a method for

producing the pharmaceutical population wherein the method comprises obtaining a mononuclear-enriched cell preparation from the peripheral blood of a donor, the mononuclear-enriched cell preparation comprising at least 50% mononuclear cells. In certain embodiments, disclosed herein is a method for producing the pharmaceutical population wherein the method comprises freezing a mononuclear-enriched cell preparation comprising at least 50% mononuclear cells.

[0060] In some embodiments, the cell preparation comprises at least 85% mononuclear cells, wherein at least 40% of the cells in the preparation are in an early-apoptotic state, wherein at least 85% of the cells in the preparation are viable cells. In some embodiments, the apoptotic cell preparation comprises no more than 15% CD15<sup>high</sup> expressing cells.

[0061] A skilled artisan would appreciate that the term “early-apoptotic state” may encompass cells that show early signs of apoptosis without late signs of apoptosis. Examples of early signs of apoptosis in cells include exposure of phosphatidylserine (PS) and the loss of mitochondrial membrane potential. Examples of late events include propidium iodide (PI) admission into the cell and the final DNA cutting. In order to document that cells are in an “early apoptotic” state, in some embodiments, PS exposure detection by Annexin-V and PI staining are used, and cells that are stained with Annexin V but not with PI are considered to be “early apoptotic cells”. In another embodiment, cells that are stained by both Annexin-V FITC and PI are considered to be “late apoptotic cells”. In another embodiment, cells that do not stain for either Annexin-V or PI are considered non-apoptotic viable cells.

[0062] A skilled artisan would appreciate that in some embodiments the terms “early apoptotic cells”, “apoptotic cell”, and “ApoCell”, and grammatical variants thereof, may be used interchangeably having all the same qualities and meanings. The skilled artisan would appreciate that the compositions and methods described herein, in some embodiments comprise early apoptotic cells.

[0063] In some embodiments, apoptotic cells comprise cells in an early apoptotic state. In another embodiment, apoptotic cells comprise cells wherein at least 90% of said cells are in an early apoptotic state. In another embodiment, apoptotic cells comprise cells wherein at least 80% of said cells are in an early apoptotic state. In another embodiment, apoptotic cells comprise cells wherein at least 70% of said cells are in an early apoptotic state. In another embodiment, apoptotic cells comprise cells wherein at least 60% of said cells are in an early apoptotic state. In another embodiment, apoptotic cells comprise cells wherein at least 50% of said cells are in an early apoptotic state.

[0064] In some embodiments, the composition comprising apoptotic cells further comprises an anti-coagulant.

[0065] In some embodiments, early apoptotic cells are stable. A skilled artisan would appreciate that

in some embodiments stability encompasses maintaining early apoptotic cell characteristics over time, for example, maintaining early apoptotic cell characteristics upon storage at about 2-8°C. In some embodiments, stability comprises maintaining early apoptotic cell characteristic upon storage at freezing temperatures, for example temperatures at or below 0°C.

5 [0066] In some embodiments, the mononuclear-enriched cell population obtained according to the production method of the early apoptotic cells for use in the methods disclosed herein undergoes freezing in a freezing medium. In some embodiments, the freezing is gradual. In some embodiments, following collection the cells are maintained at room temperature until frozen. In some embodiments, the cell-preparation undergoes at least one washing step in washing medium following cell-collection  
10 and prior to freezing.

[0067] As used herein, the terms “obtaining cells” and “cell collection” may be used interchangeably. In some embodiments, the cells of the cell preparation are frozen within 3-6 hours of collection. In some embodiments, the cell preparation is frozen within up to 6 hours of cell collection. In some  
15 embodiments, the cells of the cell preparations are frozen within 1, 2, 3, 4, 5, 6, 7, 8 hours of collection. In other embodiments, the cells of the cell preparations are frozen up to 8, 12, 24, 48, 72 hours of collection. In other embodiments, following collection the cells are maintained at 2-8°C until frozen.

[0068] In some embodiments, freezing according to the production of an early apoptotic cell population comprises: freezing the cell preparation at about -18°C to -25°C followed by freezing the  
20 cell preparation at about -80°C and finally freezing the cell preparation in liquid nitrogen until thawing. In some embodiments, the freezing according to the production of an early apoptotic cell population comprises: freezing the cell preparation at about -18°C to -25°C for at least 2 hours, freezing the cell preparation at about -80°C for at least 2 hours and finally freezing the cell preparation in liquid nitrogen until thawing. In some embodiments, the cells are kept in liquid nitrogen for at least  
25 8, 10 or 12 hours prior to thawing. In some embodiments, the cells of the cell preparation are kept in liquid nitrogen until thawing and incubation with apoptosis-inducing incubation medium. In some embodiments, the cells of the cell preparation are kept in liquid nitrogen until the day of hematopoietic stem cell transplantation. In non-limiting examples, the time from cell collection and freezing to preparation of the final population may be between 1-50 days, alternatively between 6-30  
30 days. In alternative embodiments, the cell preparation may be kept in liquid nitrogen for longer time periods, such as at least several months.

[0069] In some embodiments, the freezing according to the production of an early apoptotic cell population comprises freezing the cell preparation at about -18°C to -25°C for at least 0.5, 1, 2, 4



hours. In some embodiments, the freezing according to the production of an early apoptotic cell population comprises freezing the cell preparation at about -18°C to -25°C for about 2 hours. In some embodiments, the freezing In the production of an early apoptotic cell population comprises freezing the cell preparation at about -80°C for at least 0.5, 1, 2, 4, 12 hours.

5 [0070] In some embodiments, the mononuclear-enriched cell composition may remain frozen at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 20 months. In some embodiments, the mononuclear-enriched cell composition may remain frozen at least 0.5, 1, 2, 3, 4, 5 years. In certain embodiments, the mononuclear-enriched cell composition may remain frozen for at least 20 months.

[0071] In some embodiments, the mononuclear-enriched cell composition is frozen for at least 8, 10,  
10 12, 18, 24 hours. In certain embodiments, freezing the mononuclear-enriched cell composition is for a period of at least 8 hours. In some embodiments, the mononuclear-enriched cell composition is frozen for at least about 10 hours. In some embodiments, the mononuclear-enriched cell composition is frozen for at least about 12 hours. In some embodiments, the mononuclear-enriched cell composition is frozen for about 12 hours. In some embodiments, the total freezing time of the  
15 mononuclear-enriched cell composition (at about -18°C to -25°C, at about -80°C and in liquid nitrogen) is at least 8, 10, 12, 18, 24 hours.

[0072] In some embodiments, the freezing at least partly induces the early-apoptotic state in the cells of the mononuclear-enriched cell composition. In some embodiments, the freezing medium comprises RPMI 1640 medium comprising L-glutamine, Hepes, Hes, dimethyl sulfoxide (DMSO)  
20 and plasma. In some embodiments, the plasma in the freezing medium is an autologous plasma of the donor which donated the mononuclear-enriched cells of the population. In some embodiments, the freezing medium comprises RPMI 1640 medium comprising 2 mM L-glutamine, 10 mM Hepes, 5% Hes, 10% dimethyl sulfoxide and 20% v/v plasma.

[0073] In some embodiments, the freezing medium comprises an anti-coagulant. In certain  
25 embodiments, at least some of the media used during the production of an early apoptotic cell population, including the freezing medium, the incubation medium and the washing media comprise an anti-coagulant. In certain embodiments, all media used during the production of an early apoptotic cell population which comprise an anti-coagulant comprise the same concentration of anti-coagulant. In some embodiments, anti-coagulant is not added to the final suspension medium of the cell  
30 population.

[0074] In some embodiments, addition of an anti-coagulant at least to the freezing medium improves the yield of the cell-preparation. In other embodiments, addition of an anti-coagulant to the freezing medium improves the yield of the cell-preparation in the presence of a high triglyceride level. As

used herein, improvement in the yield of the cell-preparation relates to improvement in at least one of: the percentage of viable cells out of cells frozen, the percentage of early-state apoptotic cells out of viable cells and a combination thereof.

[0075] In some embodiments, early apoptotic cells are stable for at least 24 hours. In another embodiment, early apoptotic cells are stable for 24 hours. In another embodiment, early apoptotic cells are stable for more than 24 hours. In another embodiment, early apoptotic cells are stable for at least 36 hours. In another embodiment, early apoptotic cells are stable for 48 hours. In another embodiment, early apoptotic cells are stable for at least 36 hours. In another embodiment, early apoptotic cells are stable for more than 36 hours. In another embodiment, early apoptotic cells are stable for at least 48 hours. In another embodiment, early apoptotic cells are stable for 48 hours. In another embodiment, early apoptotic cells are stable for at least 48 hours. In another embodiment, early apoptotic cells are stable for more than 48 hours. In another embodiment, early apoptotic cells are stable for at least 72 hours. In another embodiment, early apoptotic cells are stable for 72 hours. In another embodiment, early apoptotic cells are stable for more than 72 hours.

[0076] A skilled artisan would appreciate that the term “stable” encompasses apoptotic cells that remain PS-positive (Phosphatidylserine-positive) with only a very small percent of PI-positive (Propidium iodide-positive). PI-positive cells provide an indication of membrane stability wherein a PI-positive cells permits admission into the cells, showing that the membrane is less stable. In some embodiments, stable early apoptotic cells remain in early apoptosis for at least 24 hours, for at least 36 hours, for at least 48 hours, or for at least 72 hours. In another embodiment, stable early apoptotic cells remain in early apoptosis for 24 hours, for 36 hours, for 48 hours, or for 72 hours. In another embodiment, stable early apoptotic cells remain in early apoptosis for more than 24 hours, for more than 36 hours, for more than 48 hours, or for more than 72 hours. In another embodiment, stable early apoptotic cells maintain their state for an extended time period.

[0077] In some embodiments, an apoptotic cell population is devoid of cell aggregates. In some embodiments, an apoptotic cell population is devoid of large cell aggregates. In some embodiments, an apoptotic cell population has a reduced number of cell aggregates compared to an apoptotic cell population prepared without adding an anticoagulant in a step other than cell collection (leukapheresis) from the donor. In some embodiments, an apoptotic cell population or a composition thereof, comprises an anticoagulant.

[0078] In some embodiments, apoptotic cells are devoid of cell aggregates, wherein said apoptotic cells were obtained from a subject with high blood triglycerides. In some embodiments, blood triglycerides levels of the subject are above 150 mg/dL. In some embodiments, an apoptotic cell

population is devoid of cell aggregates, wherein said apoptotic cell population is prepared from cells obtained from a subject with normal blood triglycerides. In some embodiments, blood triglycerides levels of the subject are equal to or below 150 mg/dL. In some embodiments, cell aggregates produce cell loss during apoptotic cell production methods.

5 [0079] A skilled artisan would appreciate that the terms “aggregates” or “cell aggregates” may encompass the reversible clumping of blood cells under low shear forces or at stasis. Cell aggregates can be visually observed during the incubation steps of the production of the apoptotic cells. Cell aggregation can be measured by any method known in the art, for example by visually imaging samples under a light microscope or using flow cytometry.

10 [0080] In some embodiments, the anti-coagulant is selected from the group comprising: heparin, acid citrate dextrose (ACD) Formula A and a combination thereof. In some embodiments, the anti-coagulant is selected from the group consisting of: heparin, acid citrate dextrose (ACD) Formula A and a combination thereof.

[0081] In some embodiments of methods of preparing an early apoptotic cell population and compositions thereof, an anticoagulant is added to at least one medium used during preparation of the population. In some embodiments, the at least one medium used during preparation of the population is selected from the group consisting of: the freezing medium, the washing medium, the apoptosis inducing incubation medium, and any combinations thereof.

20 [0082] In some embodiments, the anti-coagulant is selected from the group consisting of: Heparin, ACD Formula A and a combination thereof. It is to be noted that other anti-coagulants known in the art may be used, such as, but not limited to Fondaparinaux, Bivalirudin and Argatroban.

[0083] In some embodiments, at least one medium used during preparation of the population contains 5% of ACD formula A solution comprising 10 U/ml heparin. In some embodiments, anti-coagulant is not added to the final suspension medium of the cell population. As used herein, the terms “final suspension medium” and “administration medium” are used interchangeably having all the same qualities and meanings.

25 [0084] In some embodiments, at least one medium used during preparation of the population comprises heparin at a concentration of between 0.1-2.5 U/ml. In some embodiments, at least one medium used during preparation of the population comprises ACD Formula A at a concentration of between 1%-15% v/v. In some embodiments, the freezing medium comprises an anti-coagulant. In some embodiments, the incubation medium comprises an anti-coagulant. In some embodiments, both the freezing medium and incubation medium comprise an anti-coagulant. In some embodiments the anti-coagulant is selected from the group consisting of: heparin, ACD Formula A and a combination

thereof.

[0085] In some embodiments, the heparin in the freezing medium is at a concentration of between 0.1-2.5 U/ml. In some embodiments, the ACD Formula A in the freezing medium is at a concentration of between 1%-15% v/v. In some embodiments, the heparin in the incubation medium is at a concentration of between 0.1-2.5 U/ml. In some embodiments, the ACD Formula A in the incubation medium is at a concentration of between 1%-15% v/v. In some embodiments, the anticoagulant is a solution of acid-citrate-dextrose (ACD) formula A. In some embodiments, the anticoagulant added to at least one medium used during preparation of the population is ACD Formula A containing heparin at a concentration of 10 U/ml.

[0086] In some embodiments, the apoptosis inducing incubation medium used in the production of an early apoptotic cell population comprises an anti-coagulant. In some embodiments, both the freezing medium and apoptosis inducing incubation medium used in the production of an early apoptotic cell population comprise an anti-coagulant. Without wishing to be bound by any theory or mechanism, in order to maintain a high and stable cell yield in different cell compositions, regardless of the cell collection protocol, in some embodiments addition of anti-coagulants comprising adding the anticoagulant to both the freezing medium and the apoptosis inducing incubation medium during production of the apoptotic cell population. In some embodiments, a high and stable cell yield within the composition comprises a cell yield of at least 30%, preferably at least 40%, typically at least 50% cells of the initial population of cells used for induction of apoptosis.

[0087] In some embodiments, both the freezing medium and the incubation medium comprise an anti-coagulant. In some embodiments, addition of an anti-coagulant both to the incubation medium and freezing medium results in a high and stable cell-yield between different preparations of the population regardless of cell-collection conditions, such as, but not limited to, the timing and/or type of anti-coagulant added during cell collection. In some embodiments, addition of an anti-coagulant both to the incubation medium and freezing medium results in a high and stable yield of the cell-preparation regardless of the timing and/or type of anti-coagulant added during leukapheresis. In some embodiments, production of the cell-preparation in the presence of a high triglyceride level results in a low and/or unstable cell-yield between different preparations. In some embodiments, producing the cell-preparation from the blood of a donor having high triglyceride level results in a low and/or unstable cell-yield of the cell preparation. In some embodiments, the term "high triglyceride level" refers to a triglyceride level which is above the normal level of a healthy subject of the same sex and age. In some embodiments, the term "high triglyceride level" refers to a triglyceride level above about 1.7 milimole/liter. As used herein, a high and stable yield refers to a

cell yield in the population which is high enough to enable preparation of a dose which will demonstrate therapeutic efficiency when administered to a subject. In some embodiments, therapeutic efficiency refers to the ability to treat, prevent or ameliorate an immune disease, an autoimmune disease or an inflammatory disease in a subject. In some embodiments, a high and stable  
5 cell yield is a cell yield of at least 30%, possibly at least 40%, typically at least 50% of cells in the population out of cells initially frozen.

[0088] In some embodiments, in case the cell-preparation is obtained from a donor having a high triglyceride level, the donor will take at least one measure selected from the group consisting of: taking triglyceride-lowering medication prior to donation, such as, but not limited to: statins and/or  
10 bezafibrate, fasting for a period of at least 8, 10, 12 hours prior to donation, eating an appropriate diet to reduce blood triglyceride level at least 24, 48, 72 hours prior to donating and any combination thereof. .

[0089] In some embodiments, cell yield in the population relates to cell number in the composition out of the initial number of cells subjected to apoptosis induction. As used herein, the terms  
15 “induction of early apoptotic state” and “induction of apoptosis” may be used interchangeably.

[0090] In some embodiments, the mononuclear-enriched cell composition is incubated in incubation medium following freezing and thawing. In some embodiments, there is at least one washing step between thawing and incubation. As used herein, the terms “incubation medium” and “apoptosis inducing incubation medium” are used interchangeably. In some embodiments, the incubation  
20 medium comprises RPMI 1640 medium supplemented with L-glutamine, Hepes methylprednisolone and plasma. In some embodiments, the washing medium comprises 2 mM L-glutamine, 10 mM Hepes and 10% v/v blood plasma. In some embodiments, the blood plasma in in the incubation medium is derived from the same donor from whom the cells of the cell preparations are derived. In some embodiments, the blood plasma is added to the incubation medium on the day of incubation.

25 In some embodiments, incubation is performed at 37°C and 5% CO<sub>2</sub>.

[0091] In some embodiments, the incubation medium comprises methylprednisolone. In some embodiments, the methylprednisolone within the incubation medium further induces the cells in the mononuclear-enriched cell composition to enter an early-apoptotic state. In some embodiments, the cells in the mononuclear-enriched cell composition are induced to enter an early-apoptotic state both  
30 by freezing and incubating in the presence of methylprednisolone. In some embodiments, the production of an early apoptotic cell population advantageously allows induction of an early-apoptosis state substantially without induction of necrosis, wherein the cells remain stable at said early-apoptotic state for about 24 hours following preparation.

[0092] In some embodiments, the incubation medium comprises methylprednisolone at a concentration of about 10-100 µg/ml. In some embodiments, the incubation medium comprises methylprednisolone at a concentration of about 40-60 µg/ml, alternatively about 45-55 µg/ml. In some embodiments, the incubation medium comprises methylprednisolone at a concentration of 50 µg/ml.

[0093] In some embodiments, the incubation is for about 2-12 hours, possibly 4-8 hours, typically for about 5-7 hours. In some embodiments, the incubation is for about 6 hours. In some embodiments, the incubation is for at least 6 hours. In a preferred embodiment, the incubation is for 6 hours.

[0094] In some embodiments, the incubation medium comprises an anti-coagulant. In some embodiments, addition of an anti-coagulant to the incubation medium improves the yield of the cell-preparation. In some embodiments, the anti-coagulant in the incubation medium is of the same concentration as within the freezing medium. In some embodiments, the incubation medium comprises an anti-coagulant selected from the group consisting of: heparin, ACD Formula A and a combination thereof. In some embodiments, the anti-coagulant used in the incubation medium is ACD Formula A containing heparin at a concentration of 10 U/ml.

[0095] In some embodiments, the incubation medium comprises heparin. In some embodiments, the heparin in the incubation medium is at a concentration of between 0.1-2.5 U/ml. In some embodiments, the heparin in the incubation medium is at a concentration of between 0.1-2.5 U/ml, possibly between 0.3-0.7 U/ml, typically about 0.5 U/ml. In certain embodiments, the heparin in the incubation medium is at a concentration of about 0.5 U/ml.

[0096] In some embodiments, the incubation medium comprises ACD Formula A. In some embodiments, the ACD Formula A in the incubation medium is at a concentration of between 1%-15% v/v. In some embodiments, the ACD Formula A in the incubation medium is at a concentration of between 1%-15% v/v, possibly between 4%-7% v/v, typically about 5% v/v. In some embodiments, the ACD Formula A in the incubation medium is at a concentration of about 5% v/v.

[0097] In some embodiments, improvement in the yield of the cell-preparation comprises improvement in the number of the early-apoptotic viable cells of the preparation out of the number of frozen cells from which the preparation was produced.

[0098] In some embodiments, addition of an anti-coagulant to the freezing medium contributes to a high and stable yield between different preparations of the pharmaceutical population. In preferable embodiments, addition of an anti-coagulant at least to the freezing medium and incubation medium results in a high and stable yield between different preparations of the pharmaceutical composition, regardless to the cell collection protocol used.

[0099] In some embodiments, the freezing medium comprises an anti-coagulant selected from the group consisting of: heparin, ACD Formula A and a combination thereof. In some embodiments, the anti-coagulant used in the freezing medium is ACD Formula A containing heparin at a concentration of 10 U/ml. In some embodiments, the freezing medium comprises 5% v/v of ACD Formula A solution comprising heparin at a concentration of 10 U/ml.

[0100] In some embodiments, the freezing medium comprises heparin. In some embodiments, the heparin in the freezing medium is at a concentration of between 0.1-2.5 U/ml. In some embodiments, the heparin in the freezing medium is at a concentration of between 0.1-2.5 U/ml, possibly between 0.3-0.7 U/ml, typically about 0.5 U/ml. In certain embodiments, the heparin in the freezing medium is at a concentration of about 0.5 U/ml.

[0101] In some embodiments, the freezing medium comprises ACD Formula A. In some embodiments, the ACD Formula A in the freezing medium is at a concentration of between 1%-15% v/v. In some embodiments, the ACD Formula A in the freezing medium is at a concentration of between 1%-15% v/v, possibly between 4%-7% v/v, typically about 5% v/v. In some embodiments, the ACD Formula A in the freezing medium is at a concentration of about 5% v/v.

[0102] In some embodiments, addition of an anti-coagulant to the incubation medium and/or freezing medium results in a high and stable cell yield within the population regardless of the triglyceride level in the blood of the donor. In some embodiments, addition of an anti-coagulant to the incubation medium and/or freezing medium results in a high and stable cell yield within the composition the invention when obtained from the blood of a donor having normal or high triglyceride level. In some embodiments, addition of an anti-coagulant at least to the incubation medium, results in a high and stable cell yield within the composition regardless of the triglyceride level in the blood of the donor. In some embodiments, addition of an anti-coagulant to the freezing medium and incubation medium results in a high and stable cell yield within the composition regardless of the triglyceride level in the blood of the donor.

[0103] In some embodiments, the freezing medium and/or incubation medium and/or washing medium comprise heparin at a concentration of at least 0.1 U/ml, possibly at least 0.3 U/ml, typically at least 0.5 U/ml. In some embodiments, the freezing medium and/or incubation medium and/or washing medium comprise ACD Formula A at a concentration of at least 1% v/v, possibly at least 3% v/v, typically at least 5% v/v.

[0104] In some embodiments, the mononuclear-enriched cell composition undergoes at least one washing step following cell collection and prior to being re-suspended in the freezing medium and frozen. In some embodiments, the mononuclear-enriched cell composition undergoes at least one

washing step following freezing and thawing. In some embodiments, washing steps comprise centrifugation of the mononuclear-enriched cell composition followed by supernatant extraction and re-suspension in washing medium.

[00105] In some embodiments, the mononuclear-enriched cell composition undergoes at least one washing step between each stage of the production of an early apoptotic cell population. In some embodiments, anti-coagulant is added to washing media during washing steps throughout the production of an early apoptotic cell population. In some embodiments, the mononuclear-enriched cell composition undergoes at least one washing step following incubation. In some embodiments, the mononuclear-enriched cell composition undergoes at least one washing step following incubation using PBS. In some embodiments, anti-coagulant is not added to the final washing step prior to re-suspension of the cell-preparation in the administration medium. In some embodiments, anti-coagulant is not added to the PBS used in the final washing step prior to re-suspension of the cell-preparation in the administration medium. In certain embodiments, anti-coagulant is not added to the administration medium.

[00106] In some embodiments, the cell concentration during incubating is about  $5 \times 10^6$  cells/ml.

[00107] In some embodiments, the mononuclear-enriched cell composition is suspended in an administration medium following freezing, thawing and incubating, thereby resulting in the pharmaceutical population. In some embodiments, the administration medium comprises a suitable physiological buffer. Non-limiting examples of a suitable physiological buffer are: saline solution, Phosphate Buffered Saline (PBS), Hank's Balanced Salt Solution (HBSS), and the like. In some embodiments, the administration medium comprises PBS. In some embodiments, the administration medium comprises supplements conducive to maintaining the viability of the cells. In some embodiments, the mononuclear-enriched cell composition is filtered prior to administration. In some embodiments, the mononuclear-enriched cell composition is filtered prior to administration using a filter of at least  $200\mu\text{m}$ .

[00108] In some embodiments, the mononuclear-enriched cell population is re-suspended in an administration medium such that the final volume of the resulting cell-preparation is between 100-1000ml, possibly between 200-800ml, typically between 300-600ml.

[00109] In some embodiments, cell collection refers to obtaining a mononuclear-enriched cell composition. In some embodiments, washing steps performed during the production of an early apoptotic cell population are performed in a washing medium. In certain embodiments, washing steps performed up until the incubation step of the production of an early apoptotic cell population are



performed in a washing medium. In some embodiments, the washing medium comprises RPMI 1640 medium supplemented with L-glutamine and Hepes. In some embodiments, the washing medium comprises RPMI 1640 medium supplemented with 2 mM L-glutamine and 10 mM Hepes.

[00110] In some embodiments, the washing medium comprises an anti-coagulant. In some  
5 embodiments, the washing medium comprises an anti-coagulant selected from the group consisting of: heparin, ACD Formula A and a combination thereof. In some embodiments, the concentration of the anti-coagulant in the washing medium is the same concentration as in the freezing medium. In some embodiments, the concentration of the anti-coagulant in the washing medium is the same concentration as in the incubation medium. In some embodiments, the anti-coagulant used in the  
10 washing medium is ACD Formula A containing heparin at a concentration of 10 U/ml.

[00111] In some embodiments, the washing medium comprises heparin. In some  
embodiments, the heparin in the washing medium is at a concentration of between 0.1-2.5 U/ml. In some embodiments, the heparin in the washing medium is at a concentration of between 0.1-2.5 U/ml, possibly between 0.3-0.7 U/ml, typically about 0.5 U/ml. In certain embodiments, the heparin  
15 in the washing medium is at a concentration of about 0.5 U/ml.

[00112] In some embodiments, the washing medium comprises ACD Formula A. In some  
embodiments, the ACD Formula A in the washing medium is at a concentration of between 1%-15% v/v. In some embodiments, the ACD Formula A in the washing medium is at a concentration of between 1%-15% v/v, possibly between 4%-7% v/v, typically about 5% v/v. In some embodiments,  
20 the ACD Formula A in the washing medium is at a concentration of about 5% v/v.

[00113] In some embodiments, the mononuclear-enriched cell composition is thawed several  
hours prior to the intended administration of the population to a subject. In some embodiments, the mononuclear-enriched cell composition is thawed at about 33°C-39°C. In some embodiments, the mononuclear-enriched cell composition is thawed for about 30-240 seconds, preferably 40-180  
25 seconds, most preferably 50-120 seconds.

[00114] In some embodiments, the mononuclear-enriched cell composition is thawed at least  
10 hours prior to the intended administration of the population, alternatively at least 20, 30, 40 or 50 hours prior to the intended administration of the population. In some embodiments, the mononuclear-enriched cell composition is thawed at least 15-24 hours prior to the intended administration of the  
30 population. In some embodiments, the mononuclear-enriched cell composition is thawed at least about 24 hours prior to the intended administration of the population. In some embodiments, the mononuclear-enriched cell composition is thawed at least 20 hours prior to the intended administration of the population. In some embodiments, the mononuclear-enriched cell composition

is thawed 30 hours prior to the intended administration of the population. In some embodiments, the mononuclear-enriched cell composition is thawed at least 24 hours prior to the intended administration of the population. In some embodiments, the mononuclear-enriched cell composition undergoes at least one step of washing in the washing medium before and/or after thawing.

5 [00115] In some embodiments, the composition further comprises methylprednisolone. At some embodiments, the concentration of methylprednisolone does not exceed 30µg/ml.

[00116] In some embodiments, the apoptotic cells are used at a high dose. In some embodiments, the apoptotic cells are used at a high concentration. In some embodiments, human apoptotic polymorphonuclear neutrophils (PMNs) are used. In some embodiments, a group of cells,  
10 of which 50% are apoptotic cells, are used. In some embodiments, apoptotic cells are verified by May-Giemsa-stained cytopreps. In some embodiments, viability of cells are assessed by trypan blue exclusion. In some embodiments, the apoptotic and necrotic status of the cells are confirmed by annexin V/propidium iodide staining with detection by FACS.

[00117] In some embodiments, apoptotic cells disclosed herein comprise no necrotic cells. In  
15 some embodiments, apoptotic cells disclosed herein comprise less than 1% necrotic cells. In some embodiments, apoptotic cells disclosed herein comprise less than 2% necrotic cells. In some embodiments, apoptotic cells disclosed herein comprise less than 3% necrotic cells. In some embodiments, apoptotic cells disclosed herein comprise less than 4% necrotic cells. In some embodiments, apoptotic cells disclosed herein comprise less than 5% necrotic cells.

20 [00118] In some embodiments, a dose of about  $140 \times 10^6$  -  $210 \times 10^6$  apoptotic cells are administered. In some embodiments, a dose of about  $10$ - $100 \times 10^6$  apoptotic cells is administered. In some embodiments, a dose of about  $20 \times 10^6$  apoptotic cells is administered. In some embodiments, a dose of about  $30 \times 10^6$  apoptotic cells is administered. In some embodiments, a dose of about  $40 \times 10^6$  apoptotic cells is administered. In some embodiments, a dose of about  $50 \times 10^6$  apoptotic cells is  
25 administered. In some embodiments,  $60 \times 10^6$  apoptotic cells is administered. In some embodiments, a dose of about  $60 \times 10^6$  apoptotic cells is administered. In some embodiments, a dose of about  $70 \times 10^6$  apoptotic cells is administered. In some embodiments, a dose of about  $80 \times 10^6$  apoptotic cells is administered. In some embodiments, a dose of about  $90 \times 10^6$  apoptotic cells is administered. In some embodiments, a dose of about  $1$ - $15 \times 10^7$  apoptotic cells is administered. In some embodiments,  
30 a dose of about  $10 \times 10^7$  apoptotic cells is administered. In some embodiments, a dose of about  $15 \times 10^7$  apoptotic cells is administered.

[00119] In some embodiments, a dose of  $10 \times 10^6$  apoptotic cells is administered. In another embodiment, a dose of  $10 \times 10^7$  apoptotic cells is administered. In another embodiment, a dose of

10x10<sup>8</sup> apoptotic cells is administered. In another embodiment, a dose of 10x10<sup>9</sup> apoptotic cells is administered. In another embodiment, a dose of 10x10<sup>10</sup> apoptotic cells is administered. In another embodiment, a dose of 10x10<sup>11</sup> apoptotic cells is administered. In another embodiment, a dose of 10x10<sup>12</sup> apoptotic cells is administered. In another embodiment, a dose of 10x10<sup>5</sup> apoptotic cells is administered. In another embodiment, a dose of 10x10<sup>4</sup> apoptotic cells is administered. In another embodiment, a dose of 10x10<sup>3</sup> apoptotic cells is administered. In another embodiment, a dose of 10x10<sup>2</sup> apoptotic cells is administered.

[00120] In some embodiments, a high dose of apoptotic cells is administered. In some embodiments, a dose of 35x10<sup>6</sup> apoptotic cells is administered. In another embodiment, a dose of 210x10<sup>6</sup> apoptotic cells is administered. In another embodiment, a dose of 70x10<sup>6</sup> apoptotic cells is administered. In another embodiment, a dose of 140x10<sup>6</sup> apoptotic cells is administered. In another embodiment, a dose of 35-210x10<sup>6</sup> apoptotic cells is administered.

[00121] In some embodiments, a single dose of apoptotic cells is administered. In some embodiments, multiple doses of apoptotic cells are administered. In some embodiments, 2 doses of apoptotic cells are administered. In some embodiments, 3 doses of apoptotic cells are administered. In some embodiments, 4 doses of apoptotic cells are administered. In some embodiments, 5 doses of apoptotic cells are administered. In some embodiments, 6 doses of apoptotic cells are administered. In some embodiments, 7 doses of apoptotic cells are administered. In some embodiments, 8 doses of apoptotic cells are administered. In some embodiments, 9 doses of apoptotic cells are administered. In some embodiments, more than 9 doses of apoptotic cells are administered. In some embodiments, multiple doses of apoptotic cells are administered.

[00122] In some embodiments, the apoptotic cells may be administered by any method known in the art including, but not limited to, intravenous, subcutaneous, intranodal, intratumoral, intrathecal, intrapleural, intraperitoneal and directly to the thymus.

[00123] In some embodiments, the apoptotic cells are prepared from cells obtained from a subject other than the subject that will receive said apoptotic cells. In some embodiments, the methods as disclosed herein comprise an additional step that is useful in overcoming rejection of allogeneic donor cells, including one or more steps described in U.S. Patent Application 20130156794, which is incorporated herein by reference in its entirety. In some embodiments, the methods comprise the step of full or partial lymphodepletion prior to administration of the apoptotic cells, which in some embodiments, are allogeneic apoptotic cells. In some embodiments, the lymphodepletion is adjusted so that it delays the host versus graft reaction for a period sufficient to allow the allogeneic apoptotic cells to control cytokine release. In some embodiments, the methods comprise the step of

administering agents that delay egression of the allogeneic apoptotic T-cells from lymph nodes, such as 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol (FTY720), 5-[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]-3-[3-(trifluoromethyl)phenyl-1]1,2,4-oxadiazole (SEW2871), 3-(2-(hexylphenylamino)-2-oxoethylamino)propanoic acid (W123), 2-ammonio-4-(2-chloro-4-(3-phenoxyphenylthio)phenyl)-2-(hydroxymethyl)but-yl hydrogen phosphate (KRP-203 phosphate) or other agents known in the art, may be used as part of the compositions and methods as disclosed herein to allow the use of allogeneic apoptotic cells having efficacy and lacking initiation of graft vs host disease. In another embodiment, MHC expression by the allogeneic apoptotic T-cells is silenced to reduce the rejection of the allogeneic cells.

10 [00124] In some embodiments, methods comprise producing a population of mononuclear apoptotic cell comprising a decreased percent of non-quiescent non-apoptotic viable cells; a suppressed cellular activation of any living non-apoptotic cells; or a reduced proliferation of any living non-apoptotic cells; or any combination thereof, said method comprising the following steps, obtaining a mononuclear-enriched cell population of peripheral blood; freezing said mononuclear-enriched cell population in a freezing medium comprising an anticoagulant; thawing said mononuclear-enriched cell population; incubating said mononuclear-enriched cell population in an apoptosis inducing incubation medium comprising methylprednisolone at a final concentration of about 10-100 µg/mL and an anticoagulant; resuspending said apoptotic cell population in an administration medium; and inactivating said mononuclear-enriched population, wherein said inactivation occurs following apoptotic induction, wherein said method produces a population of mononuclear apoptotic cell comprising a decreased percent of non-quiescent non-apoptotic cells; a suppressed cellular activation of any living non-apoptotic cells; or a reduced proliferation of any living non-apoptotic cells; or any combination thereof.

25 [00125] In some embodiments, the methods comprise the step of irradiating a population of apoptotic cells derived from a subject prior to administration of the population of apoptotic cells to the same subject (autologous ApoCells). In some embodiments, the methods comprise the step of irradiating apoptotic cells derived from a subject prior to administration of the population of apoptotic cells to a recipient (allogeneic ApoCells).

30 [00126] In some embodiments, cells are irradiated in a way that will decrease proliferation and/or activation of residual viable cells within the apoptotic cell population. In some embodiments, cells are irradiated in a way that reduces the percent of viable non-apoptotic cells in a population. In some embodiments, the percent of viable non-apoptotic cells in an inactivated early apoptotic cell population is reduced to less than 50% of the population. In some embodiments, the percent of viable

non-apoptotic cells in an inactivated early apoptotic cell population is reduced to less than 40% of the population. In some embodiments, the percent of viable non-apoptotic cells in an inactivated early apoptotic cell population is reduced to less than 30% of the population. In some embodiments, the percent of viable non-apoptotic cells in an inactivated early apoptotic cell population is reduced to less than 20% of the population. In some embodiments, the percent of viable non-apoptotic cells in an inactivated early apoptotic cell population is reduced to less than 10% of the population. In some embodiments, the percent of viable non-apoptotic cells in an inactivated early apoptotic cell population is reduced to 0% of the population.

[00127] In another embodiment, the irradiated apoptotic cells preserve all their early apoptotic-, immune modulation-, stability-properties. In another embodiment, the irradiation step uses UV radiation. In another embodiment, the irradiation step uses X-ray radiation. In another embodiment, the radiation step uses gamma radiation. In another embodiment, the apoptotic cells comprise a decreased percent of living non-apoptotic cells, comprise a preparation having a suppressed cellular activation of any living non-apoptotic cells present within the apoptotic cell preparation, or comprise a preparation having reduced proliferation of any living non-apoptotic cells present within the apoptotic cell preparation, or any combination thereof.

[00128] In some embodiments, irradiation of apoptotic cells does not increase the population of dead cells (PI+) compared with apoptotic cells not irradiated. In some embodiments, irradiation of apoptotic cells does not increase the population of dead cells (PI+) by more than about 1% compared with apoptotic cells not irradiated. In some embodiments, irradiation of apoptotic cells does not increase the population of dead cells (PI+) by more than about 2% compared with apoptotic cells not irradiated. In some embodiments, irradiation of apoptotic cells does not increase the population of dead cells (PI+) by more than about 3% compared with apoptotic cells not irradiated. In some embodiments, irradiation of apoptotic cells does not increase the population of dead cells (PI+) by more than about 4% compared with apoptotic cells not irradiated. In some embodiments, irradiation of apoptotic cells does not increase the population of dead cells (PI+) by more than about 5% compared with apoptotic cells not irradiated. In some embodiments, irradiation of apoptotic cells does not increase the population of dead cells (PI+) by more than about 6% compared with apoptotic cells not irradiated. In some embodiments, irradiation of apoptotic cells does not increase the population of dead cells (PI+) by more than about 7% compared with apoptotic cells not irradiated. In some embodiments, irradiation of apoptotic cells does not increase the population of dead cells (PI+) by more than about 8% compared with apoptotic cells not irradiated. In some embodiments, irradiation of apoptotic cells does not increase the population of dead cells (PI+) by more than about

9% compared with apoptotic cells not irradiated. In some embodiments, irradiation of apoptotic cells does not increase the population of dead cells (PI+) by more than about 10% compared with apoptotic cells not irradiated. In some embodiments, irradiation of apoptotic cells does not increase the population of dead cells (PI+) by more than about 15% compared with apoptotic cells not irradiated.

5 In some embodiments, irradiation of apoptotic cells does not increase the population of dead cells (PI+) by more than about 20%, 25%, 30%, 35%, 40%, 45%, or 50% compared with apoptotic cells not irradiated.

[00129] In some embodiments, a cell population comprising a reduced or non-existent fraction of living non-apoptotic cells may in one embodiment provide a mononuclear early apoptotic cell population that does not have any living / viable cells. In some embodiments, a cell population comprising a reduced or non-existent fraction of living non-apoptotic cells may in one embodiment provide a mononuclear apoptotic cell population that does not elicit GVHD in a recipient.

[00130] In some embodiments, use of irradiated ApoCells removes the possible graft versus leukemia effect use of an apoptotic population (that includes a minor portion of viable cells) may cause, demonstrating that the effects shown here in the Examples (See Example 4) result from the irradiated apoptotic cells and not from a viable proliferating population of cells with cellular activity, present within the apoptotic cell population.

[00131] In another embodiment, the methods comprise the step of irradiating apoptotic cells derived from WBCs from a donor prior to administration to a recipient. In some embodiments, cells are irradiated in a way that will avoid proliferation and/or activation of residual viable cells within the apoptotic cell population. In another embodiment, the irradiated apoptotic cells preserve all their early apoptotic-, immune modulation-, stability-properties. In another embodiment, the irradiation step uses UV radiation. In another embodiment, the irradiation step uses X-ray radiation. In another embodiment, the radiation step uses gamma radiation. In another embodiment, the apoptotic cells comprise a decreased percent of living non-apoptotic cells, comprise a preparation having a suppressed cellular activation of any living non-apoptotic cells present within the apoptotic cell preparation, or comprise a preparation having reduced proliferation of any living non-apoptotic cells present within the apoptotic cell preparation, or any combination thereof.

[00132] In some embodiments, apoptotic cells comprise a pooled mononuclear apoptotic cell preparation. In some embodiments, a pooled mononuclear apoptotic cell preparation comprises mononuclear cells in an early apoptotic state, wherein said pooled mononuclear apoptotic cells comprise a decreased percent of living non-apoptotic cells, a preparation having a suppressed cellular activation of any living non-apoptotic cells, or a preparation having reduced proliferation of any

living non-apoptotic cells, or any combination thereof. In another embodiment, the pooled mononuclear apoptotic cells have been irradiated. In another embodiment, disclosed herein is a pooled mononuclear apoptotic cell preparation that in some embodiments, originates from the white blood cell fraction (WBC) obtained from donated blood.

5 [00133] In some embodiments, the apoptotic cell preparation is irradiated. In another embodiment, said irradiation comprises gamma irradiation, X-ray irradiation, or UV irradiation. In yet another embodiment, the irradiated preparation has a reduced number of non-apoptotic cells compared with a non-irradiated apoptotic cell preparation. In another embodiment, the irradiated preparation has a reduced number of proliferating cells compared with a non-irradiated apoptotic cell preparation. In  
10 another embodiment, the irradiated preparation has a reduced number of potentially immunologically active cells compared with a non-irradiated apoptotic cell population.

[00134] In some embodiments, pooled blood comprises 3rd party blood not matched between donor and recipient.

[00135] A skilled artisan would appreciate that the term “pooled” may encompass blood collected  
15 from multiple donors, prepared and possibly stored for later use. This combined pool of blood may then be processed to produce a pooled mononuclear apoptotic cell preparation. In another embodiment, a pooled mononuclear apoptotic cell preparation ensures that a readily available supply of mononuclear apoptotic cells is available. In another embodiment, cells are pooled just prior to the incubation step wherein apoptosis is induced. In another embodiment, cells are pooled following the  
20 incubation step at the step of resuspension. In another embodiment, cells are pooled just prior to an irradiation step. In another embodiment, cells are pooled following an irradiation step. In another embodiment, cells are pooled at any step in the methods of preparation.

[00136] In some embodiments, a pooled apoptotic cell preparation is derived from cells present in between about 2 and 25 units of blood. In another embodiment, said pooled apoptotic cell preparation  
25 is comprised of cells present in between about 2-5, 2-10, 2-15, 2-20, 5-10, 5-15, 5-20, 5-25, 10-15, 10-20, 10-25, 6-13, or 6-25 units of blood. In another embodiment, said pooled apoptotic cell preparation is comprised of cells present in about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 units of blood. The number of units of blood needed is also dependent upon the efficiency of WBC recovery from blood. For example, low efficiency WBC recovery would  
30 lead to the need for additional units, while high efficiency WBC recovery would lead to fewer units needed. In some embodiments, each unit is a bag of blood. In another embodiment, a pooled apoptotic cell preparation is comprised of cells present in at least 25 units of blood, at least 50 units of blood, or at least 100 units of blood.

[00137] In some embodiments, the units of blood comprise white blood cell (WBC) fractions from blood donations. In another embodiment, the donations may be from a blood center or blood bank. In another embodiment, the donations may be from donors in a hospital gathered at the time of preparation of the pooled apoptotic cell preparation. In another embodiment, units of blood comprising WBCs from multiple donors are saved and maintained in an independent blood bank created for the purpose of compositions and methods thereof as disclosed herein. In another embodiment, a blood bank developed for the purpose of compositions and methods thereof as disclosed herein, is able to supply units of blood comprising WBC from multiple donors and comprises a leukapheresis unit.

[00138] In some embodiments, the units of pooled WBCs are not restricted by HLA matching. Therefore, the resultant pooled apoptotic cell preparation comprises cell populations not restricted by HLA matching. Accordingly, in certain embodiments a pooled mononuclear apoptotic cell preparation comprises allogeneic cells.

[00139] An advantage of a pooled mononuclear apoptotic cell preparation that is derived from pooled WBCs not restricted by HLA matching, is a readily available source of WBCs and reduced costs of obtaining WBCs.

[00140] In some embodiments, pooled blood comprises blood from multiple donors independent of HLA matching. In another embodiment, pooled blood comprises blood from multiple donors wherein HLA matching with the recipient has been taken into consideration. For example, wherein 1 HLA allele, 2 HLA alleles, 3 HLA alleles, 4 HLA alleles, 5 HLA alleles, 6 HLA alleles, or 7 HLA alleles have been matched between donors and recipient. In another embodiment, multiple donors are partially matched, for example some of the donors have been HLA matched wherein 1 HLA allele, 2 HLA alleles, 3 HLA alleles, 4 HLA alleles, 5 HLA alleles, 6 HLA alleles, or 7 HLA alleles have been matched between some of the donors and recipient. Each possibility comprises an embodiment as disclosed herein.

[00141] In certain embodiments, some viable non-apoptotic cells (apoptosis resistant) may remain following the induction of apoptosis step described below (Example 1). The presence of these viable non-apoptotic cells is, in some embodiments, is observed prior to an irradiation step. These viable non-apoptotic cells may be able to proliferate or be activated. In some embodiments, the pooled mononuclear apoptotic cell preparation derived from multiple donors may be activated against the host, activated against one another, or both.

[00142] In some embodiments, an irradiated cell preparation as disclosed herein has suppressed cellular activation and reduced proliferation compared with a non-irradiated cell preparation. In



another embodiment, the irradiation comprises gamma irradiation, X-ray irradiation, or UV irradiation. In another embodiment, an irradiated cell preparation has a reduced number of non-apoptotic cells compared with a non-irradiated cell preparation. In another embodiment, the irradiation comprises about 10 Grey units (Gy). In another embodiment, the irradiation comprises about 15 Grey units (Gy). In another embodiment, the irradiation comprises about 20 Grey units (Gy). In another embodiment, the irradiation comprises about 25 Grey units (Gy). In another embodiment, the irradiation comprises about 30 Grey units (Gy). In another embodiment, the irradiation comprises about 35 Grey units (Gy). In another embodiment, the irradiation comprises about 40 Grey units (Gy). In another embodiment, the irradiation comprises about 45 Grey units (Gy). In another embodiment, the irradiation comprises about 50 Grey units (Gy). In another embodiment, the irradiation comprises about 55 Grey units (Gy). In another embodiment, the irradiation comprises about 60 Grey units (Gy). In another embodiment, the irradiation comprises about 65 Grey units (Gy). In another embodiment, the irradiation comprises about 70 Grey units (Gy). In another embodiment, the irradiation comprises about 75 Grey units (Gy). In another embodiment, the irradiation comprises about 80 Grey units (Gy).

[00143] In another embodiment, the irradiation comprises about 10-80 Grey units (Gy). In another embodiment, the irradiation comprises about 20-65 Grey units (Gy). In another embodiment, the irradiation comprises about 10-65 Grey units (Gy). In another embodiment, the irradiation comprises about 20-80 Grey units (Gy). In another embodiment, the irradiation comprises about 30-50 Grey units (Gy). In another embodiment, the irradiation comprises up to 2500 Gy. In another embodiment, an irradiated pooled apoptotic cell preparation maintains the same or a similar apoptotic profile, stability and efficacy as a non-irradiated pooled apoptotic cell preparation.

[00144] In some embodiments, a pooled mononuclear apoptotic cell preparation as disclosed herein is stable for up to 24 hours. In another embodiment, a pooled mononuclear apoptotic cell preparation is stable for at least 24 hours. In another embodiment, a pooled mononuclear apoptotic cell preparation is stable for more than 24 hours. In yet another embodiment, a pooled mononuclear apoptotic cell preparation as disclosed herein is stable for up to 36 hours. In still another embodiment, a pooled mononuclear apoptotic cell preparation is stable for at least 36 hours. In a further embodiment, a pooled mononuclear apoptotic cell preparation is stable for more than 36 hours. In another embodiment, a pooled mononuclear apoptotic cell preparation as disclosed herein is stable for up to 48 hours. In another embodiment, a pooled mononuclear apoptotic cell preparation is stable for at least 48 hours. In another embodiment, a pooled mononuclear apoptotic cell preparation is stable for more than 48 hours.

[00145] In some embodiments, methods of producing the pooled cell preparation comprising an irradiation step preserves the early apoptotic, immune modulation, and stability properties observed in an apoptotic preparation derived from a single match donor wherein the cell preparation may not include an irradiation step. In another embodiment, a pooled mononuclear apoptotic cell preparation  
5 as disclosed herein does not elicit a graft versus host disease (GVHD) response.

[00146] Irradiation of the cell preparation is considered safe in the art. Irradiation procedures are currently performed on a routine basis to donated blood to prevent reactions to WBC.

[00147] In another embodiment, the percent of apoptotic cells in a pooled mononuclear apoptotic cell preparation as disclosed herein is close to 100%, thereby reducing the fraction of living non-  
10 apoptotic cells in the cell preparation. In some embodiments, the percent of apoptotic cells is at least 40%. In another embodiment, the percent of apoptotic cells is at least 50%. In yet another embodiment, the percent of apoptotic cells is at least 60%. In still another embodiment, the percent of apoptotic cells is at least 70%. In a further embodiment, the percent of apoptotic cells is at least 80%. In another embodiment, the percent of apoptotic cells is at least 90%. In yet another  
15 embodiment, the percent of apoptotic cells is at least 99%. Accordingly, a cell preparation comprising a reduced or non-existent fraction of living non-apoptotic cells may in one embodiment provide a pooled mononuclear apoptotic cell preparation that does not elicit GVHD in a recipient. Each possibility represents an embodiment as disclosed herein.

[00148] Alternatively, in another embodiment, the percentage of living non-apoptotic WBC is  
20 reduced by specifically removing the living cell population, for example by targeted precipitation. In another embodiment, the percent of living non-apoptotic cells may be reduced using magnetic beads that bind to phosphatidylserine. In another embodiment, the percent of living non-apoptotic cells may be reduced using magnetic beads that bind a marker on the cell surface of non-apoptotic cells but not apoptotic cells. In another embodiment, the apoptotic cells may be selected for further preparation  
25 using magnetic beads that bind to a marker on the cell surface of apoptotic cells but not non-apoptotic cells. In yet another embodiment, the percentage of living non-apoptotic WBC is reduced by the use of ultrasound.

[00149] In one embodiment the apoptotic cells are from pooled third party donors.

[00150] In some embodiments, a pooled cell preparation comprises at least one cell type selected  
30 from the group consisting of: lymphocytes, monocytes and natural killer cells. In another embodiment, a pooled cell preparation comprises an enriched population of mononuclear cells. In some embodiments, a pooled mononuclear is a mononuclear enriched cell preparation comprises cell types selected from the group consisting of: lymphocytes, monocytes and natural killer cells. In

another embodiment, the mononuclear enriched cell preparation comprises no more than 15%, alternatively no more than 10%, typically no more than 5% polymorphonuclear leukocytes, also known as granulocytes (i.e., neutrophils, basophils and eosinophils). In another embodiment, a pooled mononuclear cell preparation is devoid of granulocytes.

5 [00151] In another embodiment, the pooled mononuclear enriched cell preparation comprises no more than 15%, alternatively no more than 10%, typically no more than 5% CD15<sup>high</sup> expressing cells. In some embodiments, a pooled apoptotic cell preparation comprises less than 15% CD15 high expressing cells.

[00152] In some embodiments, the pooled mononuclear enriched cell preparation disclosed herein  
10 comprises at least 80% mononuclear cells, at least 85% mononuclear cells, alternatively at least 90% mononuclear cells, or at least 95% mononuclear cells, wherein each possibility is a separate embodiment disclosed herein. According to some embodiments, the pooled mononuclear enriched cell preparation disclosed herein comprises at least 85% mononuclear cells.

[00153] In another embodiment, any pooled cell preparation that has a final pooled percent of  
15 mononuclear cells of at least 80% is considered a pooled mononuclear enriched cell preparation as disclosed herein. Thus, pooling cell preparations having increased polymorphonuclear cells (PMN) with cell preparations having high mononuclear cells with a resultant “pool” of at least 80% mononuclear cells comprises a preparation as disclosed herein. According to some embodiments, mononuclear cells comprise lymphocytes and monocytes.

20 [00154] A skilled artisan would appreciate that the term “mononuclear cells” may encompass leukocytes having a one lobed nucleus. In another embodiment, a pooled apoptotic cell preparation as disclosed herein comprises less than 5% polymorphonuclear leukocytes.

[00155] In some embodiments, the apoptotic cells are T-cells. In another embodiment, the apoptotic cells are derived from the same pooled third party donor T-cells as the CAR T-cells. In  
25 another embodiment, the apoptotic cells are derived from the CAR T-cell population.

[00156] Surprisingly, the apoptotic cells reduce production of cytokines associated with the cytokine storm including but not limited to IL-6, and interferon-gamma (IFN- $\gamma$ ), alone or in combination, while the effectiveness of CAR T-cell therapy was maintained (Example 2). In one embodiment, the apoptotic cells affect cytokine expression levels in macrophages. In another  
30 embodiment, the apoptotic cells reduce cytokine expression levels in macrophages. In one embodiment, the apoptotic cells suppress cytokine expression levels in macrophages. In one embodiment, the apoptotic cells inhibit cytokine expression levels in macrophages. In one embodiment, the apoptotic cells maintain IFN- $\gamma$  levels to match or nearly match levels present prior

to CAR –T cell administration. In another embodiment, apoptotic cells affect cytokine expression levels in macrophages but do not affect cytokine expression levels in the CAR T-cells. In another embodiment, the apoptotic cells affect cytokine expression levels in DCs, but do not affect cytokine expression levels in the CAR T-cells. It was therefore unexpected that apoptotic cells would be useful  
5 in maintaining the effectiveness CAR T-cell therapy.

[00157] In another embodiment, the effect of apoptotic cells on cytokine expression levels in macrophages, DCs, or a combination thereof, results in reduction of CRS. In another embodiment, the effect of apoptotic cells on cytokine expression levels in macrophages, DCs, or a combination thereof, results in reduction of severe CRS. In another embodiment, the effect of apoptotic cells on  
10 cytokine expression levels in macrophages, DCs, or a combination thereof, results in suppression of CRS. In another embodiment, the effect of apoptotic cells on cytokine expression levels in macrophages, DCs, or a combination thereof, results in suppression of severe CRS. In another embodiment, the effect of apoptotic cells on cytokine expression levels in macrophages, DCs, or a combination thereof, results in inhibition of CRS. In another embodiment, the effect of apoptotic cells  
15 on cytokine expression levels in macrophages, DCs, or a combination thereof, results in inhibition of severe CRS. In another embodiment, the effect of apoptotic cells on cytokine expression levels in macrophages, DCs, or a combination thereof, results in prevention of CRS. In another embodiment, the effect of apoptotic cells on cytokine expression levels in macrophages, DCs, or a combination thereof, results in prevention of severe CRS.

[00158] In another embodiment, the apoptotic cells trigger death of T-cells, but not via changes in cytokine expression levels.

[00159] In another embodiment, apoptotic cells antagonize the priming of macrophages and dendritic cells to secrete cytokines that would otherwise amplify the cytokine storm. In another embodiment, apoptotic cells increase Tregs which suppress the inflammatory response and/or  
25 prevent excess release of cytokines.

[00160] In some embodiments, administration of apoptotic cells inhibits one or more pro-inflammatory cytokines. In some embodiments, the pro-inflammatory cytokine comprises IL-1beta, IL-6, TNF-alpha, or IFN-gamma, or any combination thereof. In another embodiment, administration of apoptotic cells promotes the secretion of one or more anti-inflammatory cytokines. In some  
30 embodiments, the anti-inflammatory cytokine comprises TGF-beta, IL10, or PGE2, or any combination thereof.

[00161] In another embodiment, administration of apoptotic cells inhibits dendritic cell maturation following exposure to TLR ligands. In another embodiment, administration of apoptotic cells creates

potentially tolerogenic dendritic cells, which in some embodiments, are capable of migration, and in some embodiments, the migration is due to CCR7. In another embodiment, administration of apoptotic cells elicits various signaling events which in one embodiment is TAM receptor signaling (Tyro3, Axl and Mer) which in some embodiments, inhibits inflammation in antigen-presenting cells.

5 [00162] In some embodiments, Tyro-3, Axl, and Mer constitute the TAM family of receptor tyrosine kinases (RTKs) characterized by a conserved sequence within the kinase domain and adhesion molecule-like extracellular domains. In another embodiment, administration of apoptotic cells activates signaling through MerTK. In another embodiment, administration of apoptotic cells activates the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, which in some embodiments,  
10 negatively regulates NF- $\kappa$ B. In another embodiment, administration of apoptotic cells negatively regulates the inflammasome which in one embodiment leads to inhibition of pro-inflammatory cytokine secretion, DC maturation, or a combination thereof. In another embodiment, administration of apoptotic cells upregulates expression of anti-inflammatory genes such as *Nr4a*, *Thbs1*, or a combination thereof. In another embodiment, administration of apoptotic cells induces a high level  
15 of AMP which in some embodiments, is accumulated in a Pannexin1-dependent manner. In another embodiment, administration of apoptotic cells suppresses inflammation.

[00163] In some embodiments, methods of use of early apoptotic cells, as described herein, includes use of the early apoptotic cells or a composition thereof, in combination with an antibody. In some embodiments, the antibody is directed against a tumor cell antigen. In another embodiment,  
20 the antibody is directed against CD20. In another embodiment, the antibody is rituximab (Rtx).

[00164] In some embodiments, early apoptotic cells and an antibody are comprised in the same composition. In some embodiments, early apoptotic cells and an antibody are comprised in different compositions. In some embodiments, administration of a combination of early apoptotic cells and an antibody, or composition(s) thereof are concurrent. In some embodiments, administration of a  
25 combination of early apoptotic cells and an antibody, or composition(s) thereof comprises administration of apoptotic cells or a composition thereof, prior to the antibody. In some embodiments, administration of a combination of early apoptotic cells and an antibody, or composition(s) thereof comprises administration of apoptotic cells or a composition thereof, following administration of the antibody.

30 [00165] In another embodiment, the antibody is Trastuzumab (Herceptin; Genentech): humanized IgG1, which is directed against ERBB2. In another embodiment, the antibody is Bevacizumab (Avastin; Genentech/Roche): humanized IgG1, which is directed against VEGF. In another embodiment, the antibody is Cetuximab (Erbix; Bristol-Myers Squibb): chimeric human-murine

IgG1, which is directed against EGFR. In another embodiment, the antibody is Panitumumab (Vectibix; Amgen): human IgG2, which is directed against EGFR. In another embodiment, the antibody is Ipilimumab (Yervoy; Bristol-Myers Squibb): IgG1, which is directed against CTLA4.

[00166] In another embodiment, the antibody is Alemtuzumab (Campath; Genzyme): humanized  
 5 IgG1, which is directed against CD52. In another embodiment, the antibody is Ofatumumab (Arzerra; Genmab): human IgG1, which is directed against CD20. In another embodiment, the antibody is Gemtuzumab ozogamicin (Mylotarg; Wyeth): humanized IgG4, which is directed against CD33. In another embodiment, the antibody is Brentuximab vedotin (Adcetris; Seattle Genetics): chimeric IgG1, which is directed against CD30. In another embodiment, the antibody is 90Y-labelled  
 10 ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals): murine IgG1, which is directed against CD20. In another embodiment, the antibody is 131I-labelled tositumomab (Bexxar; GlaxoSmithKline): murine IgG2, which is directed against CD20.

[00167] In another embodiment, the antibody is Ramucirumab, which is directed against vascular endothelial growth factor receptor-2 (VEGFR-2). In another embodiment, the antibody is  
 15 ramucirumab (Cyramza Injection, Eli Lilly and Company), blinatumomab (BLINCYTO, Amgen Inc.), pembrolizumab (KEYTRUDA, Merck Sharp & Dohme Corp.), obinutuzumab (GAZYVA, Genentech, Inc.; previously known as GA101), pertuzumab injection (PERJETA, Genentech, Inc.), or denosumab (Xgeva, Amgen Inc.). In another embodiment, the antibody is Basiliximab (Simulect; Novartis). In another embodiment, the antibody is Daclizumab (Zenapax; Roche).

20 [00168] In another embodiment, the antibody administered in combination with apoptotic cells is directed to a tumor or cancer antigen or a fragment thereof, that is described herein and/or that is known in the art. In another embodiment, the antibody is directed to a tumor-associated antigen. In another embodiment, the antibody is directed to a tumor-associated antigen or a fragment thereof that is an angiogenic factor.

25 [00169] In some embodiments, antibodies described herein may be used in combination with compositions described herein, for example but not limited to a composition comprising early apoptotic cells.

[00170] *Chimeric Antigen Receptor-Expressing T-Cells (CAR T-Cells)*

[00171] In some embodiments, chimeric antigen receptors (CARs) are a type of antigen-targeted  
 30 receptor composed of intracellular T-cell signaling domains fused to extracellular tumor-binding moieties, most commonly single-chain variable fragments (scFvs) from monoclonal antibodies. CARs directly recognize cell surface antigens, independent of MHC-mediated presentation, permitting the use of a single receptor construct specific for any given antigen in all patients. Initial

CARs fused antigen-recognition domains to the CD3 $\zeta$  activation chain of the T-cell receptor (TCR) complex. While these first generation CARs induced T-cell effector function in vitro, they were largely limited by poor antitumor efficacy in vivo. Subsequent CAR iterations have included secondary costimulatory signals in tandem with CD3 $\zeta$ , including intracellular domains from CD28 or a variety of TNF receptor family molecules such as 4-1BB (CD137) and OX40 (CD134). Further, third generation receptors include two costimulatory signals in addition to CD3 $\zeta$ , most commonly from CD28 and 4-1BB. Second and third generation CARs dramatically improved antitumor efficacy, in some cases inducing complete remissions in patients with advanced cancer.

[00172] In some embodiments, a CAR T-cell is an immunoresponsive cell comprising an antigen receptor, which is activated when its receptor binds to its antigen.

[00173] In some embodiments, the CAR T-cells used in the compositions and methods as disclosed herein are first generation CAR T-cells. In some embodiments, the CAR T-cells used in the compositions and methods as disclosed herein are second generation CAR T-cells. In some embodiments, the CAR T-cells used in the compositions and methods as disclosed herein are third generation CAR T-cells. In some embodiments, the CAR T-cells used in the compositions and methods as disclosed herein are fourth generation CAR T-cells. In some embodiments, each generation of CAR T-cells is more potent than the CAR T-cells of earlier generations.

[00174] In some embodiments, first-generation CARs have one signaling domain, typically the cytoplasmic signaling domain of the CD3 TCR $\zeta$  chain.

[00175] In some embodiments, the CAR T-cells as disclosed herein are second generation CAR T-cells. In some embodiments, CAR T-cells as disclosed herein comprise a tripartite chimeric receptor (TPCR). In some embodiments, CAR T-cells as disclosed herein, comprise one or more signaling moieties that activate naïve T-cells in a co-stimulation independent manner. In some embodiments, the CAR T-cells further encode one or more members of the tumor necrosis factor receptor family, which in some embodiments, is CD27, 4-1BB (CD137), or OX40 (CD134), or a combination thereof.

[00176] Third-generation CAR T-cells attempt to harness the signaling potential of 2 costimulatory domains: in some embodiments, the CD28 domain followed by either the 4-1BB or OX-40 signaling domains. In some embodiments, the CAR T-cells used in the compositions and methods as disclosed herein further encode a co-stimulatory signaling domain, which in some embodiments is CD28. In some embodiments, the signaling domain is the CD3 $\zeta$ -chain, CD97, GDI 1a-CD18, CD2, ICOS, CD27, CD154, CDS, OX40, 4-1BB, CD28 signaling domain, or combinations thereof.

[00177] In some embodiments, telomere length and replicative capacity correlate with the

engraftment efficiency and antitumor efficacy of adoptively transferred T-cell lines. In some embodiments, CD28 stimulation maintains telomere length in T-cells.

[00178] In some embodiments, CAR-modified T-cell potency may be further enhanced through the introduction of additional genes, including those encoding proliferative cytokines (ie, IL-12) or costimulatory ligands (ie, 4-1BBL), thus producing “armored” fourth-generation CAR-modified T-cells. In some embodiments, “armored CAR T-cells,” are CAR T-cells which are protected from the inhibitory tumor microenvironment. In some embodiments, the “armored” CAR technology incorporates the local secretion of soluble signaling proteins to amplify the immune response within the tumor microenvironment with the goal of minimizing systemic side effects. In some  
10 embodiments, the signaling protein signal is IL-12, which can stimulate T-cell activation and recruitment. In some embodiments, “armored” CAR technology is especially useful in solid tumor indications, in which microenvironment and potent immunosuppressive mechanisms have the potential to make the establishment of a robust anti-tumor response more challenging.

[00179] In some embodiments, CAR T-cells are genetically modified to encode molecules  
15 involved in the prevention of apoptosis, the remodeling of the tumor microenvironment, induction of homeostatic proliferation, and chemokine receptors that promote directed T-cell homing.

[00180] In some embodiments, CAR T-cell therapy used in the compositions and methods as disclosed herein is enhanced using the expression of cytokine transgenes, combination therapy with small molecule inhibitors, or monoclonal antibodies. In some embodiments, other strategies aimed  
20 at improving CAR T-cell therapy including using dual CARs and chemokine receptors to more specifically target tumor cells are to be considered part of the CAR T-cells and CAR T-cell therapy as disclosed herein.

[00181] In some embodiments, the CAR T-cells of the compositions and methods as disclosed herein comprise a second binding domain that can lead to either an inhibitory or amplifying signal,  
25 in order to increase specificity of CAR T-cells for cancer cells versus normal cells. For example, a CAR T-cell can be engineered such that it would be triggered in the presence of one target protein, but if a second protein is present it would be inhibited. Alternatively, it could also be engineered such that two target proteins would be required for maximal activation. These approaches may increase the specificity of the CAR for tumor relative to normal tissue.

30 [00182] In some embodiments, the CAR T-cells used in the compositions and methods as disclosed herein encode antibody-based external receptor structures and cytosolic domains that encode signal transduction modules composed of the immunoreceptor tyrosine-based activation motif.

[00183] In some embodiments, the CAR T-cell further encodes a single-chain variable fragment



(scFv) that binds a polypeptide that has immunosuppressive activity. In some embodiments, the polypeptide that has immunosuppressive activity is CD47, PD-1, CTLA-4, or a combination thereof. [00184] In some embodiments, the CAR T-cell further encodes a single-chain variable fragment (scFv) that binds a polypeptide that has immunostimulatory activity. In some embodiments, the polypeptide that has immunostimulatory activity is CD28, OX-40, 4-1 BB or a combination thereof. In some embodiments, the CAR T-cell further encodes a CD40 ligand (CD40L), which, in some embodiments, enhances the immunostimulatory activity of the antigen.

[11] In some embodiments, the immune cells are cytotoxic. In some embodiments, cytotoxic cells for genetic modification can be obtained from bone marrow of the subject or a donor. In other cases, the cells are obtained from a stem cell. For example, cytotoxic cells can be derived from human pluripotent stem cells such as human embryonic stem cells or human induced pluripotent T-cells. In the case of induced pluripotent stem cells (IPSCs), such pluripotent T-cells can be obtained using a somatic cell from the subject to which genetically modified cytotoxic cells will be provided. In some embodiments, immune cells may be obtained from a subject or donor by harvesting cells by venipuncture, by apheresis methods, by white cell mobilization followed by apheresis or venipuncture, or by bone marrow aspiration.

[00185] In some embodiments, a method as disclosed herein comprises obtaining immune cells from a subject, and genetically modifying the immune cells to express a chimeric antigen receptor. In some embodiments, a method as disclosed herein comprises obtaining immune cells from a subject, genetically modifying the immune cells to express a chimeric antigen receptor and combining with apoptotic cell population resulting in reduced cytokine production in a subject but substantially unaffected cytotoxicity relative to immune cells expressing a CAR not administered with an apoptotic cell population (**Figures 10A-10B and 11**). In some embodiments, a method as disclosed herein comprises obtaining immune cells from a subject, genetically modifying the immune cells to express a chimeric antigen receptor and combining with an apoptotic cell supernatant or a composition comprising the supernatant, resulting in reduced cytokine production in a subject but substantially unaffected cytotoxicity relative to immune cells expressing a CAR not administered with an apoptotic cell supernatant. In some embodiments, administration of an apoptotic cell population or a supernatant from apoptotic cells does not reduce the efficacy of the immune cells expressing the chimeric antigen receptor.

[00186] In some embodiments, disclosed herein are immune cells, in some embodiments, CAR T-cells in which the T-cell is autologous to the subject. In some embodiments, the CAR T-cells are heterologous to the subject. In some embodiments, the CAR T-cells are allogeneic. In some

embodiments, the CAR T-cells are universal allogeneic CAR T-cells. In some embodiments, the T-cells may be autologous, allogeneic, or derived in vitro from engineered progenitor or stem cells.

[00187] In some embodiments, the CAR T-cells and apoptotic cells described herein, are both derived from the same source. In a further embodiment, the CAR T-cells and apoptotic cells described herein, are both derived from the subject (**Figure 10A and 10B**). In an alternative embodiment, the CAR T-cells and apoptotic cells described herein, are derived from different sources. In yet another embodiment, the CAR T-cells are autologous and the apoptotic cells described herein, are allogeneic (**Figure 11**). A skilled artisan would appreciate that similarly, an apoptotic cell supernatant may be made from cells derived from the same source as the CAR T-cell, which may in some embodiments be autologous cells, or an apoptotic cell supernatant may be made from cells derived from a source different from the source of CAR T-cells.

[00188] A skilled artisan would appreciate that the term "heterologous" may encompass a tissue, cell, nucleic acid molecule or polypeptide that is derived from a different organism. In some embodiments, a heterologous protein is a protein that was initially cloned from or derived from a different T-cell type or a different species from the recipient and that is not normally present in a cell or sample obtained from a cell.

[00189] Accordingly, one embodiment as disclosed herein relates to cytotoxic immune cells (e.g., NK cells or T-cells) comprising chimeric antigen receptors (CARs) whereby the cells retain their cytotoxic function. In some embodiments, the chimeric antigen receptor is exogenous to the T-cell. In some embodiments, the CAR is recombinantly expressed. In some embodiments, the CAR is expressed from a vector.

[00190] In some embodiments, the T-cell utilized to generate CAR T-cells is a naïve CD4<sup>+</sup> T-cell. In some embodiments, the T-cell utilized to generate CAR T-cells is a naïve CD8<sup>+</sup> T-cell. In some embodiments, the T-cell utilized to generate CAR T-cells is an effector T-cell. In some embodiments, the T-cell utilized to generate CAR T-cells is a regulatory T-cell (Treg). In some embodiments, the T-cell utilized to generate CAR T-cells is a cytotoxic T-cell.

[00191] Sources for genetically modified immune cells, for example T cells, have been described extensively in the literature, see for example Themelli et al. (2015) New Cell Sources for T Cell Engineering and Adoptive Immunotherapy. Cell Stem Cell 16: 357-366; Han et al. (2013) Journal of Hematology & Oncology 6:47-53; Wilkie et al. (2010) J Bio Chem 285(33):25538-25544; and van der Stegen et al. (2013) J. Immunol 191: 4589-4598. CAR T-cells are available to order from a commercial source such as Creative Biolabs (NY USA), which provides custom construction and production services for Chimeric Antigen Receptors (CAR) and also provides premade CAR

constructs stock, which can induce protective immunity encode by recombinant adenovirus vaccine. Custom made CAR T-cells may also be obtained from Promab Biotechnologies (CA USA), which can provide specifically designed CAR T-cells.

[00192] *Targeting antigens*

5 [00193] In some embodiments, the CAR binds to an epitope of an antigen via an antibody or an antibody fragment that is directed to the antigen. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a polyclonal antibody. In some embodiments, the antibody fragment is a single-chain variable fragment (scFv).

[00194] In some embodiments, the TCR binds to an epitope of an antigen via a genetically  
10 modified T-cell receptor.

[00195] In some embodiments, the CAR T-cells of the compositions as disclosed herein bind to a tumor associated antigen (TAA). In some embodiments, said tumor associated antigen is: Mucin 1, cell surface associated (MUC1) or polymorphic epithelial mucin (PEM), Arginine-rich, mutated in early stage tumors (Armet), Heat Shock Protein 60 (HSP60), calnexin (CANX),  
15 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase (MTHFD2), fibroblast activation protein (FAP), matrix metalloproteinase (MMP6), B Melanoma Antigen-1 (BAGE-1), aberrant transcript of N-acetyl glucosaminyl transferase V (GnTV), Q5H943, Carcinoembryonic antigen (CEA), Pmel, Kallikrein-4, Mammaglobin-1, MART-1, GPR143-OA1, prostate specific antigen (PSA), TRP1, Tyrosinase, FGP-5, NEU proto-oncogene,  
20 Aft, MMP-2, prostate specific membrane antigen (PSMA), Telomerase-associated protein-2, Prostatic acid phosphatase (PAP), Uroplakin II or Proteinase 3.

[00196] In some embodiments, the CAR binds to CD19 or CD20 to target B cells in the case where one would like to destroy B cells as in leukemia. CD19 is a B cell lineage specific surface receptor whose broad expression, from pro-B cells to early plasma cells, makes it an attractive target for the  
25 immunotherapy of B cell malignancies. In some embodiments, the CAR binds to ROR1, CD22, or GD2. In some embodiments, the CAR binds to NY-ESO-1. In some embodiments, the CAR binds to MAGE family proteins. In some embodiments, the CAR binds to mesothelin. In some embodiments, the CAR binds to c-erbB2. In some embodiments, the CAR binds to mutational antigens that are tumor specific, such as BRAFV600E mutations and BCR-ABL translocations. In  
30 some embodiments, the CAR binds to viral antigens which are tumor-specific, such as EBV in HD, HPV in cervical cancer, and polyomavirus in Merkel cancer. In some embodiments, the CAR T-cell binds to Her2/neu. In some embodiments, the CAR T-cell binds to EGFRvIII.

[00197] In some embodiments, the chimeric antigen receptor (CAR) T-cell binds the CD19

antigen. In some embodiments, the CAR binds the CD22 antigen. In some embodiments, the CAR binds to alpha folate receptor. In some embodiments, the CAR binds to CAIX. In some embodiments, the CAR binds to CD20. In some embodiments, the CAR binds to CD23. In some embodiments, the CAR binds to CD24. In some embodiments, the CAR binds to CD30. In some embodiments, the CAR binds to CD33. In some embodiments, the CAR binds to CD38. In some embodiments, the CAR binds to CD44v6. In some embodiments, the CAR binds to CD44v7/8. In some embodiments, the CAR binds to CD123. In some embodiments, the CAR binds to CD171. In some embodiments, the CAR binds to carcinoembryonic antigen (CEA). In some embodiments, the CAR binds to EGFRvIII. In some embodiments, the CAR binds to EGP-2. In some embodiments, the CAR binds to EGP-40. In some embodiments, the CAR binds to EphA2. In some embodiments, the CAR binds to Erb-B2. In some embodiments, the CAR binds to Erb-B 2,3,4. In some embodiments, the CAR binds to Erb-B3/4. In some embodiments, the CAR binds to FBP. In some embodiments, the CAR binds to fetal acetylcholine receptor. In some embodiments, the CAR binds to G<sub>D2</sub>. In some embodiments, the CAR binds to G<sub>D3</sub>. In some embodiments, the CAR binds to HER2. In some embodiments, the CAR binds to HMW-MAA. In some embodiments, the CAR binds to IL-11Ralpha. In some embodiments, the CAR binds to IL-13Ralpha1. In some embodiments, the CAR binds to KDR. In some embodiments, the CAR binds to kappa-light chain. In some embodiments, the CAR binds to Lewis Y. In some embodiments, the CAR binds to L1-cell adhesion molecule. In some embodiments, the CAR binds to MAGE-A1. In some embodiments, the CAR binds to mesothelin. In some embodiments, the CAR binds to CMV infected cells. In some embodiments, the CAR binds to MUC1. In some embodiments, the CAR binds to MUC16. In some embodiments, the CAR binds to NKG2D ligands. In some embodiments, the CAR binds to NY-ESO-1 (amino acids 157-165). In some embodiments, the CAR binds to oncofetal antigen (h5T4). In some embodiments, the CAR binds to PSCA. In some embodiments, the CAR binds to PSMA. In some embodiments, the CAR binds to ROR1. In some embodiments, the CAR binds to TAG-72. In some embodiments, the CAR binds to VEGF-R2 or other VEGF receptors. In some embodiments, the CAR binds to B7-H6. In some embodiments, the CAR binds to CA9. In some embodiments, the CAR binds to  $\alpha_v\beta_6$  integrin. In some embodiments, the CAR binds to 8H9. In some embodiments, the CAR binds to NCAM. In some embodiments, the CAR binds to fetal acetylcholine receptor.

[00198] In some embodiments, the chimeric antigen receptor (CAR) T-cell targets the CD19 antigen, and has a therapeutic effect on subjects with B-cell malignancies, ALL, Follicular lymphoma, CLL, and Lymphoma. In some embodiments, the CAR T-cell targets the CD22 antigen, and has a therapeutic effect on subjects with B-cell malignancies. In some embodiments, the CAR

T-cell targets alpha folate receptor or folate receptor alpha, and has a therapeutic effect on subjects with ovarian cancer or epithelial cancer. In some embodiments, the CAR T-cell targets CAIX or G250/CAIX, and has a therapeutic effect on subjects with renal cell carcinoma. In some embodiments, the CAR T-cell targets CD20, and has a therapeutic effect on subjects with  
5 Lymphomas, B-cell malignancies, B-cell lymphomas, Mantle cell lymphoma and, indolent B-cell lymphomas. In some embodiments, the CAR T-cell targets CD23, and has a therapeutic effect on subjects with CLL. In some embodiments, the CAR T-cell targets CD24, and has a therapeutic effect on subjects with pancreatic adenocarcinoma. In some embodiments, the CAR T-cell targets CD30, and has a therapeutic effect on subjects with Lymphomas or Hodgkin lymphoma. In some  
10 embodiments, the CAR T-cell targets CD33, and has a therapeutic effect on subjects with AML. In some embodiments, the CAR T-cell targets CD38, and has a therapeutic effect on subjects with Non-Hodgkin lymphoma. In some embodiments, the CAR T-cell targets CD44v6, and has a therapeutic effect on subjects with several malignancies. In some embodiments, the CAR T-cell targets CD44v7/8, and has a therapeutic effect on subjects with cervical carcinoma. In some embodiments,  
15 the CAR T-cell targets CD123, and has a therapeutic effect on subjects with myeloid malignancies. In some embodiments, the CAR T-cell targets CEA, and has a therapeutic effect on subjects with colorectal cancer. In some embodiments, the CAR T-cell targets EGFRvIII, and has a therapeutic effect on subjects with Glioblastoma. In some embodiments, the CAR T-cell targets EGP-2, and has a therapeutic effect on subjects with multiple malignancies. In some embodiments, the CAR T-cell  
20 targets EGP-40, and has a therapeutic effect on subjects with colorectal cancer. In some embodiments, the CAR T-cell targets EphA2, and has a therapeutic effect on subjects with Glioblastoma. In some embodiments, the CAR T-cell targets Erb-B2 or ErbB3/4, and has a therapeutic effect on subjects with Breast cancer and others, prostate cancer, colon cancer, various tumors. In some embodiments, the CAR T-cell targets Erb-B 2,3,4, and has a therapeutic effect on  
25 subjects with Breast cancer and others. In some embodiments, the CAR T-cell targets FBP, and has a therapeutic effect on subjects with Ovarian cancer. In some embodiments, the CAR T-cell targets fetal acetylcholine receptor, and has a therapeutic effect on subjects with Rhabdomyosarcoma. In some embodiments, the CAR T-cell targets G<sub>D2</sub>, and has a therapeutic effect on subjects with Neuroblastoma, melanoma, or Ewing's sarcoma. In some embodiments, the CAR T-cell targets G<sub>D3</sub>,  
30 and has a therapeutic effect on subjects with Melanoma. In some embodiments, the CAR T-cell targets HER2, and has a therapeutic effect on subjects with medulloblastoma, pancreatic adenocarcinoma, Glioblastoma, Osteosarcoma, or Ovarian cancer. In some embodiments, the CAR T-cell targets HMW-MAA, and has a therapeutic effect on subjects with Melanoma. In some

embodiments, the CAR T-cell targets IL-11Ralpha, and has a therapeutic effect on subjects with Osteosarcoma. In some embodiments, the CAR T-cell targets IL-13Ralpha1, and has a therapeutic effect on subjects with Glioma, Glioblastoma, or medulloblastoma. In some embodiments, the CAR T-cell targets IL-13 receptor alpha2, and has a therapeutic effect on subjects with several malignancies. In some embodiments, the CAR T-cell targets KDR, and has a therapeutic effect on subjects with tumors by targeting tumor neovasculature. In some embodiments, the CAR T-cell targets kappa-light chain, and has a therapeutic effect on subjects with B-cell malignancies (B-NHL, CLL). In some embodiments, the CAR T-cell targets Lewis Y, and has a therapeutic effect on subjects with various carcinomas or epithelial-derived tumors. In some embodiments, the CAR T-cell targets L1-cell adhesion molecule, and has a therapeutic effect on subjects with Neuroblastoma. In some embodiments, the CAR T-cell targets MAGE-A1 or HLA-A1 MAGE A1, and has a therapeutic effect on subjects with Melanoma. In some embodiments, the CAR T-cell targets mesothelin, and has a therapeutic effect on subjects with Mesothelioma. In some embodiments, the CAR T-cell targets CMV infected cells, and has a therapeutic effect on subjects with CMV. In some embodiments, the CAR T-cell targets MUC1, and has a therapeutic effect on subjects with breast or ovarian cancer. In some embodiments, the CAR T-cell targets MUC16, and has a therapeutic effect on subjects with ovarian cancer. In some embodiments, the CAR T-cell targets NKG2D ligands, and has a therapeutic effect on subjects with myeloma, ovarian, and other tumors. In some embodiments, the CAR T-cell targets NY-ESO-1 (157-165) or HLA-A2 NY-ESO-1, and has a therapeutic effect on subjects with multiple myeloma. In some embodiments, the CAR T-cell targets oncofetal antigen (h5T4), and has a therapeutic effect on subjects with various tumors. In some embodiments, the CAR T-cell targets PSCA, and has a therapeutic effect on subjects with prostate carcinoma. In some embodiments, the CAR T-cell targets PSMA, and has a therapeutic effect on subjects with prostate cancer/tumor vasculature. In some embodiments, the CAR T-cell targets ROR1, and has a therapeutic effect on subjects with B-CLL and mantle cell lymphoma. In some embodiments, the CAR T-cell targets TAG-72, and has a therapeutic effect on subjects with adenocarcinomas or gastrointestinal cancers. In some embodiments, the CAR T-cell targets VEGF-R2 or other VEGF receptors, and has a therapeutic effect on subjects with tumors by targeting tumor neovasculature. In some embodiments, the CAR T-cell targets CA9, and has a therapeutic effect on subjects with renal cell carcinoma. In some embodiments, the CAR T-cell targets CD171, and has a therapeutic effect on subjects with renal neuroblastoma. In some embodiments, the CAR T-cell targets NCAM, and has a therapeutic effect on subjects with neuroblastoma. In some embodiments, the CAR T-cell targets fetal acetylcholine receptor, and has a therapeutic effect on subjects with rhabdomyosarcoma. In some

embodiments, the CAR binds to one of the target antigens listed in Table 1 of Sadelain et al. (Cancer Discov. 2013 Apr; 3(4): 388–398), which is incorporated by reference herein in its entirety. In some embodiments, CAR T-cells bind to carbohydrate or glycolipid structures.

[00199] In some embodiments the CAR T-cells binds to an angiogenic factor, thereby targeting  
 5 tumor vasculature. In some embodiments, the angiogenic factor is VEGFR2. In some embodiments, the angiogenic factor is endoglin. In some embodiments, an angiogenic factor disclosed herein is Angiogenin; Angiopoietin-1; Del-1; Fibroblast growth factors: acidic (aFGF) and basic (bFGF); Follistatin; Granulocyte colony-stimulating factor (G-CSF); Hepatocyte growth factor (HGF)/scatter factor (SF); Interleukin-8 (IL-8); Leptin; Midkine; Placental growth factor; Platelet-derived  
 10 endothelial cell growth factor (PD-ECGF); Platelet-derived growth factor-BB (PDGF-BB); Pleiotrophin (PTN); Progranulin; Proliferin; Transforming growth factor-alpha (TGF-alpha); Transforming growth factor-beta (TGF-beta); Tumor necrosis factor-alpha (TNF-alpha); Vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF). In some embodiments, an angiogenic factor is an angiogenic protein. In some embodiments, a growth factor is an angiogenic  
 15 protein. In some embodiments, an angiogenic protein for use in the compositions and methods disclosed herein is Fibroblast growth factors (FGF); VEGF; VEGFR and Neuropilin 1 (NRP-1); Angiopoietin 1 (Ang1) and Tie2; Platelet-derived growth factor (PDGF; BB-homodimer) and PDGFR; Transforming growth factor-beta (TGF- $\beta$ ), endoglin and TGF- $\beta$  receptors; monocyte chemotactic protein-1 (MCP-1); Integrins  $\alpha$ V $\beta$ 3,  $\alpha$ V $\beta$ 5 and  $\alpha$ 5 $\beta$ 1; VE-cadherin and CD31; ephrin;  
 20 plasminogen activators; plasminogen activator inhibitor-1; Nitric oxide synthase (NOS) and COX-2; AC133; or Id1/Id3. In some embodiments, an angiogenic protein for use in the compositions and methods disclosed herein is an angiopoietin, which in some embodiments, is Angiopoietin 1, Angiopoietin 3, Angiopoietin 4 or Angiopoietin 6. In some embodiments, endoglin is also known as CD105; EDG; HHT1; ORW; or ORW1. In some embodiments, endoglin is a TGFbeta co-receptor.

25 [00200] In some embodiments, the CAR T-cells bind to an antigen associated with an infectious agent. In some embodiments, the infectious agent is *Mycobacterium tuberculosis*. In some embodiments, said *Mycobacterium tuberculosis* associated antigen is: Antigen 85B, Lipoprotein IpqH, ATP dependent helicase putative, uncharacterized protein Rv0476/MTO4941 precursor or uncharacterized protein Rv1334/MT1376 precursor.

30 [00201] In some embodiments, the CAR T-cells binds to an antibody. In some embodiments, the CAR T-cell is an “antibody-coupled T-cell receptor” (ACTR). According to this embodiment, the CAR T-cell is a universal CAR T-cell. In some embodiments, the CAR T-cell having an antibody receptor is administered before, after, or at the same time as the antibody is administered and then

binds to the antibody, bringing the T-cell in close proximity to the tumor or cancer. In some embodiments, the antibody is directed against a tumor cell antigen. In some embodiments, the antibody is directed against CD20. In some embodiments, the antibody is rituximab.

[00202] In some embodiments, the antibody is Trastuzumab (Herceptin; Genentech): humanized  
5 IgG1, which is directed against ERBB2. In some embodiments, the antibody is Bevacizumab (Avastin; Genentech/Roche): humanized IgG1, which is directed against VEGF. In some embodiments, the antibody is Cetuximab (Erbix; Bristol-Myers Squibb): chimeric human-murine IgG1, which is directed against EGFR. In some embodiments, the antibody is Panitumumab (Vectibix; Amgen): human IgG2, which is directed against EGFR. In some embodiments, the  
10 antibody is Ipilimumab (Yervoy; Bristol-Myers Squibb): IgG1, which is directed against CTLA4.

[00203] In some embodiments, the antibody is Alemtuzumab (Campath; Genzyme): humanized IgG1, which is directed against CD52. In some embodiments, the antibody is Ofatumumab (Arzerra; Genmab): human IgG1, which is directed against CD20. In some embodiments, the antibody is Gemtuzumab ozogamicin (Mylotarg; Wyeth): humanized IgG4, which is directed against CD33. In  
15 some embodiments, the antibody is Brentuximab vedotin (Adcetris; Seattle Genetics): chimeric IgG1, which is directed against CD30. In some embodiments, the antibody is 90Y-labelled ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals): murine IgG1, which is directed against CD20. In some embodiments, the antibody is 131I-labelled tositumomab (Bexxar; GlaxoSmithKline): murine IgG2, which is directed against CD20.

[00204] In some embodiments, the antibody is Ramucirumab, which is directed against vascular endothelial growth factor receptor-2 (VEGFR-2). In some embodiments, the antibody is ramucirumab (Cyramza Injection, Eli Lilly and Company), blinatumomab (BLINCYTO, Amgen Inc.), pembrolizumab (KEYTRUDA, Merck Sharp & Dohme Corp.), obinutuzumab (GAZYVA, Genentech, Inc.; previously known as GA101), pertuzumab injection (PERJETA, Genentech, Inc.),  
25 or denosumab (Xgeva, Amgen Inc.). In some embodiments, the antibody is Basiliximab (Simulect; Novartis). In some embodiments, the antibody is Daclizumab (Zenapax; Roche).

[00205] In some embodiments, the antibody to which the CAR T-cell is coupled is directed to a tumor or cancer antigen or a fragment thereof, that is described herein and/or that is known in the art. In some embodiments, the antibody to which the CAR T-cell is coupled is directed to a tumor-associated antigen. In some embodiments, the antibody to which the CAR T-cell is coupled is directed  
30 to a tumor-associated antigen or a fragment thereof that is an angiogenic factor.

[00206] In some embodiments, the antibody to which the CAR T-cell is coupled is directed to a tumor or cancer antigen or a fragment thereof, that is described herein and/or that is known in the art.



[00207] In some embodiments, antibodies described herein may be used in combination with compositions described herein, for example but not limited to a composition comprising CAR-T cells or early apoptotic cells, or any combination thereof.

[00208] *Pharmaceutical Compositions*

5 [00209] In some embodiments, disclosed herein is a pharmaceutical composition for treating, preventing, inhibiting the growth of, or reducing the incidence of a cancer or a tumor. In some embodiments, disclosed herein is a pharmaceutical composition for increasing the survival of a subject suffering from a cancer or a tumor. In some embodiments, disclosed herein is a pharmaceutical composition for reducing the size or reducing the growth rate of a tumor or a cancer.

10 [00210] In some embodiments, a pharmaceutical composition comprises an early apoptotic cell population as described herein. In some embodiments, a pharmaceutical composition comprises an early apoptotic cell population as described herein, and a pharmaceutically acceptable excipient.

[00211] As used herein, the terms “composition” and “pharmaceutical composition” may in some embodiments, be used interchangeably having all the same qualities and meanings. In some  
15 embodiments, disclosed herein is a pharmaceutical composition for the treatment of a condition or disease as described herein.

[00212] In some embodiments, pharmaceutical compositions disclosed here are for maintaining or increasing the proliferation rate of a genetically modified immune cells. In a further embodiment, methods for maintaining or increasing the proliferation rate of genetically modified immune cells  
20 further comprise reducing or inhibiting the incidence of cytokine release syndrome (CRS) or cytokine storm. In some embodiments, disclosed herein are pharmaceutical compositions for increasing the efficacy of a genetically modified immune cell therapy. In some embodiments, compositions used in the methods for increasing the efficacy of an immune cell therapy further comprise reducing or inhibiting the incidence of CRS or a cytokine storm. In some embodiments, disclosed herein are  
25 compositions for methods treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating a cancer of a tumor in a subject. In some embodiments, compositions used in the methods for treating, preventing, reducing the incidence of, ameliorating, or alleviating a cancer or a tumor in a subject, further comprise reducing or inhibiting the incidence of CRS or a cytokine storm.

[00213] In some embodiments, a genetically modified immune cell comprises a chimeric antigen  
30 receptor CAR T-cell. In some embodiments, a genetically modified immune cell comprises a cytotoxic T lymphocyte. In some embodiments, a genetically modified receptor comprises a genetically modified T-cell receptor.

[00214] In some embodiments, a pharmaceutical composition comprises an early apoptotic cell

population.

[00215] In some embodiments, a pharmaceutical composition for the treatment of a condition or a disease as described herein comprises an effective amount of a CAR T-cell as described herein in, and a pharmaceutically acceptable excipient. In some embodiments, a pharmaceutical composition  
5 for the treatment of a condition or a disease as described herein comprises an effective amount of a cytotoxic T-cell, as described herein, and a pharmaceutically acceptable excipient. In still another embodiment, a pharmaceutical composition for the treatment of a condition or a disease as described herein comprises an effective amount of an early apoptotic cell population, as described herein in a pharmaceutically acceptable excipient.

10 [00216] In some embodiments, the condition or disease as described herein is a tumor or cancer. In some embodiments, disclosed herein is a composition comprising the genetically modified immune cell or receptor thereof, for example a CAR T-cell, that binds to a protein or peptide of interest as described herein. In some embodiments, the protein or peptide of interest comprises a tumor antigen or a fragment thereof.

15 [00217] In some embodiments, a composition disclosed herein and used in methods disclosed herein comprises apoptotic cells, and a pharmaceutically acceptable excipient. In some embodiments, a composition comprising apoptotic cells is used in methods disclosed herein for example for treating, preventing, inhibiting the growth of, delaying disease progression, reducing the tumor load, or reducing the incidence of a cancer or a tumor in a subject, or any combination thereof.

20 [00218] In some embodiments, a composition comprising an effective amount of a CAR T-cell, or a TCR T-cell, may be the same composition as comprises an apoptotic cell population. In still another embodiment, a composition comprising an effective amount of a genetically modified immune cell, for example a CAR T-cell, is not the same composition as comprises an apoptotic cell population. In some embodiments, a composition comprises a chimeric antigen receptor-expressing T-cell (CAR  
25 T-cell) and apoptotic cells, and a pharmaceutically acceptable excipient.

[00219] In some embodiments, apoptotic cells comprised in a composition comprise apoptotic cells in an early apoptotic state. In some embodiments, apoptotic cells comprised in a composition are pooled third party donor cells.

[00220] In some embodiments, a composition comprising a genetically modified immune cells, for  
30 example a CAR T-cell, further comprises an additional pharmaceutical composition for preventing, suppressing, or modulating cytokine release in a patient with cytokine release syndrome or experiencing a cytokine storm. In some embodiments, a composition comprising a genetically modified immune cells, for example a CAR T-cell, and apoptotic cells further comprises an additional

pharmaceutical composition for preventing, suppressing, or modulating cytokine release in a patient with cytokine release syndrome or experiencing a cytokine storm.

[00221] In some embodiments, the additional pharmaceutical composition comprises a CTLA-4 blocking agent, which In some embodiments is Ipilimumab. In some embodiments, the additional pharmaceutical composition comprises an alpha-1 anti-trypsin, as disclosed herein, or a fragment thereof, or an analogue thereof. In some embodiments, the additional pharmaceutical composition comprises a tellurium-based compound, a disclosed herein. In some embodiments, the additional pharmaceutical composition comprises an immune modulating agent, as disclosed herein. In some embodiments, the additional pharmaceutical composition comprises a CTLA-4 blocking agent, an alpha-1 anti-trypsin or fragment thereof or analogue thereof, a tellurium-based compound, or an immune modulating compound, or any combination thereof.

[00222] In some embodiments, the composition comprising the genetically modified immune cell, for example a CAR T-cell and the pharmaceutical composition comprising any one of a CTLA-4 blocking agent, an alpha-1 anti-trypsin or fragment thereof or analogue thereof, apoptotic cells, a tellurium-based compound, or an immune modulating agent comprises a single composition. In some embodiments, the composition comprising the genetically modified immune cell, for example CAR T-cells and the pharmaceutical composition comprising any one of a CTLA-4 blocking agent, an alpha-1 anti-trypsin or fragment thereof or analogue thereof, apoptotic cells, a tellurium-based compound, or an immune modulating agent, or any combination thereof, comprises multiple compositions, wherein each of the genetically modified immune cell, which In some embodiments is CAR T-cells, the CTLA-4 blocking agent, the alpha-1 anti-trypsin or fragment thereof or analogue thereof, the apoptotic cells, the tellurium-based compound, or the immune modulating agent, or any combination thereof, are comprised in a separate composition. In some embodiments, the composition comprising the genetically modified immune cell, for example CAR T-cells and the pharmaceutical composition comprising any one of a CTLA-4 blocking agent, an alpha-1 anti-trypsin or fragment thereof or analogue thereof, apoptotic cells, a tellurium-based compound, or an immune modulating agent, or any combination thereof, comprises multiple compositions, wherein each of the genetically modified immune cell, which In some embodiments is CAR T-cells, the CTLA-4 blocking agent, the alpha-1 anti-trypsin or fragment thereof or analogue thereof, the apoptotic cells, the tellurium-based compound, or the immune modulating agent, or any combination thereof, are comprised in multiple compositions.

[00223] In some embodiments, a composition comprises apoptotic cells and an additional agent. In some embodiments, a composition comprises apoptotic cells and an antibody or a functional

fragment thereof. In some embodiments, a composition comprises apoptotic cells and an RtX antibody or a functional fragment thereof. In some embodiments, apoptotic cells and an antibody or a functional fragment thereof may be comprised in separate compositions. In some embodiments, apoptotic cells and an antibody or a functional fragment thereof may be comprised in the same composition.

[00224] A skilled artisan would appreciate that a "pharmaceutical composition" may encompass a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

[00225] In some embodiments, disclosed herein is a pharmaceutical composition for treating, preventing, inhibiting the growth of, or reducing the incidence of a cancer or a tumor. In some embodiments, disclosed herein is a pharmaceutical composition for increasing the survival of a subject suffering from a cancer or a tumor. In some embodiments, disclosed herein is a pharmaceutical composition for reducing the size or reducing the growth rate of a tumor or a cancer.

In some embodiments, disclosed herein is a pharmaceutical comprising for reducing tumor load in a subject suffering from a cancer or a tumor. In some embodiments, disclosed herein is a pharmaceutical comprising for delaying disease progression in a subject suffering from a cancer or a tumor. In some embodiments, disclosed herein is a pharmaceutical composition comprising for reducing the incidence of cancer or a tumor in a subject suffering from a cancer or a tumor. In some embodiments, disclosed herein is a pharmaceutical composition comprising for reducing the size and or growth rate of a cancer or tumor in a subject suffering from a cancer or a tumor.

[00226] A skilled artisan would appreciate that the phrases "physiologically acceptable carrier", "pharmaceutically acceptable carrier", "physiologically acceptable excipient", and "pharmaceutically acceptable excipient", may be used interchangeably may encompass a carrier, excipient, or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered active ingredient.

[00227] A skilled artisan would appreciate that an "excipient" may encompass an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. In some embodiments, excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.

[00228] Techniques for formulation and administration of drugs are found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.

[00229] In some embodiments, compositions are administered at the same time. In an alternative embodiment, compositions are administered at different times. In some embodiments, compositions comprising apoptotic cells are administered prior to infusion or genetically modified immune cells or receptors thereof. In some embodiments, compositions comprising apoptotic cells are administered prior to CAR- T-cell infusion.

[00230] In some embodiments, compositions are administered at the same time. In an alternative embodiment, compositions are administered at different times. In some embodiments, compositions comprising apoptotic cells are administered prior to administration of an antibody or fragment thereof, or a composition comprising an antibody or fragment thereof.

[00231] In some embodiments, compositions comprising apoptotic cells are administered about 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 36 hours, 48 hours, 60 hours, or 72 hours prior to an antibody or fragment thereof, or composition comprising the antibody or fragment thereof. In some embodiments, compositions comprising apoptotic cell supernatants are administered about 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 36 hours, 48 hours, 60 hours, or 72 hours prior to an antibody or fragment thereof, or composition comprising the antibody or fragment thereof.

[00232] In some embodiments, compositions comprising apoptotic cells are administered about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, or 15 days prior to an antibody or fragment thereof, or composition comprising the antibody or functional fragment thereof. In some embodiments, compositions comprising apoptotic cell supernatants are administered about 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, or 8 weeks prior to an antibody or functional fragment thereof, or composition comprising the antibody or functional fragment thereof.

[00233] In some embodiments, compositions comprising apoptotic cells are administered after infusion of an antibody or fragment thereof, or composition comprising the antibody or fragment thereof. In some embodiments, composition comprising apoptotic cells are administered after an antibody or fragment thereof, or composition comprising the antibody or fragment thereof. In some embodiments, compositions comprising apoptotic cell supernatants are administered after administration of an antibody or fragment thereof, or composition comprising the antibody or fragment thereof. In some embodiments, compositions comprising apoptotic cell supernatants are administered after administration of an antibody or fragment thereof, or composition comprising the antibody or fragment thereof. In some embodiments, compositions comprising apoptotic cells are

administered about 24 hours after an antibody or fragment thereof, or composition comprising the antibody or fragment thereof. In some embodiments, compositions comprising apoptotic cells are administered after administration of an antibody or fragment thereof, or composition comprising the antibody or fragment thereof. In some embodiments, compositions comprising apoptotic cells are administered about 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 36 hours, 48 hours, 60 hours, or 72 hours after administration of an antibody or fragment thereof, or composition comprising the antibody or fragment thereof. In some embodiments, compositions comprising apoptotic cell supernatants are administered about 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 36 hours, 48 hours, 60 hours, or 72 hours after administration of an antibody or fragment thereof, or composition comprising the antibody or fragment thereof.

[00234] In some embodiments, compositions comprising apoptotic cells are administered about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, or 15 days after an antibody or fragment thereof, or composition comprising the antibody or functional fragment thereof. In some embodiments, compositions comprising apoptotic cell supernatants are administered about 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, or 8 weeks after an antibody or functional fragment thereof, or composition comprising the antibody or functional fragment thereof.

[00235] In some embodiments, a composition comprising apoptotic cells is administered independent of CAR T-cells. In some embodiments, a composition comprising apoptotic cells is administered in combination with an additional agent. In some embodiments, the additional agent is an antibody.

[00236] In some embodiments, the composition as disclosed herein comprises a therapeutic composition. In some embodiments, the composition as disclosed herein comprises a therapeutic efficacy.

[00237] In some embodiments, a composition as disclosed herein is administered once. In some embodiments, the composition is administered twice. In some embodiments, the composition is administered three times. In some embodiments, the composition is administered four times. In some embodiments, the composition is administered at least four times. In some embodiments, the composition is administered more than four times.

[00238] In some embodiments, CAR T-cells as disclosed herein are administered once. In some embodiments, CAR T-cells are administered twice. In some embodiments, CAR T-cells are administered three times. In some embodiments, CAR T-cells are administered four times. In some

embodiments, CAR T-cells are administered at least four times. In some embodiments, the composition is administered more than four times.

[00239] In some embodiments, the composition as disclosed herein is a therapeutic composition. In some embodiments, the composition as disclosed herein has therapeutic efficacy.

5 [00240] In some embodiments, disclosed herein is a composition which provides reduced inflammatory cytokine or chemokine release compared to a composition comprising CAR T-cells alone, but with comparable cytotoxicity compared to a composition comprising CAR T-cells alone.

[00241] A skilled artisan would appreciate that the phrases "physiologically acceptable carrier", "pharmaceutically acceptable carrier", "physiologically acceptable excipient", and "pharmaceutically acceptable excipient", may be used interchangeably may encompass a carrier, excipient, or a diluent  
10 that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered active ingredient.

[00242] A skilled artisan would appreciate that an "excipient" may encompass an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. In  
15 some embodiments, excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.

[00243] Techniques for formulation and administration of drugs are found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.

20 [00244] In some embodiments, the composition as disclosed herein comprises a therapeutic composition. In some embodiments, the composition as disclosed herein comprises a therapeutic efficacy.

[00245] *Formulations*

[00246] Pharmaceutical compositions disclosed herein comprising early apoptotic cell  
25 populations, can be conveniently provided as sterile liquid preparations, e.g., isotonic aqueous solutions, suspensions, emulsions, dispersions, or viscous compositions, which may be buffered to a selected pH. Liquid preparations are normally easier to prepare than gels, other viscous compositions, and solid compositions. Additionally, liquid compositions are somewhat more convenient to administer, especially by injection. Viscous compositions, on the other hand, can be formulated  
30 within the appropriate viscosity range to provide longer contact periods with specific tissues. Liquid or viscous compositions can comprise carriers, which can be a solvent or dispersing medium containing, for example, water, saline, phosphate buffered saline, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like) and suitable mixtures thereof.

[00247] Sterile injectable solutions can be prepared by incorporating the early apoptotic cell population described herein and utilized in practicing the methods disclosed herein, in the required amount of the appropriate solvent with various amounts of the other ingredients, as desired. Such compositions may be in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose, dextrose, or the like. The compositions can also be lyophilized. The compositions can contain auxiliary substances such as wetting, dispersing, or emulsifying agents (e.g., methylcellulose), pH buffering agents, gelling or viscosity enhancing additives, preservatives, flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired. Standard texts, such as "REMINGTON'S PHARMACEUTICAL SCIENCE", 17th edition, 1985, incorporated herein by reference, may be consulted to prepare suitable preparations, without undue experimentation.

[00248] Various additives which enhance the stability and sterility of the compositions, including antimicrobial preservatives, antioxidants, chelating agents, and buffers, can be added. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin. According to the disclosure herein, however, any vehicle, diluent, or additive used would have to be compatible with the genetically modified immunoresponsive cells or their progenitors.

[00249] The compositions or formulations described herein can be isotonic, i.e., they can have the same osmotic pressure as blood and lacrimal fluid. The desired isotonicity of the compositions as disclosed herein may be accomplished using sodium chloride, or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol or other inorganic or organic solutes. Sodium chloride may be preferred particularly for buffers containing sodium ions.

[00250] Viscosity of the compositions, if desired, can be maintained at the selected level using a pharmaceutically acceptable thickening agent. Methylcellulose may be preferred because it is readily and economically available and is easy to work with.

[00251] Other suitable thickening agents include, for example, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, and the like. The preferred concentration of the thickener will depend upon the agent selected. The important point is to use an amount that will achieve the selected viscosity. Obviously, the choice of suitable carriers and other additives will depend on the exact route of administration and the nature of the particular dosage form, e.g., liquid dosage form (e.g., whether the composition is to be formulated into a solution, a suspension, gel or



another liquid form, such as a time release form or liquid-filled form).

[00252] Those skilled in the art will recognize that the components of the compositions or formulations should be selected to be chemically inert and will not affect the viability or efficacy of the early apoptotic cell populations as described herein, for use in the methods disclosed herein. This will present no problem to those skilled in chemical and pharmaceutical principles, or problems can be readily avoided by reference to standard texts or by simple experiments (not involving undue experimentation), from this disclosure and the documents cited herein.

[00253] The skilled artisan can readily determine the amount of cells and optional additives, vehicles, and/or carrier in compositions and to be administered in methods disclosed herein.

Typically, any additives (in addition to the active cell(s) and/or agent(s)) are present in an amount of 0.001 to 50% (weight) solution in phosphate buffered saline, and the active ingredient is present in the order of micrograms to milligrams, such as about 0.0001 to about 5 wt %. In some embodiments about 0.0001 to about 1 wt %. In still another embodiment, about 0.0001 to about 0.05 wt% or about 0.001 to about 20 wt %. In a further embodiment, about 0.01 to about 10 wt %. In some embodiments, about 0.05 to about 5 wt %. Of course, for any composition to be administered to an animal or human, and for any particular method of administration, it is preferred to determine therefore: toxicity, such as by determining the lethal dose (LD) and LD50 in a suitable animal model e.g., rodent such as mouse; and, the dosage of the composition(s), concentration of components therein and timing of administering the composition(s), which elicit a suitable response. Such determinations do not require undue experimentation from the knowledge of the skilled artisan, this disclosure and the documents cited herein. And, the time for sequential administrations can be ascertained without undue experimentation.

[00254] *Methods of Use*

[00255] In some embodiments, disclosed herein are methods for treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating a cancer or a tumor comprising the step of administering a composition as disclosed herein.

[00256] In some embodiments, disclosed herein are methods of treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating a cancer or a tumor in a subject comprising the step of administering a composition comprising apoptotic cells. In some embodiments, disclosed herein are methods of treating, preventing, inhibiting the growth of, delaying disease progression, reducing the tumor load, or reducing the incidence of a cancer or a tumor in a subject, or any combination thereof. In some embodiments, methods disclosed herein reduce the size and or growth rate of a tumor or cancer. In some embodiments, methods disclosed herein increase the survival of a

subject suffering from a tumor or cancer. In some embodiments, use of apoptotic cells or a composition thereof increases the efficacy of genetically modified immune cell therapy, for example but not limited to CAR T-cell therapy.

[00257] In another embodiment, disclosed herein are methods for treating, preventing, inhibiting, 5 reducing the incidence of, ameliorating, or alleviating a cancer or a tumor comprising the step of administering chimeric antigen receptor-expressing T-cells (CAR T-cells) and a composition comprising an additional agent, wherein said additional agent comprises apoptotic cells, a CTLA-4 blocking agent, an alpha-1 anti-trypsin or fragment or analog thereof, a tellurium-based compound, or an immune modulating agent, or any combination thereof, wherein said method treats, prevents, 10 inhibits, reduces the incidence of, ameliorates or alleviates a cancer or a tumor in said subject compared with a subject administered said genetically modified immune cells and not administered the additional agent.

[00258] In another embodiment, administration of apoptotic cells or compositions thereof does not 15 reduce the efficacy for treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating a cancer or a tumor, of said administering chimeric antigen receptor-expressing T-cells. In another embodiment, administration of an additional agent comprising apoptotic cells, a CTLA-4 blocking agent, an alpha-1 anti-trypsin or fragment or analog thereof, a tellurium-based compound, or an immune modulating agent, or any combination thereof, or compositions thereof does not reduce the efficacy for treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating 20 a cancer or a tumor, of said administering chimeric antigen receptor-expressing T-cells.

[00259] In another embodiment, administration of apoptotic cells or compositions thereof increases the efficacy for treating, preventing, inhibiting, reducing the incidence of, ameliorating, or 25 alleviating a cancer or a tumor, of said administering chimeric antigen receptor-expressing T-cells, for example a CAR T-cells. In another embodiment, administration of an additional agent comprising apoptotic cells, a supernatant from apoptotic cells, a CTLA-4 blocking agent, an alpha-1 anti-trypsin or fragment or analog thereof, a tellurium-based compound, or an immune modulating agent, or any combination thereof, or compositions thereof increases the efficacy for treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating a cancer or a tumor, of said administering chimeric antigen receptor-expressing T-cells.

30 [00260] In some embodiments, methods increasing the efficacy of a genetically modified immune cell cancer therapy, for example a CAR T-cell therapy, comprise administering said genetically modified immune cells and an additional agent comprising apoptotic cells, a supernatant from apoptotic cells, a CTLA-4 blocking agent, an alpha-1 anti-trypsin or fragment or analog thereof, a

tellurium-based compound, or an immune modulating agent, or any combination thereof, or compositions thereof, wherein the efficacy is increased compared with a subject not administered said additional agent. In another embodiment said genetically modified immune cells are T-cells. In another embodiment, a T-cell is a naïve T-cell. In another embodiment, a T-cell is a naïve CD4<sup>+</sup> T-cell. In another embodiment, a T-cell is a naïve T-cell. In another embodiment, a T-cell is a naïve CD8<sup>+</sup> T-cell. In another embodiment, the genetically modified immune cell is a natural killer (NK) cell. In another embodiment, the genetically modified immune cell is a dendritic cell. In still another embodiment, the genetically modified T-cell is a cytotoxic T lymphocyte (CTL cell). In another embodiment, the genetically modified T-cell is a regulatory T-cell (Treg). In another embodiment, the genetically modified T-cell is a chimeric antigen receptor (CAR) T-cell. In another embodiment, the genetically modified T-cell is a genetically modified T-cell receptor cell (TCR T-cell). In another embodiment, methods increasing the efficacy of a CAR T-cell cancer therapy comprise administering said genetically modified immune cells and an additional agent comprising apoptotic cells, a CTLA-4 blocking agent, an alpha-1 anti-trypsin or fragment or analog thereof, a tellurium-based compound, or an immune modulating agent, or any combination thereof, or compositions thereof, wherein the efficacy is increased compared with a subject not administered said additional agent.

[00261] In another embodiment, methods herein reduce the level of production of at least one pro-inflammatory cytokine compared with the level of said pro-inflammatory cytokine in a subject receiving an immune cancer therapy and not administered an additional agent. In another embodiment, methods herein inhibit or reduce the incidence of cytokine release syndrome or cytokine storm in a subject undergoing a genetically modified immune cell cancer therapy and not administered an additional agent.

[00262] In another embodiment, methods disclosed herein reduce IL-6.

[00263] In another embodiment, methods herein increase the production of at least one cytokine compared with the level of said cytokine in a subject receiving an immune cancer therapy and not administered an additional agent. In some embodiments, the additional agent is apoptotic cells. In other embodiment, the additional agent is an apoptotic cell supernatant. In another embodiment, methods disclosed herein increase IL-2.

[00264] A skilled artisan would appreciate that the term “production” as used herein in reference to a cytokine, may encompass expression of the cytokine as well as secretion of the cytokine from a cell. In some embodiments, increased production of a cytokine results in increased secretion of the cytokine from the cell. In an alternate embodiment, decreased production of a cytokine results in decreased secretion of the cytokine from the cell. In another embodiment, methods disclosed herein

decrease secretion of at least one cytokine. In another embodiment, methods disclosed herein decrease secretion of IL-6. In another embodiment, methods disclosed herein increase secretion of at least one cytokine. In another embodiment, methods disclosed herein increase secretion of IL-2.

[00265] In another embodiment, a cell secreting at least one cytokine is a tumor cell. In another  
5 embodiment, a cell secreting at least one cytokine is a T-cell. In another embodiment, a cell secreting  
at least one cytokine is an immune cell. In another embodiment, a cell secreting at least one cytokine  
is a macrophage. In another embodiment, a cell secreting at least one cytokine is a B cell lymphocyte.  
In another embodiment, a cell secreting at least one cytokine is a mast cell. In another embodiment,  
a cell secreting at least one cytokine is an endothelial cell. In another embodiment, a cell secreting at  
10 least one cytokine is a fibroblast. In another embodiment, a cell secreting at least one cytokine is a  
stromal cell. A skilled artisan would recognize that the level of cytokines may be increased or  
decreased in cytokine secreting cells depending on the environment surrounding the cell.

[00266] In yet another embodiment, an additional agent used in the methods disclosed herein  
increases secretion of at least one cytokine. In yet another embodiment, an additional agent used in  
15 the methods disclosed herein maintains secretion of at least one cytokine. In still another  
embodiment, an additional agent used in the methods disclosed herein does not decrease secretion of  
at least one cytokine. In another embodiment, an additional agent used in the methods disclosed  
herein increases secretion of IL-2. In another embodiment, an additional agent used in the methods  
disclosed herein increases secretion of IL-2R. In another embodiment, an additional agent used in  
20 the methods disclosed herein maintains secretion levels of IL-2. In another embodiment, an additional  
agent used in the methods disclosed herein maintains secretion levels of IL-2R. In another  
embodiment, an additional agent used in the methods disclosed herein does not decrease secretion  
levels of IL-2R. In another embodiment, an additional agent used in the methods disclosed herein  
maintains or increases secretion levels of IL-2. In another embodiment, an additional agent used in  
25 the methods disclosed herein maintains or increases secretion levels of IL-2R. In another  
embodiment, an additional agent used in the methods disclosed herein does not decrease secretion  
levels of IL-2R.

[00267] In still a further embodiment, an additional agent used in the methods disclosed herein  
decreases secretion of IL-6. In another embodiment, an additional agent used in the methods  
30 disclosed herein maintains, increases, or does not decrease secretion levels of IL-2 while decreasing  
secretion of IL-6. In another embodiment, an additional agent used in the methods disclosed herein  
maintains, increases, or does not decrease secretion levels of IL-2R while decreasing secretion of IL-  
6.

[00268] In some embodiments, methods of increasing the efficacy of a CAR T-cell cancer therapy disclosed herein comprises decreasing the level of IL-6 in said subject, said method comprising administering CAR T-cells and an additional agent comprising apoptotic cells, a CTLA-4 blocking agent, an alpha-1 anti-trypsin or fragment or analog thereof, a tellurium-based compound, or an immune modulating agent, or any combination thereof, or compositions thereof, wherein the efficacy is increased compared with a subject not administered said additional agent. In another embodiment, methods of increasing the efficacy of a CAR T-cell cancer therapy disclosed herein comprises increasing the level of IL-2 in said subject, said method comprising administering CAR T-cells and an additional agent comprising apoptotic cells, a CTLA-4 blocking agent, an alpha-1 anti-trypsin or fragment or analog thereof, a tellurium-based compound, or an immune modulating agent, or any combination thereof, or compositions thereof, wherein the efficacy is increased compared with a subject not administered said additional agent. In another embodiment, methods of increasing the efficacy of a CAR T-cell cancer therapy disclosed herein comprises increasing proliferation of said CAR T-cells, said method comprising administering CAR T-cells and an additional agent comprising apoptotic cells, a CTLA-4 blocking agent, an alpha-1 anti-trypsin or fragment or analog thereof, a tellurium-based compound, or an immune modulating agent, or any combination thereof, or compositions thereof, wherein the efficacy and proliferation of said CAR T-cells is increased compared with a subject not administered said additional agent.

[00269] In some embodiments, methods of increasing the efficacy of CAR T-cell cancer therapy, decrease or inhibit cytokine production in the subject, said methods comprising the step of administering a composition comprising CAR T-cells and a CTLA-4 blocking agent, an alpha-1 anti-trypsin or fragment or analog thereof, a tellurium-based compound, or an immune modulating agent, or any combination thereof, or compositions thereof. In another embodiment, methods of treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating a cancer or tumor also decrease or inhibit cytokine production in the subject, said methods comprising the step of administering a composition comprising CAR T-cells and a CTLA-4 blocking agent, an alpha-1 anti-trypsin or fragment or analog thereof, a tellurium-based compound, or an immune modulating agent, or any combination thereof, or compositions thereof.

[00270] In another embodiment, disclosed herein are methods of treating cytokine release syndrome or cytokine storm in a subject undergoing CAR T-cell cancer therapy.

[00271] In another embodiment, methods of treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating a cancer or tumor, decrease or inhibit cytokine production in a subject, said methods comprising the step of administering a composition comprising CAR T-

cells and a CTLA-4 blocking agent, an alpha-1 anti-trypsin or fragment or analog thereof, a tellurium-based compound, or an immune modulating agent, or any combination thereof, or compositions thereof.

[00272] In another embodiment, disclosed herein is a method of treating a cancer or a tumor in a subject, said method comprising the step of administering to said subject any of the compositions as described herein. In another embodiment, disclosed herein is a method of preventing a cancer or a tumor in a subject, said method comprising the step of administering to said subject any of the compositions as described herein. In another embodiment, disclosed herein is a method of inhibiting a cancer or a tumor in a subject, said method comprising the step of administering to said subject any of the compositions as described herein. In another embodiment, disclosed herein is a method of reducing a cancer or a tumor in a subject, said method comprising the step of administering to said subject any of the compositions as described herein. In another embodiment, disclosed herein is a method of ameliorating a cancer or a tumor in a subject, said method comprising the step of administering to said subject any of the compositions as described herein. In another embodiment, disclosed herein is a method of alleviating a cancer or a tumor in a subject, said method comprising the step of administering to said subject any of the compositions as described herein.

[00273] In some embodiments, disclosed herein are methods of maintaining or increasing the proliferation rate of a genetically modified immune cell during an immunotherapy, the method comprising the step of administering a composition comprising apoptotic cells during the immunotherapy. In another embodiment, said genetically modified immune cells comprise a T-cell, a naïve T-cell, a naïve CD4+ T-cell, a naïve CD8+ T-cell, a natural killer (NK) cell, a dendritic cell, a cytotoxic T lymphocyte (CTL cell), a regulatory T-cell (Treg), a chimeric antigen receptor (CAR) T-cell, or a genetically modified T-cell receptor (TCR) cell. In another embodiment, disclosed herein are methods of maintaining or increasing the proliferation rate of a CAR T-cell during an immunotherapy, the method comprising the step of administering a composition comprising apoptotic cells during the immunotherapy.

[00274] In another embodiment, methods of maintaining or increasing the proliferation rate of the genetically modified immune cells does not reduce or inhibit the efficacy of the immunotherapy. For example, in another embodiment, methods of maintaining or increasing the proliferation rate of CAR T-cells does not reduce or inhibit the efficacy of the CAR T-cell cancer therapy. In another embodiment, methods of maintaining or increasing the proliferation rate of the genetically modified immune cells, for example CAR T-cells, decrease or inhibit cytokine production in the subject.

[00275] In another embodiment, compositions and methods as disclosed herein utilize combination

therapy with apoptotic cells as disclosed herein, and one or more CTLA-4-blocking agents such as Ipilimumab. In some embodiments, CTLA-4 is a potent inhibitor of T-cell activation that helps to maintain self-tolerance. In some embodiments, administration of an anti-CTLA-4 blocking agent, which in another embodiment, is an antibody, produces a net effect of T-cell activation. In another  
5 embodiment, compositions and methods as disclosed herein utilize combined therapy comprising apoptotic cells, CAR T-cells, and one or more CTLA-4-blocking agents.

[00276] In some cases, a polypeptide of and for use in the methods as disclosed herein comprises at least one conservative amino acid substitution relative to an unmodified amino acid sequence. In other cases, the polypeptide comprises a non-conservative amino acid substitution. In such cases,  
10 polypeptides having such modifications exhibit increased stability or a longer half-life relative to a polypeptide lacking such an amino acid substitution.

[00277] In some embodiment, "treating" comprises therapeutic treatment and "preventing" comprises prophylactic or preventative measures, wherein the object is to prevent or lessen the targeted pathologic condition or disorder as described hereinabove. Thus, in some embodiments,  
15 treating may include directly affecting or curing, suppressing, inhibiting, preventing, reducing the severity of, delaying the onset of, reducing symptoms associated with the disease, disorder or condition, or a combination thereof. Thus, in some embodiments, "treating," "ameliorating," and "alleviating" refer inter alia to delaying progression, expediting remission, inducing remission, augmenting remission, speeding recovery, increasing efficacy of or decreasing resistance to  
20 alternative therapeutics, or a combination thereof. In some embodiments, "preventing" refers, inter alia, to delaying the onset of symptoms, preventing relapse to a disease, decreasing the number or frequency of relapse episodes, increasing latency between symptomatic episodes, or a combination thereof. In some embodiments, "suppressing" or "inhibiting", refers inter alia to reducing the severity of symptoms, reducing the severity of an acute episode, reducing the number of symptoms, reducing  
25 the incidence of disease-related symptoms, reducing the latency of symptoms, ameliorating symptoms, reducing secondary symptoms, reducing secondary infections, prolonging patient survival, or a combination thereof.

[00278] A skilled artisan would appreciate that the term "antigen recognizing receptor" may encompass a receptor that is capable of activating an immune cell (e.g., a T-cell) in response to  
30 antigen binding. Exemplary antigen recognizing receptors may be native or endogenous T-cell receptors or chimeric antigen receptors in which a tumor antigen-binding domain is fused to an intracellular signaling domain capable of activating an immune cell (e.g., a T-cell).

[00279] In some embodiments, methods described herein increase the survival of a subject

suffering from a cancer or a tumor, and comprise administering an early apoptotic cell population to said subject, wherein the method increases the survival of the subject.

[00280] A skilled artisan would appreciate that the term "disease" may encompass any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ. Examples of diseases include neoplasia or pathogen infection of cell.

[00281] A skilled artisan would appreciate that the term "effective amount" may encompass an amount sufficient to have a therapeutic effect. In some embodiments, an "effective amount" is an amount sufficient to arrest, ameliorate, or inhibit the continued proliferation, growth, or metastasis (e.g., invasion, or migration) of a neoplasia.

[00282] A skilled artisan would appreciate that the term "neoplasia" may encompass a disease characterized by the pathological proliferation of a cell or tissue and its subsequent migration to or invasion of other tissues or organs. Neoplasia growth is typically uncontrolled and progressive, and occurs under conditions that would not elicit, or would cause cessation of, multiplication of normal cells. Neoplasias can affect a variety of cell types, tissues, or organs, including but not limited to an organ selected from the group consisting of bladder, bone, brain, breast, cartilage, glia, esophagus, fallopian tube, gallbladder, heart, intestines, kidney, liver, lung, lymph node, nervous tissue, ovaries, pancreas, prostate, skeletal muscle, skin, spinal cord, spleen, stomach, testes, thymus, thyroid, trachea, urogenital tract, ureter, urethra, uterus, and vagina, or a tissue or cell type thereof. Neoplasias include cancers, such as sarcomas, carcinomas, or plasmacytomas (malignant tumor of the plasma cells).

[00283] A skilled artisan would appreciate that the term "pathogen" may encompass a virus, bacteria, fungi, parasite or protozoa capable of causing disease.

[00284] A skilled artisan would appreciate that the term "tumor antigen" or "tumor associated antigen" may encompass an antigen (e.g., a polypeptide) that is uniquely or differentially expressed on a tumor cell compared to a normal or non- IS neoplastic cell. With reference to the compositions and methods disclosed herein, a tumor antigen includes any polypeptide expressed by a tumor that is capable of activating or inducing an immune response via an antigen recognizing receptor (e.g., CD 19, MUCI) or capable of suppressing an immune response via receptor-ligand binding (e.g., CD47, PD-L1/L2, B7.1/2).

[00285] A skilled artisan would appreciate that the term "virus antigen" may encompass a polypeptide expressed by a virus that is capable of inducing an immune response.

[00286] The terms "comprises", "comprising", and are intended to have the broad meaning ascribed to them in U.S. Patent Law and can mean "includes", "including" and the like. Similarly, the



term “consists of” and “consists essentially of” have the meanings ascribed to them in U.S. Patent Law. The compositions and methods as disclosed herein are envisioned to either comprise the active ingredient or specified step, consist of the active ingredient or specified step, or consist essentially of the active ingredient or specified step.

5 [00287] A skilled artisan would appreciate that the term "treatment" may encompass clinical intervention in an attempt to alter the disease course of the individual or cell being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Therapeutic effects of treatment include, without limitation, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease,  
10 preventing metastases, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. By preventing progression of a disease or disorder, a treatment can prevent deterioration due to a disorder in an affected or diagnosed subject or a subject suspected of having the disorder, but also a treatment may prevent the onset of the disorder or a symptom of the disorder in a subject at risk for the disorder or suspected of having the  
15 disorder.

[00288] A skilled artisan would appreciate that the term "subject" may encompass a vertebrate, in some embodiments, to a mammal, and in some embodiments, to a human. Subject may also refer, in some embodiments, to domesticated such as cows, sheep, horses, cats, dogs and laboratory animals such as mice, rats, gerbils, hamsters, etc.

20 [00289] In some embodiments, disclosed herein are CAR T-cells in which the CAR is directed to a peptide of interest. In some embodiments, the CAR binds to a peptide of interest. In another embodiment, the CAR targets a peptide of interest. In another embodiment, the CAR activates a peptide of interest. In another embodiment, the CAR is a ligand of the peptide of interest. In another embodiment, the peptide of interest is a ligand of the CAR. Each of these embodiments is to be  
25 considered part disclosed herein.

[00290] One approach to immunotherapy involves engineering a patient's own immune cells to create genetically modified immune cells that will recognize and attack their tumor. Immune cells are collected and genetically modified, as described herein, for example to produce chimeric antigen receptors (CAR) on their cell surface that will allow the immune cell, for example a T-cell, to  
30 recognize a specific protein antigen on a tumor or cancer cell. An expanded population of genetically modified immune cells, for example CAR T-cells, is then administered to the patient. In some embodiments, the administered cells multiply in the patient's body and recognize and kill cancer and tumor cells that harbor the antigen on their surface. In another embodiment, the administered cells

multiply in a patient's body and recognize and kill tumor-associated antigens, which leads to the death of cancer and tumor cells.

[00291] In some embodiments, an IL-6 receptor antagonist, which in some embodiments is tocilizumab is used with the compositions and methods as disclosed herein.

5 [00292] In some embodiments, adoptively transferred T-cells engraft and expand more efficiently in a lymphopenic host. Thus, in some embodiments, the subject is subjected to lymphodepletion prior to transfer of CAR T-cells or other modified immune cells. In another embodiment, the subject receiving the CAR T-cells is given T-cell-supportive cytokines.

[00293] In some embodiments, the T-cells are effector T-cells. In another embodiment, the T-cells are naïve T-cells. In another embodiment, the T-cells are central memory (T<sub>CM</sub>) T-cells. In another embodiment, the T-cells are Th17 cells. In another embodiment, the T-cells are T stem memory cells. In another embodiment, the T-cells have high replicative capacity. In another embodiment, T-cell expansion occurs in the patient. In another embodiment, small numbers of cells may be transferred to a patient. In another embodiment, T-cell expansion occurs *in vitro*. In another embodiment, large numbers of cells may be transferred to a patient, cells and/or supernatants may be transferred to a patient on multiple occasions, or a combination thereof.

[00294] In some embodiments, an advantage of CAR T-cells is that because they are specific for cell-surface molecules, they overcome the constraints of MHC-restricted TCR recognition and avoid tumor escape through impairments in antigen presentation or human leukocyte antigen expression.

20 [00295] In some embodiments, disclosed herein is a method of reducing a tumor burden in a subject, said method comprising the step of administering to said subject any of the compositions as described herein.

[00296] In some embodiments, reducing the tumor burden comprises reducing the number of tumor cells in the subject. In another embodiment, reducing the tumor burden comprises reducing tumor size in the subject. In another embodiment, reducing the tumor burden comprises eradicating the tumor in the subject.

[00297] In another embodiment, disclosed herein is a method of inducing tumor cell death in a subject, said method comprising the step of administering to said subject any of the compositions as described herein. In another embodiment, a method as disclosed herein for inducing tumor cell death in a subject comprises administering immune cells, such as NK cells or T-cells comprising engineered chimeric antigen receptors with at least an additional agent to decrease toxic cytokine release or "cytokine release syndrome" (CRS) or "severe cytokine release syndrome" (sCRS) or "cytokine storm" in the subject.

[00298] In another embodiment, disclosed herein is a method of increasing, extending, or lengthening the survival of a subject having neoplasia, comprising the step of administering to said subject any of the compositions as described herein. In another embodiment, a method of increasing or lengthening the survival of a subject comprises administering immune cells, such as NK cells or  
5 T-cells comprising engineered chimeric antigen receptors with at least an additional agent to decrease toxic cytokine release or "cytokine release syndrome" (CRS) or "severe cytokine release syndrome" (sCRS) or "cytokine storm" in the subject.

[00299] In another embodiment, disclosed herein is a method of increasing, extending, or lengthening the survival of a subject having neoplasia, comprising the step of administering to said  
10 subject any of the compositions as described herein.

[00300] In some embodiments, disclosed herein is a method of delaying cancer progression in a subject, comprising a step of administering to the subject any of the compositions or combinations of compositions described herein. In some embodiments, disclosed herein is a method of delaying progression of a leukemia or lymphoma in a subject, comprising a step of administering to the subject  
15 any of the compositions or combinations of compositions described herein. In some embodiments, disclosed herein is a method of increasing, extending, or prolonging the survival of a subject suffering from a cancer or a tumor, comprising a step of administering to the subject any of the compositions or combinations of compositions described herein. In some embodiments, disclosed herein is a method of increasing, extending, or prolonging the survival of a subject suffering from a leukemia or  
20 lymphoma, comprising administering to the subject any of the compositions or combinations of compositions described herein. In some embodiments, disclosed herein is a method of reducing the tumor cell burden in a subject, comprising administering to the subject any of the compositions or combinations of compositions described herein. In some embodiments, tumor burden is reduced the liver and bone marrow.

[00301] In another embodiment, disclosed herein is a method of preventing neoplasia in a subject, said method comprising the step of administering to the subject any of the compositions or combinations of compositions described herein. In some embodiments, the neoplasia is selected from the group consisting of blood cancer, B cell leukemia, multiple myeloma, lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, non-Hodgkin's lymphoma, ovarian cancer, or a combination  
30 thereof.

[00302] In another embodiment, disclosed herein is a method of treating blood cancer in a subject in need thereof, comprising the step of administering to said subject any of the compositions as described herein. In some embodiments, the blood cancer is selected from the group consisting of B

cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, and non-Hodgkin's lymphoma.

[00303] In another embodiment, disclosed herein is a method of treating a solid tumor in a subject in need thereof, comprising the step of administering to said subject any of the compositions as described herein. In some embodiments, the solid tumor is selected from the group comprising any tumor of cellular or organ origin including a tumor of unknown origin; any peritoneal tumor either primary or metastatic; a tumor of gynecological origin or gastrointestinal origin or pancreatic origin or blood vessel origin, any solid tumor, i.e. adenocarcinoma, hematological solid tumor, melanoma etc. In some embodiments, a solid tumor comprises a sarcoma or a carcinoma, a fibrosarcoma, a myxosarcoma, a liposarcoma, a chondrosarcoma, an osteogenic sarcoma, a chordoma, an angiosarcoma, an endotheliosarcoma, a lymphangiosarcoma, a lymphangioendotheliosarcoma, a synovioma, a mesothelioma, an Ewing's tumor, a leiomyosarcoma, a rhabdomyosarcoma, a colon carcinoma, a pancreatic cancer or tumor, a breast cancer or tumor, an ovarian cancer or tumor, a prostate cancer or tumor, a squamous cell carcinoma, a basal cell carcinoma, an adenocarcinoma, a sweat gland carcinoma, a sebaceous gland carcinoma, a papillary carcinoma, a papillary adenocarcinomas, a cystadenocarcinoma, a medullary carcinoma, a bronchogenic carcinoma, a renal cell carcinoma, a hepatoma, a bile duct carcinoma, a choriocarcinoma, a seminoma, an embryonal carcinoma, a Wilms' tumor, a cervical cancer or tumor, a uterine cancer or tumor, a testicular cancer or tumor, a lung carcinoma, a small cell lung carcinoma, a bladder carcinoma, an epithelial carcinoma, a glioma, an astrocytoma, a medulloblastoma, a craniopharyngioma, an ependymoma, a pinealoma, a hemangioblastoma, an acoustic neuroma, an oligodendroglioma, a schwannoma, a meningioma, a melanoma, a neuroblastoma, or a retinoblastoma. In another related aspect, the tumor or cancer comprises a metastasis of a tumor or cancer.

[00304] In some embodiments, administration comprises administering a composition comprising CAR T-cells. In some embodiments, administration comprises administering a composition comprising early apoptotic cells. In some embodiments, administration comprises administering a composition comprising a supernatant obtained from early apoptotic cells. In some embodiments, administration comprises administering a combination of compositions described herein. In some embodiments, administration comprises administering CAR T-cells and apoptotic cells in the same or different compositions. In some embodiments, administration comprises administering CAR T-cells in combination with an additional agent as described herein. In some embodiments, administration comprises administering apoptotic cells and an antibody or fragment thereof in the same or different compositions.

[00305] In some embodiments, combination therapy provides a synergistic effect. In some embodiments, methods of use an early apoptotic cells in combination with CAR T-cells increases CAR T-cell efficacy in comparison to use of CAR T-cells alone. In some embodiments, methods of use an early apoptotic cells in combination with CAR T-cells extends the survival time of a subject suffering from a cancer or tumor in comparison to use of CAR T-cells alone. In some embodiments, methods of use an early apoptotic cells in combination with CAR T-cells extends the survival time of a subject suffering from a lymphoma or leukemia in comparison to use of CAR T-cells alone.

[00306] In some embodiments, methods of use an early apoptotic cells in combination with an antibody or fragment thereof delays the onset of cancer or the appearance of a tumor, in comparison to use of either apoptotic cells or the antibody alone. In some embodiments, methods of use an early apoptotic cells in combination with an antibody or fragment thereof delays the progression of a cancer, in comparison to use of either apoptotic cells or the antibody alone. In some embodiments, methods of use an early apoptotic cells in combination with an antibody or fragment thereof delays the growth of a tumor, in comparison to use of either apoptotic cells or the antibody alone. In some embodiments, methods of use an early apoptotic cells in combination with an antibody or fragment thereof extends the survival time of a subject suffering from a cancer or tumor in comparison to use of either apoptotic cells or the antibody alone. In some embodiments, methods of use an early apoptotic cells in combination with an antibody or fragment thereof extends the survival time of a subject suffering from a lymphoma or leukemia in comparison to use of either apoptotic cells or the antibody alone.

[00307] In some embodiments, methods of use comprising administration of an early apoptotic cells in combination with an antibody or fragment thereof comprising RtX, delays the onset of cancer or the appearance of a tumor, in comparison to use of either apoptotic cells or the antibody alone. In some embodiments, methods of use an early apoptotic cells in combination with an antibody or fragment thereof comprising RtX, delays the progression of a cancer, in comparison to use of either apoptotic cells or the antibody alone. In some embodiments, methods of use an early apoptotic cells in combination with an antibody or fragment thereof comprising RtX, delays the growth of a tumor, in comparison to use of either apoptotic cells or the antibody alone. In some embodiments, methods of use an early apoptotic cells in combination with an antibody or fragment thereof comprising RtX, extends the survival time of a subject suffering from a cancer or tumor in comparison to use of either apoptotic cells or the antibody alone. In some embodiments, methods of use an early apoptotic cells in combination with an antibody or fragment thereof comprising RtX, extends the survival time of a subject suffering from a lymphoma or leukemia in comparison to use of either apoptotic cells or the

antibody alone.

[00308] In some embodiments, methods of use described herein reduce tumor load. A skilled artisan would appreciate that the term "tumor load" may refer to the number of cancer cells, the size of a tumor, or the amount of cancer in the body. The term "tumor load" may be used interchangeably with the term "tumor burden" having all the same meanings and qualities. In some embodiments, methods of use comprising administration of an early apoptotic cells reduces the number of cancer cells in a subject, reduces the size of a tumor in a subject, or reduces the amount of cancer in the body of a subject, or any combination thereof compared with a subject not administered apoptotic cells. In some embodiments, methods of use comprising administration of an early apoptotic cells in combination with an antibody or fragment thereof reduces the number of cancer cells in a subject, reduces the size of a tumor in a subject, or reduces the amount of cancer in the body of a subject, or any combination thereof, compared with a subject not administered apoptotic cells or not administer the antibody, or the combination thereof In some embodiments, methods of use comprising administration of an early apoptotic cells in combination with a RtX antibody or fragment thereof reduces the number of cancer cells in a subject, reduces the size of a tumor in a subject, or reduces the amount of cancer in the body of a subject, or any combination thereof, compared with a subject not administered apoptotic cells, the RtX antibody, or the combination thereof.

[00309] In some embodiments, a method of decreasing or inhibiting cytokine production in a subject experiencing cytokine release syndrome or cytokine storm or vulnerable to a cytokine release syndrome or cytokine storm, as disclosed herein, decreases or inhibits cytokine production. In another embodiment, the method decreases or inhibits pro-inflammatory cytokine production. In a further embodiment, the method decreases or inhibits at least one pro-inflammatory cytokine. In another embodiment, wherein the subject is undergoing CAR T-cell cancer therapy, the method does not reduce the efficacy of the CAR T-cell therapy.

[00310] For treatment, the amount administered is an amount effective in producing the desired effect. An effective amount can be provided in one or a series of administrations. An effective amount can be provided in a bolus or by continuous perfusion.

[00311] A skilled artisan would recognize that an "effective amount" (or, "therapeutically effective amount") may encompass an amount sufficient to effect a beneficial or desired clinical result upon treatment. An effective amount can be administered to a subject in one or more doses. In terms of treatment, an effective amount is an amount that is sufficient to palliate, ameliorate, stabilize, reverse or slow the progression of the disease, or otherwise reduce the pathological consequences of the disease. The effective amount is generally determined by the physician on a case-by-case basis and

is within the skill of one in the art. Several factors are typically taken into account when determining an appropriate dosage to achieve an effective amount. These factors include age, sex and weight of the subject, the condition being treated, the severity of the condition and the form and effective concentration of the antigen-binding fragment administered.

5 [00312] In some embodiments, methods disclosed herein comprise administering a composition comprising a genetically modified cell, and the additional agent or combination thereof, comprised in a single composition. In another embodiment, methods comprise administering a composition comprising a CAR T-cell, and the additional agent or combination thereof, comprised in a single composition. In another embodiment, methods comprise administering a composition comprising a  
10 TCR T-cell, and the additional agent or combination thereof, comprised in a single composition.

[00313] In some embodiments, methods disclosed herein comprise administering a composition comprising a genetically modified cell, and the additional agent or combination thereof, comprised in a at least two compositions. In another embodiment, methods comprise administering a composition comprising a CAR T-cell, and the additional agent or combination thereof, comprised  
15 in at least two compositions. In another embodiment, methods comprise administering a composition comprising a TCR T-cell, and the additional agent or combination thereof, comprised in at least two compositions.

[00314] For adoptive immunotherapy using antigen-specific T-cells, for example CAR T-cells, cell doses in the range of  $10^6$ - $10^{10}$  (e.g.,  $10^9$ ) are typically infused. Upon administration of the genetically  
20 modified cells into the host and subsequent differentiation, T-cells are induced that are specifically directed against the specific antigen. "Induction" of T-cells may include inactivation of antigen-specific T-cells such as by deletion or anergy. Inactivation is particularly useful to establish or reestablish tolerance such as in autoimmune disorders. The modified cells can be administered by any method known in the art including, but not limited to, intravenous, subcutaneous, intranodal,  
25 intratumoral, intrathecal, intrapleural, intraperitoneal and directly to the thymus. In some embodiments, the T-cells are not administered intraperitoneally. In some embodiments, the T-cells are administered intratumorally.

[00315] Compositions comprising CAR T-cells can be provided systemically or directly to a subject for the treatment of a neoplasia, pathogen infection, or infectious disease. In some  
30 embodiments, cells disclosed herein are directly injected into an organ of interest (e.g., an organ affected by a neoplasia). Alternatively, compositions comprising CAR T-cells are provided indirectly to the organ of interest, for example, by administration into the circulatory system (e.g., the tumor vasculature). Expansion and differentiation agents can be provided prior to, during or after

administration of the cells to increase production of T-cells *in vitro* or *in vivo*.

[00316] As described above in methods disclosed herein, compositions comprising additional agents may be provided prior to, concurrent with, or following administrations of the genetically modified immune cells. In some embodiments, in methods disclosed herein genetically modified immune cells for example CAR T-cells are administered prior to an additional agent as disclosed herein. In another embodiment, in methods disclosed herein genetically modified immune cells for example CAR T-cells are administered concurrent with an additional agent, as disclosed herein. In another embodiment, in methods disclosed herein genetically modified immune cells for example CAR T-cells are administered following administration of an additional agent.

[00317] In some embodiments, methods disclosed herein administer compositions comprising apoptotic cells as disclosed herein.

[00318] The CAR T-cells can be administered in any physiologically acceptable vehicle, normally intravascularly, although they may also be introduced into bone or other convenient site where the cells may find an appropriate site for regeneration and differentiation (e.g., thymus). Usually, at least  $1 \times 10^5$  cells will be administered, eventually reaching  $1 \times 10^{10}$  or more. Genetically modified immunoresponsive cells disclosed herein may comprise a purified population of cells. Those skilled in the art can readily determine the percentage of genetically modified immunoresponsive cells in a population using various well-known methods, such as fluorescence activated cell sorting (FACS). In some embodiments, ranges of purity in populations comprising genetically modified immunoresponsive cells are about 50 to about 55%, about 55 to about 60%, and about 65 to about 70%. In other embodiments, the purity is about 70 to about 75%, about 75 to about 80%, about 80 to about 85%. In further embodiments, the purity is about 85 to about 90%, about 90 to about 95%, and about 95 to about 100%. Dosages can be readily adjusted by those skilled in the art (e.g., a decrease in purity may require an increase in dosage). The cells can be introduced by injection, catheter, or the like. If desired, factors can also be included, including, but not limited to, interleukins, e.g. IL-2, IL-3, IL-6, IL-11, IL7, IL12, IL15, IL21, as well as the other interleukins, the colony stimulating factors, such as G-, M- and GM-CSF, interferons, e.g. gamma-interferon and erythropoietin.

[00319] Compositions include pharmaceutical compositions comprising genetically modified immunoresponsive cells or their progenitors and a pharmaceutically acceptable carrier. Administration can be autologous or heterologous. For example, immunoresponsive cells, or progenitors can be obtained from one subject, and administered to the same subject or a different, compatible subject. Peripheral blood derived immunoresponsive cells disclosed herein or their progeny (e.g., *in vivo*, *ex vivo* or *in vitro* derived) can be administered via localized injection,



including catheter administration, systemic injection, localized injection, intravenous injection, or parenteral administration. When administering a therapeutic composition as disclosed herein (e.g., a pharmaceutical composition containing a genetically modified immunoresponsive cell), it will generally be formulated in a unit dosage injectable form (solution, suspension, emulsion).

5 [00320] In another embodiment, disclosed herein is a method of producing a composition comprising CAR T-cells or other immune cells as disclosed herein and apoptotic cells or an apoptotic cell supernatant, the method comprising introducing into the T-cell or immune cell the nucleic acid sequence encoding the CAR that binds to an antigen of interest. In an alternative embodiment, the compositions comprising CAR T-cells or other immune cells as disclosed herein are separate from  
10 the composition comprising apoptotic cells.

[00321] In some embodiments, disclosed herein is a method of treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating a malignancy comprising the step of administering a composition comprising chimeric antigen receptor-expressing T-cells (CAR T-cells) and apoptotic cells.

15 [00322] A skilled artisan would appreciate that an anti-tumor immunity response elicited by the genetically modified immune cells, for example CAR-modified T cells, may be an active or a passive immune response. In addition, the CAR mediated immune response may be part of an adoptive immunotherapy approach in which CAR-modified T-cells induce an immune response specific to the antigen binding moiety in the CAR.

20 [00323] A skilled artisan would appreciate that immunotherapeutics may encompass the use of immune effector cells and molecules to target and destroy cancer cells. The immune effector may be, for example, an antibody specific for some marker on the surface of a tumor cell. The antibody alone may serve as an effector of therapy or it may recruit other cells to actually effect cell killing. The antibody also may be conjugated to a drug or toxin (chemotherapeutic, radionuclide, ricin A chain,  
25 cholera toxin, pertussis toxin, etc.) and serve merely as a targeting agent. Alternatively, the effector may be a lymphocyte carrying a surface molecule that interacts, either directly or indirectly, with a tumor cell target. Various effector cells include cytotoxic T cells and NK cells.

[00324] In some embodiments, the early apoptotic cells and compositions thereof, as disclosed herein may be used to treat, prevent, inhibit the growth of, or reduce the incidence of, any  
30 hematological tumor known in the art. In some embodiments, the early apoptotic cells and compositions thereof, as disclosed herein may be used to treat, prevent, inhibit the growth of, or reduce the incidence of, any diffuse cancer known in the art, for example but not limited to diffuse breast cancer, wherein a solid tumor is not formed in the breast. In some embodiments, the early

apoptotic cells and compositions thereof, as disclosed herein may be used to extend the survival time of any hematological tumor known in the art. In some embodiments, the early apoptotic cells and compositions thereof, as disclosed herein may be used to extend the survival time of any diffuse cancer known in the art, for example but not limited to diffuse breast cancer, wherein a solid tumor is not formed in the breast.

[00325] In some embodiments, the early apoptotic cells and compositions thereof, as disclosed herein may be used to increase the survival of a subject suffering from any hematological tumor known in the art. In some embodiments, the early apoptotic cells and compositions thereof, as disclosed herein may be used to increase the survival of a subject suffering from any diffuse cancer known in the art, for example but not limited to diffuse breast cancer, wherein a solid tumor is not formed in the breast.

[00326] In some embodiments, the early apoptotic cells and compositions thereof, as disclosed herein may be used to reduce the growth rate of any hematological tumor known in the art. In some embodiments, the early apoptotic cells and compositions thereof, as disclosed herein may be used to reduce the growth rate any diffuse cancer known in the art, for example but not limited to diffuse breast cancer, wherein a solid tumor is not formed in the breast.

[00327] In some embodiments, the tumor or cancer being treated comprises a metastasis of a tumor or cancer. In some embodiments, methods of use herein prevent or reduce metastasis of a tumor or cancer. In some embodiments, methods of use herein inhibit the growth or reduce the incidence of metastasis.

[00328] In some embodiments, the subject is a human subject. In some embodiments, the subject is a child. In some embodiments, the subject is an adult. In some embodiments, the subject is animal mammal.

[00329] In some embodiments, a method disclosed herein comprises administering an early apoptotic cell population comprising a mononuclear enriched cell population, as described in detail above. In some embodiments, a method disclosed herein comprises administering an early apoptotic cell population comprising a stable population cell, wherein said cell population is stable for greater than 24 hours. Stable populations of early apoptotic cells have been described in detail above. In some embodiments, a method disclosed herein comprises administering an early apoptotic cell population comprising a population of cells devoid of cell aggregates. Early apoptotic cell populations devoid of aggregates and methods of making them have been described in detail above.

[00330] In some embodiments, a method disclosed herein comprises administering an autologous early apoptotic cell population to a subject in need. In some embodiments, a method disclosed herein

comprises administering an allogeneic early apoptotic cell population to a subject in need.

[00331] In some embodiments, methods of administration of early apoptotic cell populations or compositions thereof comprise administering a single infusion of said apoptotic cell population or composition thereof. In some embodiments, a single infusion may be administered as a prophylactic to a subject predetermined to be at risk for a cancer or tumor. In some embodiments, a single infusion may be administered to a subject having a cancer or tumor on a regular basis as a part of the subject therapeutic treatment. In some embodiments, a single infusion may be administered as a prophylactic to a subject having a cancer or tumor in order to prevent, reduce the risk of, or delay the appearance of metastatic cancer.

[00332] In some embodiments, methods of administration of early apoptotic cell populations or compositions thereof comprise administering multiple infusions of said apoptotic cell population or composition thereof. In some embodiments, multiple infusions may be administered as a prophylactic to a subject predetermined to be at risk for a cancer or tumor. In some embodiments, multiple infusions may be administered to a subject having a cancer or tumor on a regular basis as a part of the subject therapeutic treatment. In some embodiments, multiple infusions may be administered as a prophylactic to a subject having a cancer or tumor in order to prevent, reduce the risk of, or delay the appearance of metastatic cancer.

[00333] In some embodiments, multiple infusions comprise at least two infusions. In some embodiments, multiple infusions comprise 2 infusions. In some embodiments, multiple infusions comprise more than 2 infusions. In some embodiments, multiple infusions comprise at least 3 infusions. In some embodiments, multiple infusions comprise 3 infusions. In some embodiments, multiple infusions comprise more than 3 infusions. In some embodiments, multiple infusions comprise at least 4 infusions. In some embodiments, multiple infusions comprise 4 infusions. In some embodiments, multiple infusions comprise more than 4 infusions. In some embodiments, multiple infusions comprise at least 5 infusions. In some embodiments, multiple infusions comprise 5 infusions. In some embodiments, multiple infusions comprise more than 5 infusions. In some embodiments, multiple infusions comprise at least six infusions. In some embodiments, multiple infusions comprise 6 infusions. In some embodiments, multiple infusions comprise more than 6 infusions. In some embodiments, multiple infusions comprise at least 7 infusions. In some embodiments, multiple infusions comprise 7 infusions. In some embodiments, multiple infusions comprise more than 7 infusions. In some embodiments, multiple infusions comprise at least 8 infusions. In some embodiments, multiple infusions comprise 8 infusions. In some embodiments, multiple infusions comprise more than 8 infusions. In some embodiments, multiple infusions

comprise at least nine infusions. In some embodiments, multiple infusions comprise 9 infusions. In some embodiments, multiple infusions comprise more than 9 infusions. In some embodiments, multiple infusions comprise at least 10 infusions. In some embodiments, multiple infusions comprise 10 infusions. In some embodiments, multiple infusions comprise more than 10 infusions.

5 [00334] In some embodiments, multiple infusions comprise smaller amounts of early apoptotic cell, wherein the total dosage of cells administered is the sum of the infusions.

[00335] In some embodiments, multiple infusions are administered over a period of hours. In some embodiments, multiple infusions are administered over a period of days. In some embodiments, multiple infusions are administered over a period of hours, wherein there is at least 12 hours between  
10 infusions. In some embodiments, multiple infusions are administered over a period of hours, wherein there is at least 24 hours between infusions. In some embodiments, multiple infusions are administered over a period of hours, wherein there is at least a day between infusions. In some embodiments, multiple infusions are administered over a period of hours, wherein there is at least two days between infusions. In some embodiments, multiple infusions are administered over a period  
15 of hours, wherein there is at least three days between infusions. In some embodiments, multiple infusions are administered over a period of hours, wherein there is at least four days between infusions. In some embodiments, multiple infusions are administered over a period of hours, wherein there is at least five days between infusions. In some embodiments, multiple infusions are administered over a period of hours, wherein there is at least six days between infusions. In some  
20 embodiments, multiple infusions are administered over a period of hours, wherein there is at least seven days between infusions. In some embodiments, multiple infusions are administered over a period of hours, wherein there is at least a week between infusions. In some embodiments, multiple infusions are administered over a period of hours, wherein there is at least two weeks between infusions.

25 [00336] In some embodiments, the amount of cells in multiple infusions is essentially equivalent one to the other. In some embodiments, the amount of cells in multiple infusions is different one to the other.

[00337] In some embodiments, the methods described herein further comprise administering an additional chemotherapeutic agent or an immune modulator to said subject.

30 [00338] In some embodiments, an additional chemotherapeutic agent or immune modulator is administered concurrent or essentially concurrent with the early apoptotic cells. In some embodiments, an additional chemotherapeutic agent or immune modulator is comprised in the same composition as the early apoptotic cells. In some embodiments, an additional chemotherapeutic agent

or immune modulator is comprised in a different composition as the early apoptotic cells.

[00339] In some embodiments, an additional chemotherapeutic agent or immune modulator is administered prior to the administration of the early apoptotic cells. In some embodiments, an additional chemotherapeutic agent or immune modulator is administered following the  
5 administration of the early apoptotic cells.

[00340] In some embodiments, the chemotherapeutic agent comprises alkylating agents, nitrogen mustards, nitrosoureas, tetrazines, aziridines, cisplatins and derivatives, non-classical alkylating agents, mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide, busulfan, N-Nitroso-N-methylurea (MNU), carmustine (BCNU), lomustine (CCNU), semustine (MeCCNU),  
10 fotemustine, streptozotocin, dacarbazine, mitozolomide, temozolomide, thiotepa, mitomycin, diaziquone (AZQ), cisplatin, carboplatin, oxaliplatin, procarbazine, hexamethylmelamine, antimetabolites, anti-folates, methotrexate, pemetrexed, fluoropyrimidines, fluorouracil, capecitabine, deoxynucleoside analogues, cytarabine, gemcitabine, decitabine, azacitidine, fludarabine, nelarabine, cladribine, clofarabine, and pentostatin, thiopurines, thioguanine,  
15 mercaptopurine, anti-microtubule agents, vinca alkaloids, taxanes, vincristine, vinblastine, semi-synthetic vinca alkaloids, vinorelbine, vindesine, vinflunine, paclitaxel, docetaxel, podophyllotoxin, etoposide, teniposide, topoisomerase inhibitors, irinotecan, topotecan, camptothecin, etoposide, doxorubicin, mitoxantrone, teniposide, catalytic inhibitors, novobiocin, merbarone, aclarubicin, cytotoxic antibiotics, anthracyclines, bleomycins, mitomycin C, mitoxantrone, actinomycin,  
20 doxorubicin, daunorubicin, epirubicin, idarubicin, anthracyclines, pirarubicin, aclarubicin, mitoxantrone, bleomycin, mitomycin, targeted therapies, monoclonal antibodies, naked monoclonal antibodies, conjugated monoclonal antibodies, chemolabeled antibodies, bispecific monoclonal antibodies, or any combination thereof.

[00341] In some embodiments, an immune modulator comprises an antibody or a functional  
25 fragment thereof. In some embodiments, an antibody or functional fragment thereof comprises a monoclonal antibody, a single chain antibody, an Fab fragment, an F(ab')<sub>2</sub> fragment, or an Fv fragment.

[00342] In some embodiments, disclosed herein are active fragments of any one of the polypeptides or peptide domains disclosed herein. A skilled artisan would appreciate that the term "a fragment"  
30 may encompass at least 5, 10, 13, or 15 amino acids. In other embodiments a fragment is at least 20 contiguous amino acids. Fragments disclosed herein can be generated by methods known to those skilled in the art or may result from normal protein processing (e.g., removal of amino acids from the nascent polypeptide that are not required for biological activity or removal of amino acids by

alternative mRNA splicing or alternative protein processing events).

[00343] The terms “antibody” and “immunoglobulin” are used interchangeably in the broadest sense and specifically refer to a polyclonal antibody, a monoclonal antibody, or any fragment thereof, which retains the binding activity of the antibody. In certain embodiments, methods disclosed herein  
5 comprise use of a chimeric antibody, a humanized antibody, or a human antibody.

[00344] In some embodiments, the term "antibody" refers to intact molecules as well as functional fragments thereof, such as Fab, F(ab')<sub>2</sub>, and Fv that are capable of specifically interacting with a desired target as described herein, for example, binding to phagocytic cells. In some embodiments, the antibody fragments comprise:

10 [00345] (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule, which can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain;

[00346] (2) Fab', the fragment of an antibody molecule that can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy  
15 chain; two Fab' fragments are obtained per antibody molecule;

[00347] (3) (Fab')<sub>2</sub>, the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; F(ab')<sub>2</sub> is a dimer of two Fab' fragments held together by two disulfide bonds;

[00348] (4) Fv, a genetically engineered fragment containing the variable region of the light chain  
20 and the variable region of the heavy chain expressed as two chains; and

[00349] (5) Single chain antibody ("SCA"), a genetically engineered molecule containing the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.

[00350] Methods of making these fragments are known in the art. (See for example, Harlow and  
25 Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988, incorporated herein by reference).

[00351] In some embodiments, the antibody fragments may be prepared by proteolytic hydrolysis of the antibody or by expression in *E. coli* or mammalian cells (e.g. Chinese hamster ovary cell culture or other protein expression systems) of DNA encoding the fragment.

30 [00352] Antibody fragments can, in some embodiments, be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab')<sub>2</sub>. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the

sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments. Alternatively, an enzymatic cleavage using pepsin produces two monovalent Fab' fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. Pat. Nos. 4,036,945 and 4,331,647, and references contained therein, which patents are hereby  
5 incorporated by reference in their entirety. See also Porter, R. R., Biochem. J., 73: 119-126, 1959. Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

[00353] Fv fragments comprise an association of VH and VL chains. This association may be noncovalent, as described in Inbar *et al.*, Proc. Nat'l Acad. Sci. USA 69:2659-62, 1972. Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. Preferably, the Fv fragments comprise VH and VL chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a  
15 structural gene comprising DNA sequences encoding the VH and VL domains connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as *E. coli*. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing sFvs are described, for example, by Whitlow and Filpula, Methods, 2: 97-105, 1991; Bird *et al.*, Science 242:423-426,  
20 1988; Pack *et al.*, Bio/Technology 11:1271-77, 1993; and Ladner *et al.*, U.S. Pat. No. 4,946,778, which is hereby incorporated by reference in its entirety.

[00354] Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for  
25 example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick and Fry, Methods, 2: 106-10, 1991.

[00355] In some embodiments, the antibodies or fragments as described herein may comprise "humanized forms" of antibodies. In some embodiments, the term "humanized forms of antibodies" refers to non-human (e.g. murine) antibodies, which are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab'). sub.2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in  
30 which residues form a complementary determining region (CDR) of the recipient are replaced by

residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones *et al.*, Nature, 321:522-525 (1986); Riechmann *et al.*, Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].

[00356] Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones *et al.*, Nature, 321:522-525 (1986); Riechmann *et al.*, Nature 332:323-327 (1988); Verhoeven *et al.*, Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

[00357] Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks *et al.*, Mol. Biol., 222:581 (1991)]. The techniques of Cole *et al.* and Boerner *et al.* are also available for the preparation of human monoclonal antibodies (Cole *et al.*, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner *et al.*, J. Immunol., 147(1):86-95 (1991)]. Similarly, human can be made by introducing of human immunoglobulin loci into transgenic animals, e.g. mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425;



5,661,016, and in the following scientific publications: Marks *et al.*, Bio/Technology 10, 779-783 (1992); Lonberg *et al.*, Nature 368 856-859 (1994); Morrison, Nature 368 812-13 (1994); Fishwild *et al.*, Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14, 826 (1996); Lonberg and Huszar, Intern. Rev. Immunol. 13 65-93 (1995).

5 [00358] In some embodiments, the immune modulator comprises an anti-CD20 monoclonal antibody. In some embodiments, the antiCD20 monoclonal antibody is Rituximab. Rituximab is commercially available and sold under the name Rituxan<sup>®</sup>, marketed jointly by Biogen and Genentech USA, Inc.

[00359] In some embodiments, methods disclosed herein comprise a first-line therapy.

10 [00360] A skilled artisan would appreciate that the term “first-line therapy” may encompass the first treatment given for a disease. It is often part of a standard set of treatments, such as surgery followed by chemotherapy and radiation. When used by itself, first-line therapy is the one accepted as the best treatment. If it doesn’t cure the disease or it causes severe side effects, other treatment may be added or used instead. Also called induction therapy, primary therapy, and primary treatment.

15 [00361] In some embodiments, methods disclosed herein comprise an adjuvant therapy.

[00362] A skilled artisan would appreciate that the term “adjuvant therapy” may encompass a treatment that is given in addition to the primary or initial treatment. In some embodiments, adjuvant therapy may comprise an additional cancer treatment given prior to the primary treatment in preparation of a further treatment. In some embodiments, adjuvant therapy may comprise an  
20 additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, targeted therapy, or biological therapy.

[00363] In some embodiments, a method disclosed herein, reduces the minimal residual disease, increases remission, increases remission duration, reduces tumor relapse rate, decreases the size of  
25 said tumor, decreases growth rate of said tumor or said cancer, prevents metastasis of said tumor or said cancer, or reduces the rate of metastasis of said tumor or said cancer, or any combination thereof.

[00364] A skilled artisan would appreciate that the term “minimal residual disease” may encompass small numbers of cancer cells that remain in the patient during treatment or after treatment when the patient has no symptoms or signs of disease.

30 [00365] Additionally, the term “remission” may encompass a decrease or disappearance of signs and symptoms of cancer, though cancer may still be in the body. In some embodiments, remission may comprise partial remission, wherein some, but not all, signs and symptoms of cancer have disappeared. In some embodiments, remission comprises complete remission, wherein all signs and

symptoms of cancer have disappeared, although cancer still may be in the body. In some embodiments, methods disclosed herein may comprise a remission induction therapy, wherein the initial treatment with early apoptotic cells or compositions thereof, decreases the signs or symptoms of cancer or make them disappear.

5 [00366] A skilled artisan would appreciate that the term “relapse” may encompass the return of a disease or the signs and symptoms of a disease after a period of improvement. In some embodiments, methods used herein lead to a relapse-free survival, wherein the relapse-free survival encompasses the length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer.

10 [00367] A skilled artisan would appreciate that the term “metastasis” encompasses the spread of cancer cells from the place where they first formed to another part of the body. In metastasis, cancer cells break away from the original (primary) tumor, travel through the blood or lymph system, and form a new tumor in other organs or tissues of the body. In some embodiments, the new, metastatic tumor is the same type of cancer as the primary tumor. For example, if breast cancer spreads to the  
15 lung, the cancer cells in the lung are breast cancer cells, not lung cancer cells.

[00368] ***Malignancies***

[00369] In some embodiments, CAR T-cells are utilized in methods of treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating a cancer or a tumor wherein the methods comprise the step of administering chimeric antigen receptor-expressing T-cells (CAR T-cells). As disclosed herein, these methods may further comprise administering an additional agent in  
20 an effort to inhibit or decrease the incidence of CRS or cytokine storm.

[00370] In some embodiments, a method disclosed herein increases the survival of the subject. In some embodiments, disclosed herein is a method of increasing or lengthening the survival of a subject having a diffuse cancer, comprising the step of administering an early apoptotic cell population to  
25 said subject, wherein the method increases the survival of the subject.

[00371] In some embodiments, a cancer is a B-cell malignancy. In some embodiments, the B-cell malignancy is leukemia. In another embodiment, the B-cell malignancy is acute lymphoblastic leukemia (ALL). In another embodiment, the B-cell malignancy is chronic lymphocytic leukemia.

[00372] In some embodiments, the cancer is leukemia. In some embodiments, the cancer is  
30 lymphoma. In some embodiments, the lymphoma is large B-cell lymphoma.

[00373] In some embodiments, the cancer comprises a solid tumor. In some embodiments, the solid tumor comprises an abdominal tumor.

[00374] In some embodiments, methods described herein reduce the size or reduce the growth rate

of a cancer or a tumor, and comprise administering an early apoptotic cell population to said subject, wherein the method reduces the size or the growth rate of a cancer or tumor. In some embodiments, disclosed herein is a method of reducing the growth rate of a diffuse cancer, comprising the step of administering an early apoptotic cell population to said subject, wherein the method reduces the growth rate of the cancer. In some embodiments, disclosed herein is a method of reducing the size or reducing the growth rate of a solid cancer or tumor, comprising the step of administering an early apoptotic cell population to a subject, wherein the method reduces the size or reduces the growth rate of the solid cancer or tumor.

[00375] In some embodiments, a cancer may comprise a solid tumor. In some embodiments, a solid tumor comprises an abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancer), or malignant (cancer). Different types of solid tumors are named for the type of cells that form them. Examples of solid tumors are sarcomas, carcinomas, and lymphomas. Leukemias (cancers of the blood) generally do not form solid tumors. In some embodiments, a solid tumor comprises a sarcoma or a carcinoma.

[00376] In some embodiments, solid tumors are neoplasms (new growth of cells) or lesions (damage of anatomic structures or disturbance of physiological functions) formed by an abnormal growth of body tissue cells other than blood, bone marrow or lymphatic cells. In some embodiments, a solid tumor consists of an abnormal mass of cells which may stem from different tissue types such as liver, colon, breast, or lung, and which initially grows in the organ of its cellular origin. However, such cancers may spread to other organs through metastatic tumor growth in advanced stages of the disease.

[00377] In some embodiments, examples of solid tumors comprise sarcomas, carcinomas, and lymphomas. In some embodiments, a solid tumor comprises a sarcoma or a carcinoma. In some embodiments, the solid tumor is an intra-peritoneal tumor.

[00378] In some embodiments, a solid tumor comprises, but is not limited to, lung cancer, breast cancer, ovarian cancer, stomach cancer, esophageal cancer, cervical cancer, head and neck cancer, bladder cancer, liver cancer, and skin cancer. In some embodiments, a solid tumor comprises a fibrosarcoma, a myxosarcoma, a liposarcoma, a chondrosarcoma, an osteogenic sarcoma, a chordoma, an angiosarcoma, an endotheliosarcoma, a lymphangiosarcoma, a lymphangioendotheliosarcoma, a synovioma, a mesothelioma, an Ewing's tumor, a leiomyosarcoma, a rhabdomyosarcoma, a colon carcinoma, a pancreatic cancer or tumor, a breast cancer or tumor, an ovarian cancer or tumor, a prostate cancer or tumor, a squamous cell carcinoma, a basal cell carcinoma, an adenocarcinoma, a sweat gland carcinoma, a sebaceous gland carcinoma, a papillary

carcinoma, a papillary adenocarcinomas, a cystadenocarcinoma, a medullary carcinoma, a bronchogenic carcinoma, a renal cell carcinoma, a hepatoma, a bile duct carcinoma, a choriocarcinoma, a seminoma, an embryonal carcinoma, a Wilm's tumor, a cervical cancer or tumor, a uterine cancer or tumor, a testicular cancer or tumor, a lung carcinoma, a small cell lung carcinoma,  
 5 a bladder carcinoma, an epithelial carcinoma, a glioma, an astrocytoma, a medulloblastoma, a craniopharyngioma, an ependymoma, a pinealoma, a hemangioblastoma, an acoustic neuroma, an oligodendroglioma, a schwannoma, a meningioma, a melanoma, a neuroblastoma, or a retinoblastoma.

[00379] In some embodiments, the solid tumor comprises an Adrenocortical Tumor (Adenoma and Carcinoma), a Carcinoma, a Colorectal Carcinoma, a Desmoid Tumor, a Desmoplastic Small Round  
 10 Cell Tumor, an Endocrine Tumor, an Ewing Sarcoma, a Germ Cell Tumor, a Hepatoblastoma a Hepatocellular Carcinoma, a Melanoma, a Neuroblastoma, an Osteosarcoma, a Retinoblastoma, a Rhabdomyosarcoma, a Soft Tissue Sarcoma Other Than Rhabdomyosarcoma, and a Wilms Tumor. In some embodiments, the solid tumor is a breast tumor. In another embodiment, the solid tumor is a prostate cancer. In another embodiment, the solid tumor is a colon cancer. In some embodiments, the  
 15 tumor is a brain tumor. In another embodiment, the tumor is a pancreatic tumor. In another embodiment, the tumor is a colorectal tumor.

[00380] In some embodiments, early apoptotic cells or compositions thereof as disclosed herein, have therapeutic and/or prophylactic efficacy against a cancer or a tumor, for example sarcomas and carcinomas (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma,  
 20 chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic  
 25 carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, uterine cancer, testicular cancer, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, schwannoma, meningioma, melanoma, neuroblastoma, and  
 30 retinoblastoma).

[00381] In some embodiments, the early apoptotic cells and compositions thereof as disclosed herein may be used to treat, prevent, inhibit the growth of, or reduce the incidence of, any solid tumor known in the art.

[00382] In some embodiments, the early apoptotic cells and compositions thereof as disclosed herein, may be used to increase the survival of a subject suffering from any solid tumor as disclosed herein or known in the art.

[00383] In some embodiments, the early apoptotic cells and compositions thereof as disclosed  
5 herein, may be used to reduce the size or reduce the growth rate any solid tumor as disclosed herein or known in the art.

[00384] In some embodiments, a cancer may be a diffuse cancer, wherein the cancer is widely spread; not localized or confined. In some embodiments, a diffuse cancer may comprise a non-solid tumor. Examples of diffuse cancers include leukemias. Leukemias comprise a cancer that starts in  
10 blood-forming tissue, such as the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the bloodstream.

[00385] In some embodiments, a diffuse cancer comprises a B-cell malignancy. In some embodiments, the diffuse cancer comprises leukemia. In some embodiments, the cancer is lymphoma. In some embodiments, the lymphoma is large B-cell lymphoma.

[00386] In some embodiments, the diffuse cancer or tumor comprises a hematological tumor. In  
15 some embodiments, hematological tumors are cancer types affecting blood, bone marrow, and lymph nodes. Hematological tumors may derive from either of the two major blood cell lineages: myeloid and lymphoid cell lines. The myeloid cell line normally produces granulocytes, erythrocytes, thrombocytes, macrophages, and masT-cells, whereas the lymphoid cell line produces B, T, NK and  
20 plasma cells. Lymphomas (e.g. Hodgkin's Lymphoma), lymphocytic leukemias, and myeloma are derived from the lymphoid line, while acute and chronic myelogenous leukemia (AML, CML), myelodysplastic syndromes and myeloproliferative diseases are myeloid in origin.

[00387] In some embodiments, a non-solid (diffuse) cancer or tumor comprises a hematopoietic malignancy, a blood cell cancer, a leukemia, a myelodysplastic syndrome, a lymphoma, a multiple  
25 myeloma (a plasma cell myeloma), an acute lymphoblastic leukemia, an acute myelogenous leukemia, a chronic myelogenous leukemia, a Hodgkin lymphoma, a non-Hodgkin lymphoma, or plasma cell leukemia.

[00388] In another embodiment, early apoptotic cells and compositions thereof, as disclosed herein have therapeutic and/or prophylactic efficacy against diffuse cancers, for example but not limited to  
30 leukemias (e.g., acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute myeloblastic leukemia, acute promyelocyte leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroleukemia, chronic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia), polycythemia vera, lymphoma (Hodgkin's disease, non-Hodgkin's

disease), Waldenstrom's macroglobulinemia, heavy chain disease.

[00389] The compositions and methods as disclosed herein may be used to treat, prevent, inhibit, ameliorate, reduce the incidence of, or alleviate any hematological tumor known in the art.

[00390] A skilled artisan would appreciate that the use of the term "comprising" throughout, may in certain embodiments be replaced by the use of the term "consisting essentially of" or "consisting of". The skilled artisan would appreciate that the term "comprising" is intended to mean that the system includes the recited elements, but not excluding others which may be optional. For example a composition comprising early apoptotic cells but not limited to this population of cells. Further, the term "consisting essentially of" may encompass a method that includes the recited elements, for example a composition consisting essentially of early apoptotic cells but exclude other elements that may have an essential significant effect on the performance of the method. Thus, such a composition may still include a pharmaceutically acceptable excipient that does not comprise an essential activity in treating cancer. Further, "consisting of" encompasses excluding more than traces of other elements. Thus, such a composition consisting of early apoptotic cells would not include more than traces of other elements as disclosed herein.

[00391] A skilled artisan would appreciate that the term "about", may encompass a deviance of between 0.0001-5% from the indicated number or range of numbers. Further, it may encompass a deviance of between 1 -10% from the indicated number or range of numbers. In addition, it may encompass a deviance of up to 25% from the indicated number or range of numbers.

[00392] A skilled artisan would appreciate that the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "an agent" or "at least an agent" may include a plurality of agents, including mixtures thereof.

[00393] Throughout this application, various embodiments disclosed herein may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

[00394] Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases "ranging/ranges between" a first

indicated number and a second indicated number and “ranging/ranges from” a first indicated number “to” a second indicated number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals there between.

5

## EXAMPLES

### *EXAMPLE 1: Apoptotic Cell Production*

[00395] **Objective:** To produce early-apoptotic cells.

[00396] **Methods:** Methods of making populations of early-apoptotic cells have been well documented in International Publication No. WO 2014/087408 and United States Application  
10 Publication No. US2015/0275175-A1, see for example, the Methods section preceding the Examples at “Early apoptotic cell population Preparation” and “Generation of apoptotic cells” (paragraphs [0223] through [0288]), and Examples 11, 12, 13, and 14, which are incorporated herein in their entirety).

[00397] The flow chart presented in **Figure 1** provides an overview of one embodiment of the steps  
15 used during the process of producing a population of early apoptotic cells, wherein anticoagulants were included in the thawing and induction of apoptosis steps. As is described in detailed in Example 14 of International Publication No. WO 2014/087408 and United States Application Publication No. US US-2015-0275175-A1, early apoptotic cell populations were prepared wherein anti-coagulants were added at the time of freezing, or at the time of incubation, or at the time of freezing and at the  
20 time of incubation. The anticoagulant used was acid-citrate dextrose, NIH Formula A (ACD formula A) was supplemented with 10 U/ml heparin to a final concentration of 5% ACD of the total volume and 0.5 U/ml heparin.

[00398] Briefly: The cells were collected and then frozen with addition of 5% anticoagulant citrate dextrose formula A and 10U/ml heparin (ACDhep) to the freezing media. Thawing, incubation in an  
25 apoptosis induction media containing 5% ACDhep, and final product preparation were performed in a closed system.

[00399] Apoptosis and viability analysis, potency assay, and cell population characterization were performed in each experiment. In order to establish consistence in production of the early apoptotic cell product, the final product (FP) of initial batches of apoptotic cells were stored at 2-8°C and  
30 examined at t0, t24h, t48h and t72h. At each point apoptosis analysis, short potency assay (Applicants CD14+ frozen cells), trypan blue measurement and cell population characterization were performed. The FP was tested for cell count to assess average cell loss during storage and apoptosis and viability analysis.

[00400] The methods sections cited above and Example 11 of International Publication No. WO 2014/087408 and United States Application Publication No. US US-2015-0275175-A1 provide details of preparing other embodiment of apoptotic cell populations in the absence of anti-coagulants, and are incorporated herein in full.

5 [00401] *Methods of preparing irradiated apoptotic cells*: Similar methods were used to prepare an inactivated apoptotic cell population, wherein a mononuclear early apoptotic cell population comprises a decreased percent of non-quiescent non-apoptotic cells, or a population of cells having a suppressed cellular activation of any living non-apoptotic cells, or a population of cells having a reduced proliferation of any living non-apoptotic cells, or any combination thereof.

10 [00402] Briefly, an enriched mononuclear cell fraction was collected via leukapheresis procedure from healthy, eligible donors. Following apheresis completion, cells were washed and resuspended with freezing media comprising 5% Anticoagulant Citrate Dextrose Solution-Formula A (ACD-A) and 0.5U\ml heparin. Cell were then gradually frozen and transferred to liquid nitrogen for long term storage.

15 [00403] For preparation of irradiated ApoCells, cryopreserved cells were thawed, washed and resuspended with apoptosis induction media comprising 5% ACD-A, 0.5U\ml heparin sodium and 50µg/ml methylprednisolone. Cells were then incubated for 6 hours at 37°C in 5% CO<sub>2</sub>. At the end of incubation, cells were collected, washed and resuspended in Hartmann's solution using a cell processing system (Fresenius Kabi, Germany). Following manufacturing completion, ApoCell were  
20 irradiated at 4000 cGy using g-camera at the radiotherapy unit, Hadassah Ein Kerem. Apoptosis and viability of ApoCell determined using AnnexinV and PI (MBL, MA, USA) staining ( $\geq 40\%$  and  $\leq 15\%$ , respectively) via Flow cytometer. Results analyzed using FCS express software.

[00404] This irradiated ApoCell population is considered to include early apoptotic cells, wherein any viable cells present have suppressed cellular activity and reduced or no proliferation capabilities.

25 In certain cases, the ApoCell population has no viable non-apoptotic cells.

### **Results:**

[00405] The stability of the FP produced with inclusion of anticoagulant at freezing and incubation (apoptotic induction) and then stored at 2-8°C are shown below in Table 1.

[00406] **Table 1: Cell count\***- performed using a MICROS 60 hematology analyzer.

FP Time point	Cell concentration (x10 <sup>6</sup> cells\ml)	% of cell loss
t0	20.8	NA
t24h	20.0	-3.85



t48h	20.0	-3.85
t72h	19.7	-5.3

\* Results Representative of 6 (six) experiments.

[00407] When manufacturing the cells without including an anticoagulant in the induction medium, cells were stable for 24 hours and less stable thereafter.

[00408] Use of anticoagulants unexpectedly extended the stability of the apoptotic cell population for at least 72 hours, as shown in Table 1.

[00409] **Table 2: Trypan blue measurement**

FP Time point	trypan blue positive cells (%)
t0	3.0
t24h	5.9
t48h	5.2
t72h	6.5

[00410] The results of Table 2 show viability of the FP remained high for at least 72 hours.

[00411] **Table 3: Apoptosis analysis-** (AnPI staining) performed using Flow Cytometry

FP Time point	1.5mM Ca		
	An-PI- (%)	An+PI- (%)	An+PI+ (%)
t0	44.3	50.9	4.8
t24h	39.0	55.9	5.1
t48h	34.8	60.1	5.1
t72h	33.4	60.5	6.1

[00412] The results of Table 3 show that the percent apoptotic cells versus necrotic cells was maintained over at extended time period of at least 72 hours post preparation of the cells, as was the percentage of early apoptotic cells.

[00413] Inclusion of anticoagulants both at the time of freezing and during induction of apoptosis resulted in the most consistently high yield of stable early-apoptotic cells (average yield of early apoptotic cells  $61.3 \pm 2.6\%$  versus  $48.4 \pm 5.0\%$ , wherein 100% yield is based on the number of cells at freezing). This high yield was maintained even after 24 hours storage at 2-8°C.

[00414] Next a comparison was made between the inclusion of the anticoagulant at freezing or thawing or both, wherein percent (%) recovery was measured as well as stability. Anticoagulant was included in the apoptotic incubation mix for all populations. Table 4 presents the results of these

studies.

[00415] **Table 4:** Yield and stability comparison of final products (FP) manufactured from cells collected, with ("+") or without ("-") addition of anticoagulant during freezing ("F") and thawing ("Tha")

Donor ID	# of Collected Cells ( $\times 10^9$ , 100%)	% Cell Recovery in Final Product of Collected Cells							
		FP t0				FP t24h*			
		F-/Tha-	F-/Tha+	F+/Tha+	F+/Tha-	F-/Tha-	F-/Tha+	F+/Tha+	F+/Tha-
<b>1</b>	13.3	52.1	53.4	62.5	62	52.1	48.9	62.5	62
<b>2</b>	13.6	50.5	36.7	53.5	63.5	47.6	36.7	53.1	59.7
<b>3</b>	15.0	42.7	42	53.6	58.4	42.7	41.7	53.6	57.8
<b>Avg</b>	14.0	48.4 $\pm$ 5.0	44.0 $\pm$ 8.5	56.5 $\pm$ 5.2	61.3 $\pm$ 2.6	47.5 $\pm$ 4.7	42.4 $\pm$ 6.1	56.4 $\pm$ 5.3	59.8 $\pm$ 2.1

5

[00416] Additional population analysis comparisons of early apoptotic cell populations (batches of cells) prepared with and without anti-coagulant added, show the consistency of these results.

[00417] **Table 5: Cell population analysis comparison between batches prepared with and without anticoagulant**

Test	Specification	At Thawing		ApoCell Time 0 h		ApoCell Time 24 h Storage	
		w/o ACDhep	+ACDhep	w/o ACDhep	+ACDhep	w/o ACDhep	+ACDhep
Change in Total Cell Count Percent change (min-max)	>35.0%	85.5 (79.5-92.5)	82.8 (67.7-96.4)	49.9 (46.6-52.3)	66.7 (62.5-71.2)	49.0 (46.6-50.3)	66.7 (62.5-71.2)
Changes in ApoCell Percent change Range (min-max)	90.0 $\pm$ 10.0%			100	100	98.2 (96.2-100)	100
Cell viability PI exclusion Percent viable Range (min-	> 85.0%	98.0 (97.4-98.4)	96.0 (91.9-98.1)	98.5 (97.9-99.2)	94.6 (93.5-95.5)	97.7 (96.4-98.6)	94.5 (93.4-95.1)

max)							
Identity/ Purity	CD3 (T cells): 71.9 (50.0-85.0)	75.7 (71.6-81.4)	66.5 (60.1-70.1)	73.3 (70.3-78.3)	62.8 (61.1-65.3)	71.6 (61.5-79.1)	64.2 (61.6-68.1)
Analysis of cell phenotype Average (%)	ApoCell CD3: 71.6 (50.0-85.0)						
(maximal calculated range)	CD19 (B cells): 9.3 (3.0-15.0)	7.5 (4.0-11.1)	9.8 (8.6-12.0)	9.0 (7.6-10.2)	9.9 (9.3-10.2)	9.5 (8.6-10.3)	9.7 (9.2-10.4)
	ApoCell CD19: 9.5 (4-15)						
	CD14 (monocytes): 10.1 (2.5-22.0)	9.8 (6.4-13.0)	14.0 (8.8-22.1)	11.6 (10.2-13.3)	15.4 (8.2-19.3)	9.3 (4.8-17.2)	16.1 (9.0-20.4)
	ApoCell CD14: 10.6 (2.5-22.0)						
	CD15 <sup>high</sup> (granulocytes): 0.4 (0-6.0)	0.2 (0-0.3)	0.46 (0.18-0.69)	0.2 (0.1-0.4)	0.083 (0.08-0.09)	0.1 (0.1-0.2)	0.09 (0.07-0.1)
	ApoCell CD15 <sup>high</sup> : 0.2 (0-2.0)						
	CD 56 (NK): 7.2 (1.5-22.0)	7.4 (2.4-11.0)	10.1 (6.6-14.2)	4.7 (2.7-8.0)	11.2 (7.2-14.2)	4.9 (2.2-9.2)	10.0 (6.4-13.0)
	ApoCell CD56: 5.2 (1.5-15.0)						

[00418] *Percentage of final product cells (yield) in the presence or absence of anticoagulants.*

Similar to the results presented above at Table 1, the data presented in Table 4 demonstrates that early apoptotic cells manufactured from cells frozen in the presence of anticoagulant had a beneficial effect on average yield of fresh final product (FP t0) as compared to cells frozen without anticoagulant. The beneficial effect was seen when anticoagulant was used while freezing only ( $61.3 \pm 2.6\%$  versus  $48.4 \pm 5.0\%$ ), or both freezing and thawing ( $56.5 \pm 5.2\%$  versus  $48.4 \pm 5.0\%$ ). The beneficial effect was less significant when anticoagulant was used upon thawing only ( $44.0 \pm 8.5\%$  versus  $48.4 \pm 5.0\%$ ). These were non-high triglyceride samples.

[00419] *Effect of anticoagulants on aggregation.* No cell aggregations were seen in these 3 non-

high triglyceride samples, or in 21 additional samples (data not shown). However, in 41 other non-high triglyceride samples manufactured without anticoagulants (data not shown), mild aggregates were seen in 10 (24.4%) and severe aggregates in 5 (12.2%); thus, anticoagulants avoid completely cell aggregates.

5 [00420] *Effect of anticoagulants on stability.* Fresh FPs manufactured with- or without anticoagulants were stored at 2–8°C for 24 hours to determine whether addition of ACDhep to the manufacturing procedure impairs the stability of the FP. Cells were sampled following 24 hours of storage and yield was calculated In cell count. Similar to the results shown in Table 1 for extended time periods (up to 72 hours), Table 4 shows that the beneficial effect was kept and observed when  
10 anticoagulant was used while freezing only ( $59.8 \pm 2.1\%$  versus  $47.5 \pm 4.7\%$ ), or both freezing and thawing ( $56.4 \pm 5.3\%$  versus  $47.5 \pm 4.7\%$ ). The beneficial effect was less significant when anticoagulant was added only upon thawing ( $42.4 \pm 6.1\%$  versus  $47.5 \pm 4.7\%$ ). These were all non-high triglyceride samples. These results show minimal cell loss following 24 hours of FP storage in all treatments with significant advantage to cells treated with anticoagulant during both freezing and  
15 thawing. Average loss of cells treated with anticoagulant during freezing only was  $2.3 \pm 3.2\%$  compared to  $1.9 \pm 3.3\%$  without anticoagulants, upon thawing only was  $3.0 \pm 4.7$  compared to  $1.9 \pm 3.3\%$  without anticoagulants, and  $0.2 \pm 0.4\%$  compared to  $1.9 \pm 3.3\%$  without anticoagulants when cells were both frozen and thawed with ACDhep. In summary, the beneficial effect of anticoagulants on yield was kept for at least 24 hours.

20 [00421] The characteristics of a representative cell population of the FP are shown below in Table 6.

[00422] **Table 6:** Characterization of the cell population of fresh (t0) FP manufactured from cells collected with ("+") or without ("-") addition of anticoagulant during freezing ("F") and thawing ("Tha") procedures.\*

Do nor ID	FP t0																			
	F-/Tha-					F-/Tha+					F+/Tha+					F+/Tha-				
	C	CD	CD	CD	CD	CD	CD	CD	CD	CD	C	CD	CD	CD	CD	C	CD	CD	CD	CD
	D3 + (%) )	19+ (%)	56+ (%)	14+ (%)	15+ (%)	3+ (%)	19+ (%)	56+ (%)	14+ (%)	15+ (%)	D3 + (%) )	19+ (%)	56+ (%)	14+ (%)	15+ (%)	D3 + (%) )	19+ (%)	56+ (%)	14+ (%)	15+ (%)
1-3	62.2±6.1	5.6±0.7	9.8±0.9	13.5±1.1	0±0	61±6.1	8.6±0.4	8.6±0.9	14.1±1.1	0±0	63.9±5.8	7.4±0.6	9.4±0.8	13.3±1.9	0±0	61.9±6.0	11.5±1.1	10.1±1.0	14.3±1.3	0±0

25 \*Induction of apoptosis was performed using a medium containing anticoagulant for all batches.

[00423] The results of Table 6 show the cell characteristics of the final products (FP) manufactured

with or without anticoagulant at freezing and thawing. Batches were sampled, stained for mononuclear markers, and analyzed via flow cytometry to determine the cell distribution in each sample and to examine whether the addition of anticoagulant affected the cell population. As presented in Table 5, there were no significant differences detected in cell populations manufactured with or without anticoagulants at freezing or thawing. The average T cell population (CD3+ cells) in fresh FP was  $62.3 \pm 1.2\%$  between treatments compared to  $62.9 \pm 1.1\%$  before freezing; the average B cell population (CD19+ cells) was  $8.3 \pm 2.5\%$  between treatments compared to  $3.1 \pm 0.8\%$  before freezing; the average natural killer cell population (CD56+ cells) was  $9.5 \pm 0.7\%$  between treatments compared to  $12.9 \pm 0.5\%$  before freezing; the average monocyte cell population (CD14+ cells) was  $13.8 \pm 0.5\%$  between treatments compared to  $17.5 \pm 0.3\%$  before freezing; and the average granulocyte population (CD15+ cells) was  $0.0\%$  in the fresh FP compared to  $0.35 \pm 0.2\%$  at freezing.

[00424] The potency of the early apoptotic population was also examined.

[00425] **Table 7:** Potency analysis of fresh (t0) FP manufactured from cells with ("+") or without ("-") addition of anticoagulant during freezing ("F") and thawing ("Tha") procedures.

Donor ID # Treatment	FP t0							
	F-/Tha-		F-/Tha+		F+/Tha+		F+/Tha-	
Median fluorescence	DR	CD86	DR	CD86	DR	CD86	DR	CD86
DCs 1:2 Early apoptotic cell population +LPS	3%	28%	4% <i>up from LPS</i>	24%	5%	24%	9%	15%
DCs 1:4 Early apoptotic cell population +LPS	4%	38%	6%	35%	6%	34%	6%	24%
DCs 1:8 Early apoptotic cell population +LPS	13%	Not done	10%	45%	15%	54%	8%	48%

[00426] The results presented in Table 7 are from a potency assay performed to determine the ability of each final product to enhance a tolerogenic state in immature dendritic cells (iDCs) following stimulation with (LPS). The tolerogenic effect was determined by assessing downregulation of co-stimulatory molecule HLA-DR and CD86 expression on iDCs following  
5 interaction with the early apoptotic cell populations and different treatments leading to LPS upregulation. The analysis was performed on DCsign+ cells. Results represent the percent delay in maturation following interaction with early apoptotic cell population and following addition of LPS versus LPS-induced maturation. The experiment tested the potency of fresh FP (t0) manufactured with- or without anticoagulant. Results presented in Table 7 show that apoptotic cells manufactured  
10 with or without anticoagulant enhance the tolerance effect of both co-stimulatory markers in a dose-dependent manner.

[00427] The early apoptotic cells produced herein were from non-high triglyceride samples. This consistent high yield of stable early apoptotic cells was produced even in the cases when the donor plasma is high in triglycerides (*See for example*, Examples 12 and 13 of International Publication No.  
15 WO 2014/087408 and United States Application Publication No. US US-2015-0275175-A1). Note that anti-coagulants were not added to the PBS media used for formulation of the final early apoptotic cell dose for infusion.

[00428] **Summary**

[00429] The objective of this study was to produce a stable, high yield early apoptotic cell  
20 population. The rationale for use of anticoagulants was that aggregates were seen first in patients with high-triglycerides, but later in a significant portion of other patients. A concern here was the disclosure in United States Patent No. US 6,489,311 that the use of anticoagulants prevented cell apoptosis.

[00430] In short, with minimal impact on the composition, viability, stability, and the apoptotic  
25 nature of the cells, there was a significant improvement of at least 10-20% in the number of collected cells in the final product (Yield) when anticoagulant was added. In this study an up to 13% increase in yield was shown, which represents 26.8% augmentation in yield in controlled conditions but in real GMP conditions it went up to 33% and more augmentations in cell number then can be produced in a single collection. This effect is crucial, since it may avoid the need for a second apheresis from  
30 a donor.

[00431] This effect was surprising because the anticipated impact was expected to be dissolution of mild aggregates. It had been hypothesized that thawing cells with anticoagulant reduced the amount of aggregates. When formed, these aggregates eventually lead to massive cell loss. Cells collected

and frozen without anticoagulant demonstrated aggregate formation at thawing, immediately after wash. Furthermore, a high level of aggregates was also detected in cells that were frozen without anticoagulant and resuspended with media containing anticoagulant. No aggregates were seen in cells that were both frozen and resuspended with media containing anticoagulant. Taken together, it was  
5 conclude that the addition of anticoagulants during freezing and apoptosis induction is of high importance, and did not appear to negatively impact the induction of early apoptosis on the cell population.

[00432] Recovery of early apoptotic cells was further tested, for example, following 24 hours of storage at 2–8°C, for stability purposes, during which an average cell loss of 3–4.7% was measured,  
10 regardless of manufacturing conditions, with favorable results for cells that were both frozen and thawed with media containing anticoagulant ( $0.2 \pm 0.4\%$  cell loss following 24 hours of FP storage), suggesting that addition of anticoagulant is critical during freezing and thawing, but once finally formulated, the early apoptotic cell population is stable. Extended time point studies showed this stability to at least 72 hours.

[00433] Apoptosis and viability, as well as cell composition of the FP product were not significantly affected by the addition of anticoagulant at the freezing and/or thawing stage. Values measured from a wide variety of characteristics were similar, indicating the ACDhep did not change the early apoptotic cell characteristics and the final product met the acceptance criteria of  $\geq 40\%$  apoptotic cells.

[00434] The assay used to test apoptotic cells potency was based on immature dendritic cells (iDCs), DCs that are characterized by functions such as phagocytosis, antigen presentation, and cytokine production.

[00435] The HLA-DR (MHC class II) membrane molecule and co-stimulatory molecule CD86 were selected as markers to detect the tolerogenic effects of antigen-presenting cells (APCs). Using  
25 flow cytometry, changes in expression of HLA-DR and CD86 on iDCs were measured following stimulation with LPS, as well as in the presence of the early apoptotic cell population manufactured with- or without anticoagulant and stimulated with LPS. Early apoptotic cell populations were offered to DCs in ascending ratios of 1:2, 1:4, and 1:8 iDCs : early apoptotic cell population. As presented in Table 6, it was shown that early apoptotic cell population enhanced the tolerogenic effect over  
30 stimulated DCs in a dose-dependent manner, with slightly better results for early apoptotic cell population manufactured with anticoagulant both at freezing and apoptosis induction.

[00436] Taken together, it was concluded that addition of anticoagulant to both freezing and apoptosis media is of high importance to increase cell recovery and avoid massive cell loss due to

aggregates, and to avoid in many cases a second round of apheresis from a donor. It was shown that all cells met acceptance criteria for the validated FP, indicating that the addition of anticoagulant does not impair the FP.

5                    **EXAMPLE 2: Effect of Apoptotic Cells Treatment on a non-Solid Tumor Model**

[00437] **Objective:** To test the effect of apoptotic cells on a non-solid tumor model where the cancer is widely spread and not localized or confined, in order to determine apoptotic cells efficacy on the survival in cancer.

[00438] **Methods:**

10 [00439] *Raji cells*

[00440] Raji cells were purchased from ECACC (Cat. #: 85011429), and routinely cultured in complete medium (RPMI-1640 supplemented with 10% H.I. FBS, 1% Glutamax, 1% Penicillin / Streptomycin), and maintained at a concentration of  $3 \times 10^5 - 3 \times 10^6$  cells/ml.

[00441] *Apoptotic cells* were prepared as described in Example 1. Early apoptotic cells produced  
15 were at least 50% annexin V-positive and less than 5% PI-positive cells.

[00442] *Non-solid (diffuse) tumor model*

[00443] SCID mice received a single IV injection of  $10^5$  Raji cells on day 1 of the experiment. A control group of SCID mice received a single IV injection of saline solution. (3 cohorts were tested; leukemia was induced in 2 cohorts using Raji cells, and 1 cohort was maintained as a control.)

20 [00444] *Solid tumor model*

[00445] SCID mice will receive a single IP injection of  $10^5$  Raji cells on day 1 of the experiment, wherein control groups will receive a single IP injection of saline solution.

[00446] *Apoptotic cell treatment*

[00447] In a preliminary study, mice received an infusion of early apoptotic cells 6 days after the  
25 infusion of Raji cells. In later studies, the mice from one of the leukemic cohorts above received 3 infusions of early apoptotic cells ( $30 \times 10^6$  cells) starting 6 days after the infusion of Raji cells.

[00448] **Results**

[00449] SCID mice have no T-cells and therefore no ability to recover from leukemia without therapy.

30 [00450] Surprising, in the preliminary study and as shown in **Figure 2**, the apoptotic cell infusion (APO) 6 days after the infusion of Raji, significantly prolonged tumor free death in SCID injected with CD19+ Raji, compared with mice that did not receive an apoptotic cell infusion (NO APO).



[00451] In the leukemic (NO APO) cohort, 70% of mice receiving Raji cells survived through their lifespan, compared to 94% of mice receiving both Raji cells and apoptotic cells (n=51 animals in total, p<0.001). As expected, 100% of control mice survived through their expected lifespan (**Figure 3A**). In the leukemic cohort, 9% of mice receiving Raji cells and no apoptotic cells survived through up to 12% above the expected lifespan, compared to 47% of mice receiving both Raji cells and apoptotic cells (**Figure 3B**). No mice receiving Raji cells and no apoptotic cells survived through greater than 30% of the expected lifespan, compared to 41% of mice receiving both Raji cells and apoptotic cells (**Figure 3C**). No mice receiving Raji cells and no apoptotic cells attained complete remission, compared to 10% of mice receiving both Raji cells and apoptotic cells (**Figure 3D**).

[00452] *Conclusion:*

[00453] Administration of an apoptotic cell infusion maintained and increased the lifespan of leukemic mice, wherein in certain instances mice administered early apoptotic cells attained complete remission (**Figures 2 and 3A-3D**).

### **EXAMPLE 3: Effect of Combined Apoptotic Cell and anti-CD20 mAb Treatment on a Diffuse Tumor Model**

[00454] *Objective:* To test the effect of administering a combination of early apoptotic cells and anti-CD20 mAb on a diffuse (non-solid) tumor model, wherein the cancer is widely spread and not localized or confined, in order to determine the efficacy on survival of this combination therapy.

[00455] Raji cells, apoptotic cells, non-solid (diffuse) tumor model, solid tumor model, and apoptotic cell treatment were as described in Example 2 above.

[00456] *anti-CD20 mAb*

[00457] Commercially available anti-CD20 mAb was acquired from Roche.

[00458] *anti-CD20 mAb treatment*

[00459] Mice received an IV infusion of 5 mg of anti-CD20 mAb.

[00460] *Combined Apoptotic cell and anti-CD20 mAb treatment*

[00461] Starting at day 6 following Raji cell administration, mice received three IV infusions of  $30 \times 10^6$  apoptotic cells each. In addition, mice received an IV infusion of 5 mg of anti-CD20 mAb.

[00462] *Results*

[00463] 100% of mice receiving Raji cells, Raji cells + anti-CD20 mAb, and Raji cells + antiCD20 + apoptotic cells survived through the expected lifespan of leukemic mice, compared to 86% of mice

receiving both Raji cells and apoptotic cells (n=28 animals in total,  $p<0.0002$ ) (**Figure 4A**). No mice receiving Raji cells survived longer than 24% above the expected lifespan, compared to 29% of mice receiving both Raji cells + apoptotic cells, and 100% of mice receiving either Raji cells + anti-CD20 mAb or Raji cells + antiCD20 + apoptotic cells (**Figure 4B**). No mice receiving Raji cells survived longer than 59% above the expected lifespan, compared to 29% of mice receiving both Raji cells + apoptotic cells, 57% of mice receiving Raji cells + anti-CD20 mAb, and 100% of mice receiving Raji cells + antiCD20 + apoptotic cells (**Figure 4C**). No mice receiving Raji cells survived longer than 76% above the expected lifespan, compared to 29% of mice receiving both Raji cells + apoptotic cells, 14% of mice receiving Raji cells + anti-CD20 mAb, and 85% of mice receiving Raji cells + antiCD20 + apoptotic cells (**Figure 4D**). No mice receiving either Raji cells or Raji cells + anti-CD20 mAb survived longer than 100% above the expected lifespan of a mouse, compared to 29% of mice receiving either Raji cells + apoptotic cells or Raji cells + antiCD20 + apoptotic cells (**Figure 4E**).

[00464] *Conclusion:*

[00465] Apoptotic cell infusions increased the lifespan of leukemic mice, increased the number of mice attaining complete remission, and enhanced anti-CD20 mAb therapeutic effect (**Figures 4A-4E**).

**EXAMPLE 4: Apoptotic cells downregulate Cytokine Release Syndrome (CRS) and increases CAR-T-cell efficacy**

[00466] **Objective:** To test the effects of irradiated early apoptotic cells on cytokines and CAR T cell cytotoxicity over an extended time period. To demonstrate the *in vivo* efficacy of CD19-CAR T-cells. To demonstrate the synergistic effect of irradiated early apoptotic cells and CD19-CAR T-cells.

[00467] **Methods:** CD19-expressing HeLa cells (ProMab) were used alone or after co-incubation with human macrophages for *in vitro* and intraperitoneal experiments in mice. Raji was used *in vivo* for leukemia induction. LPS and IFN- $\gamma$  were used to trigger additional cytokine release. Second generation, CD28-bearing, CD19-specific CAR-modified cells were used (either purchased from ProMab or produced using a retronectin manufacturing protocol or a polybrene manufacturing protocol) for anti-tumor effect against CD19-bearing cells. Cytotoxicity assay was examined *in vivo* (7-AAD flow cytometry) and *in vitro* (survival curves; tumor load in bone marrow and liver, flow cytometry and immunohistochemistry). CRS occurred spontaneously or in response to LPS and IFN- $\gamma$ . Mouse IL-10, IL-1 $\beta$ , IL-2, IP-10, IL-4, IL-5, IL-6, IFN- $\alpha$ , IL-9, IL-13, IFN- $\gamma$ , IL-12p70, GM-CSF, TNF- $\alpha$ , MIP-1 $\alpha$ , MIP-1 $\beta$ , IL-17A, IL-15/IL-15R, IL-7, and 32 human cytokines were evaluated

(Luminex technology, MAPIX system; MILLIPLEX Analyst, Merck Millipore). Mouse IL-6Ra, MIG (CXCL9), and TGF- $\beta$ 1 were evaluated (Quantikine ELISA, R&D systems). IFN- $\gamma$  effect was evaluated (STAT1 phosphorylation, biological products). Human macrophages and dendritic cells were generated from monocytes. Irradiated early apoptotic cells were produced generally as presented in Example 1 above;  $\geq 40\%$  of cells were Annexin V-positive;  $\leq 15\%$  were PI-positive.

[00468] **Mice:** SCID-Bg mice (female, 7-8 wk) were injected with 2 consecutive doses of  $0.25 \times 10^6$  HeLa-CD19 cells, intra-peritoneally (i.p) on days 1 and 2 of experiment. On day 9 mice received i.p. dose of  $10 \times 10^6$  4000-rad (cGy) irradiated ApoCell (using a cell processing system) and an i.p. dose of a population of  $10 \times 10^6$  CAR-T cell cells comprising either  $0.5 \times 10^6$  CAR-T positive cells or  $2.2 \times 10^6$  CAR-T positive cells, on the following day. As control, mice received  $10 \times 10^6$  activated mononuclear cells or Mock-T cells. Mice were kept in an SPF animal facility in compliance with institutional IACUC guidelines. Mice were weighted twice a week and monitored daily for clinical signs and peritonitis. End point was defined as severe peritonitis manifested as enlarged and tense abdomen, lethargy, reduced mobility or increased respiratory effort. Survival analysis was performed according to the Kaplan-Meier method.

[00469] **Results:** Significant downregulation ( $p < 0.01$ ) of pro-inflammatory cytokines, including IL-6, IP-10, TNF- $\alpha$ , MIP-1 $\alpha$ , MIP-1 $\beta$ , was documented (Data not shown). IFN- $\gamma$  was not downregulated, but its effect on macrophages and dendritic cells was inhibited at the level of phosphorylated STAT1 (Data not shown). IFN- $\gamma$  induced expression of CXCL10 and CXCL9 in macrophages was reduced (Data not shown).

[00470] In the experiment wherein  $0.5 \times 10^6$  CAR-T positive cells were used, 2 mice per group were sacrificed on day 17 and 21. HeLa-CD19 treated mice showed peritonitis manifested as blood accumulation in the peritoneum, enlarged spleen and tumor loci (Data not shown). Mice treated with control MNCs had a little bit less blood in peritoneum and less tumor loci. Mice treated with CAR-T or with CAR-T and irradiated ApoCell had no signs of peritonitis. This observation correlated to the survival curve presented in **Figure 5A**.

[00471] In the experiment wherein  $2.2 \times 10^6$  CAR-T positive cells were used, the same pattern of effect as seen with four-fold fewer CAR T-cells was observed (**Figure 5B**). CAR-T treatment prolonged survival of mice with peritoneal HeLa-CD19 ( $p = 0.0002$ ). The effect was more significant in this experiment, probably due to the higher number of infused CAR T cells ( $2.2$  versus  $0.5 \times 10^6$  CAR-T positive cells). Even with the more significant and prolonged effect, the irradiated early apoptotic cells had a synergistic effect and prolonged survival ( $p = 0.0032$ ). E/T ratios for CAR T were comparable in the presence/absence of irradiated apoptotic cells *in vitro*. Surprisingly, CAR T

cell therapy given in the presence of irradiated apoptotic cells ameliorated survival of mice with a significant and reproducible addition of at least 12 days ( $p < 0.0032$ , **Figures 5A and 5B**) in comparison to CAR therapy alone.

[00472] **Conclusion:** CAR-T cell treatment prolonged survival of mice with peritoneal HeLa-CD19 cells. Administration of irradiated early apoptotic cells one day before CAR-T had a synergistic effect and prolonged mice survival for more than 10 days ( $p < 0.044$ , log-rank test), compared to CAR-T cell treatment alone.

[00473] The irradiated apoptotic cell infusion had a dramatic synergistic effect to CD19-specific CAR T cells in treating CD19-bearing Hela cells in SCID mice. In this example, similar results were observed to the results presented in Examples 2 and 3. By using irradiated apoptotic cells in this Example, compared with Examples 2 and 3, the possibility of a “graft versus leukemia effect” has been removed. Thus, this surprising synergistic effect appears to be mediated via irradiated apoptotic cells provided.

[00474] CRS evolves from several factors, including tumor biology, interaction with monocytes/macrophages/dendritic cells, and as a response to the CAR T cell effect and expansion. Apoptotic cells decrease pro-inflammatory cytokines originating from innate immunity, and inhibit the IFN- $\gamma$  effect on monocytes/macrophages/dendritic cells without harming IFN- $\gamma$  levels or CAR-T cytotoxicity, and with significant increase in CAR-T cell efficacy. Unexpectedly, treatment with apoptotic cells complements CAR-T cell therapy, effectively extending the anti-cancer effect of the CAR-T cell therapy.

[00475] **EXAMPLE 5: Effect of ApoCell (Early Apoptotic Cells) on Leukemia/Lymphoma**

[00476] **Objective:** The work presented here had three main goals: (1) Evaluating the effect of ApoCell in a leukemia-lymphoma mouse model in terms of disease onset, progression, and ensuing death; (2) Assessing the distribution of tumor cells in a mouse model of leukemia-lymphoma after treatment with ApoCell; and (3) Assessing a possible synergistic effect of ApoCell and Rituximab (RtX) in the treatment of leukemia-lymphoma in SCID-Bg mice. As part of the work to meet these objectives, measurement of the survival of leukemic mice following ApoCell administration was measured. As well, the distribution of tumor cells was measured after treatment with ApoCell.

[00477] **Methods:**

[00478] **Mice.** Female SCID-Bg mice, 7 weeks-old (ENVIGO, Jerusalem, Israel), were injected intravenously with  $0.1 \times 10^6$  Raji cells per mouse. Mice received 3 doses of  $30 \times 10^6$  ApoCell intravenously on days 5, 8, and 11 of the experiment. For combinational therapy, mice received one

dose (day 8) of RtX (2 or 5 mg/kg; Mabthera, Roche, Basel, Switzerland) 1.5h after ApoCell administration.

[00479] Mice were followed daily and weighed twice a week. The endpoint was defined as death, or sacrifice due to the development of either of the following symptoms: paraplegia (lower body paralysis), loss of 20% from mouse start weight, lethargy, reduced mobility, or increased respiratory effort.

[00480] Survival analysis was performed according to the Kaplan-Meier method. Mice were kept in a specific-pathogen-free (SPF) animal facility in compliance with institutional Animal Care and Use Committee (IACUC) guidelines.

[00481] *Raji cell line*. This human Burkitt's lymphoma cell line was purchased from the European Collection of Authenticated Cell Cultures (ECACC, Cat. #: 85011429), and routinely cultured in complete medium (RPMI-1640 supplemented with 10% heat inactivated FBS, 1% glutamax, 1% penicillin / streptomycin).

[00482] *ApoCell*. Essentially, as described in Example 1. Briefly, an enriched mononuclear cell fraction was collected via leukapheresis from healthy, eligible donors. Following apheresis completion, cells were washed and resuspended with freezing media composed of PlasmaLyte A pH 7.4, 5% human serum albumin, 10% dimethyl sulfoxide (DMSO), 5% anticoagulant citrate dextrose solution formula A (ACD-A) and 0.5U/ml heparin. Cells were then gradually frozen and transferred to liquid nitrogen for long-term storage.

[00483] For preparation of ApoCell, cryopreserved cells were thawed, washed and resuspended with apoptosis induction media, composed of RPMI 1640 supplemented with 2 mM L-glutamine and 10 mM hepes, 10% autologous plasma, 5% ACD-A, 0.5U/ml heparin sodium and 50µg/ml methylprednisolone. Cells were then incubated for 6 hours at 37°C in 5% CO<sub>2</sub>. At the end of incubation, cells were collected, washed and resuspended in Hartmann's solution using a cell processing system (Fresenius Kabi, Bad Homburg, Germany). ApoCell was centrifuged at 290g, for 10 min at 2-8°C, and resuspended in Hartmann's solution for injection. Apoptosis and viability of ApoCell were determined using Annexin V and propidium iodide (PI, Medical & Biological Laboratories, Nagoya, Japan) using FCS express software.

[00484] **Flow cytometry**. Mouse spleen, liver, and bone marrow were collected from sacrificed mice (following deterioration of clinical signs, as defined above) and analyzed by flow-cytometry (FACSCalibur, BD, Franklin Lakes, NJ, USA) for the presence of the Raji tumor (anti-CD20).

[00485] **Results:**

[00486] **Part A: ApoCell delays disease onset and ensuing death in leukemic mice**

[00487] **Figure 6** is a Kaplan-Meier survival plot presenting 3 individual experiments (*RPMI group*, n = 15; *Raji group*, n = 23; *Raji + ApoCell group*, n = 24). In each experiment, female SCID-Bg mice (7–8 weeks of age) were injected intravenously with  $0.1 \times 10^6$  Raji cells and a control group was injected with RPMI. Subsequently, mice were administered with three doses of  $30 \times 10^6$  ApoCell by intravenous administration (IV), on days 5, 8, and 11. Mice were followed daily and weighed twice a week. Endpoint was defined as death, or sacrifice due to the development of either of the following symptoms: paraplegia (lower body paralysis), loss of 20% from mouse start weight, lethargy, reduced mobility, or increased respiratory effort. Experimental details are given in Table 11. Significant beneficial effect by ApoCell was seen ( $p=0.002$ , Log-rank (Mantel-Cox) test).

[00488] **Table 11: Experimental details of Figure 6 plot**

Group	Number of mice	Survival details		Notes
		Mean day of sacrifice	Range (days)	
<b>RPMI</b>	15			DFS* is shown for all mice
<b>Raji</b>	23	22	21 – 25	
<b>Raji + ApoCell</b>	24	28	19 – >53	2 mice DFS* on day 53 / 60 (termination of experiment)

\* DFS = disease free survival

[00489] The data for the individual studies is presented in **Figures 7A-7C**.

[00490] As depicted above, mice treated with 3 doses of ApoCell after the administration of Raji cells had a slower disease progression, and died significantly later ( $p=0.0020$ ) than untreated mice.

[00491] Leukemic mice treated with ApoCell had a significant delay in the onset of symptoms, demonstrated a slower disease progression, and died later than the control untreated mice. Interestingly, about 10 percent of the mice administered with Raji cells and ApoCell did not develop any of the expected symptoms characteristic in this leukemia / lymphoma model, and remained healthy until termination of the experiments (day 53 or 60).

[00492] *ApoCell reduce tumor load in leukemic mice*

[00493] Upon sacrifice, following the deterioration of clinical signs as described above, organs of interest were collected for analysis, namely the liver, spleen, and bone-marrow. Cells of these target organs were analyzed by flow cytometry for the presence of human tumor cells (Raji cells are positive for CD20).

[00494] The data below (Table 12) describes the average percent cell population in target organs of the sacrificed mice from the 3 experiments described above; values of individual mice in each experiment can be found in Tables 13-18, which follow.

[00495] **Table 12: Average percent of tumor population in Spleen, Bone Marrow and Liver**  
5 (Flow cytometry)

Tissue	Treatment	# of mice	% CD20 <sup>+</sup> cells (average $\pm$ SD)
Spleen	RPMI	5	0
	Raji	10	0
	Raji + ApoCell	8	1.1 $\pm$ 3
Bone-Marrow	RPMI	5	0
	Raji	10	16.5 $\pm$ 8.8
	Raji + ApoCell	8	6.8 $\pm$ 9.2 (P=0.02, t-test)
Liver	RPMI	5	0
	Raji	10	11.2 $\pm$ 12
	Raji + ApoCell	8	4.5 $\pm$ 7.5 (P=0.06, t-test)

[00496] *In vivo experiment 011*

[00497] **FACS analysis of CD20<sup>+</sup> cells in bone marrow, spleen, and liver:**

[00498] One mouse receiving three doses of ApoCell was healthy when sacrificed on day 60.

10 [00499] Liver, spleen, and bone marrow cells were collected and analyzed by flow cytometry (FACSCalibur, BD) for the presence of human CD20-FITC (Biolegend, Cat. # 302206); mIgG1-FITC (Biolegend, Cat. # 400110).

[00500] *In vivo experiment 019*

[00501] **FACS analysis of tumor cells in bone marrow, spleen, and liver:**

15 [00502] Mouse spleen, liver, and bone marrow cells were collected from mice who were sacrificed following clinical deterioration, as defined in the methods) and analyzed by flow cytometry (FACSCalibur, BD) for the presence of **human CD20** (FITC).

[00503] The results of analysis of Spleen, Bone marrow, and Liver are presented in Tables 13-15 below.

20 [00504] **Table 13: Spleen**

Spleen			
Mouse	Treatment	Day of sacrifice	CD20 <sup>+</sup>
A1	RPMI		0

A2			0
A3			0
B2	Raji	22	0
B3		22	0
B5		22	0
B6		22	0
B2 (020)		25	0
B3 (020)		25	0
C1	Raji + ApoCell	28	0
C2		53 (healthy)	8.7
C4		22	0
C6		22	0
C7		28	0

[00505] Table 14: Bone Marrow

Bone marrow			
Mouse	Treatment	Day of sacrifice	CD20+
A1	RPMI		0
A2			0
A3			0
B2	Raji	22	18.7
B3		22	11.3
B5		22	10.5
B6		22	14.5
B2 (020)		25	21
B3 (020)		25	0
C1	Raji + ApoCell	28	1
C2		53 (healthy)	0.5
C4		22	0.6
C6		22	17.5
C7		28	1.4

[00506] Table 15: Liver

Liver			
Mouse	Treatment	Day of sacrifice	CD20+
A1	RPMI		0
A2			0



A3			0
B2	Raji	22	4.4
B3		22	6.5
B5		22	1.7
B6		22	5.4
B2 (020)		25	26.4
B3 (020)		25	5.9
C1	Raji + Apo Cell	28	9.8
C2		53 (healthy)	0.5
C4		22	3
C6		22	5
C7		28	22.7

[00507] ***In vivo experiment 023***

[00508] Expression (%) of CD20 tumor cells in the spleen, bone marrow, and liver, as determined by flow cytometry. Mouse spleen, liver, and bone marrow were collected from sacrificed mice  
 5 (following clinical deterioration, as defined in methods) and analyzed by flow cytometry (FACSCalibur, BD) for the presence of **human CD20** (FITC). The results for Spleen, bone marrow, and liver for the individual mice are presented in Tables 16-18 below.

[00509] **Table 16: Spleen**

Spleen			
Treatment	Mouse	Day of sacrifice	CD20+
Raji	B1	22	0
	B2	25	0
	B3	22	0
	B4	22	0.2
Raji + ApoCell	C1	22	0.2
	C4	22	0.3
	C5	41	0.1
	C6	47	0
Raji + RtX 2mg/kg	E1	32	0
	E2	32	0.7
	E6	32	0
Raji + RtX 2mg/kg + ApoCell	F1	40	0
	F2	43	0.1
	F4	35	0
	F5	32	0
	F6	35	0
	F7	57	0.4
Raji + RtX	G1	34	0

5mg/kg	G3	34	0.1
	G4	43	0
	G5	40	0
	G7	40	0.1
Raji + RtX 5mg/kg + ApoCell	H1	40	0.4
	H3	36	
	H4	36	
	H5	40	0
	H6	40	0
	H7	53	0

[00510] Table 17: Bone Marrow

Bone marrow			
Treatment	Mouse	Day of sacrifice	CD20+
Raji	B1	22	18
	B2	25	22.5
	B3	22	33.6
	B4	22	14.9
Raji + ApoCell	C1	22	24.3
	C4	22	1.8
	C5	41	7.8
	C6	47	0
Raji + RtX 2mg/kg	E1	32	0.8
	E2	32	3.1
	E6	32	3
Raji + RtX 2mg/kg + ApoCell	F1	40	4.1
	F2	43	0.4
	F4	35	0.2
	F5	32	0.8
	F6	35	0.2
	F7	57	0.4
Raji + RtX 5mg/kg	G1	34	2.1
	G3	34	0.5
	G4	43	4.3
	G5	40	2.2
	G7	40	2.6
Raji + RtX 5mg/kg + ApoCell	H1	40	0.9
	H3	36	0
	H4	36	0
	H5	40	1.6
	H6	40	1.3
	H7	53	1.8

[00511] **Table 18: Liver**

Liver			
Treatment	Mouse	Day of sacrifice	CD20+
Raji	B1	22	6.4
	B2	25	42.6
	B3	22	5
	B4	22	8.1
Raji + ApoCell	C1	22	2.5
	C4	22	2.2
	C5	41	0.4
	C6	47	0
Raji + RtX 2mg/kg	E1	32	2.1
	E2	32	1.2
	E6	32	0.4
Raji + RtX 2mg/kg + ApoCell	F1	40	0
	F2	43	
	F4	35	0
	F5	32	7.3
	F6	35	5
	F7	57	0
Raji + RtX 5mg/kg	G1	34	1
	G3	34	7.3
	G4	43	1.4
	G5	40	0.9
	G7	40	5.7
Raji + RtX 5mg/kg + ApoCell	H1	40	0.8
	H3	36	0.1
	H4	36	0
	H5	40	0.5
	H6	40	25.1
	H7	53	3.4

[00512] **Preliminary Conclusions:** In conclusion, tumor distribution in the mouse organs correlated the beneficial effect seen in survival plots and was significantly reduced in bone-marrow and liver in treated mice.

[00513] **Part B: Synergistic effect of ApoCell and Rituximab (RtX) in the treatment of leukemia/lymphoma**

[00514] Next, it was examined whether the ApoCell treatment was synergistic with other conventional treatments of leukemia/lymphoma by evaluating the combined effect of RtX and ApoCell on leukemic mice in two experiments.

[00515] **Objectives:** Measurement of the survival of leukemic mice following rtx and ApoCell

administration, and detect tumor cells in bone marrow, liver, and spleen in leukemic mice.

[00516] **Results:**

[00517] ***ApoCell acts synergistically with rtx in the treatment of leukemic mice***

[00518] **Methods:** The following work is a representative description of the results obtained in the combination therapy experiments (ApoCell and rtx). Briefly, female SCID-Beige mice were injected intravenously with  $0.1 \times 10^6$  Raji cells ( $n = 7$  in all groups). Mice received three doses of  $30 \times 10^6$  ApoCell intravenously on days 5, 8, and 12. On day 8, 1.5 h after ApoCell injection, the mice received a single IV dose of 2 or 5mg/kg RtX. Mice were followed daily and weighted twice a week. The endpoint was defined as death, or sacrifice due to the development of one or more of the following symptoms: paraplegia (lower body paralysis), loss of 20% from starting weight, lethargy, reduced mobility, or increased respiratory effort.

[00519] **Results:**

[00520] As shown in **Figure 8**, ApoCell had a beneficial effect corroborating the results presented in **Figure 6**. Rituxan (RtX) alone had a superior effect to ApoCell both in 2 mg and 5 mg dosage but the combination of ApoCell and Rituxan had a synergistic effect at both in 2 mg ( $p=0.104$ ) and in 5 mg dosage, although the synergistic effect seen in 5 mg did not reach statistical significance. Tumor distribution in the mouse organs correlated the beneficial effect (Table 19).

[00521] **Table 19:** Statistical analysis of the survival distributions (Log-rank (Mantel-Cox) test)

Compared groups		Statistical test (P value)
Group 1	Group 2	Log-rank (Mantel-Cox) Test
Raji	Raji + rtx (2mg/Kg)	0.0002
Raji	Raji + rtx (2mg/Kg) + ApoCell	0.0002
Raji	Raji + rtx (5mg/Kg)	0.0002
Raji	Raji + rtx (5mg/Kg) + ApoCell	0.0002
Raji + Rituxan (2mg/Kg)	Raji + Rituxan (2mg/Kg) + ApoCell	0.0104

[00522] ***End of experiment – Day 57***

[00523] One mouse (Raji + RtX 2mg/kg + ApoCell) was declared disease free upon termination of the experiment.

[00524] The synergistic effect in one 2 mg RtX dose was measured in an additional experiment. As was clearly shown in this experiment (**Figure 9**), the synergistic effect of ApoCell and RtX was again verified as significant ( $p=0.01$ ).

[00525] As shown in Table 20, the spleen was not populated by tumor cells (0.1-0.3 represents

background staining) and was used as a control. In contrast, bone marrow and liver were tumor targets. There was a reduced tumor population (Rajji-cells, as measured using CD20 marker) in bone marrow and liver following treatment by ApoCell and RtX separately, and the benefit increased when the two were given in combination;  $p=0.0034$  (\*\*) for Raji + rtx (2mg/Kg) + ApoCell, and 0.0031 (\*\*) for Raji + rtx (5mg/Kg) + ApoCell (T-test. As expected, RtX significantly reduces tumor burden in the target organs of the leukemic mice. Interestingly, treatment with ApoCell alone reduced tumor cells in those organs to levels comparable to treatment with conventional RtX therapy.

[00526] **Table 20:** Average tumor cell population in the spleen, bone-marrow, and liver (flow cytometry)

Tissue	Treatment	# of mice		Statistical test (P value)
			CD20+	T-Test
Spleen	Raji	7	0	
	Raji + ApoCell	4	<b>0.3</b> $\pm$ 0.4	
	Raji + rtx (2mg/Kg)	3	<b>0.2</b> $\pm$ 0.4	
	Raji + rtx (2mg/Kg) + ApoCell	6	<b>0.1</b> $\pm$ 0.1	
	Raji + rtx (5 mg/Kg)	7	0	
	Raji + rtx (5 mg/Kg) + ApoCell	4	<b>0.1</b> $\pm$ 0.2	
Bone Marrow	Raji	6	<b>18.3</b> $\pm$ 11	
	Raji + ApoCell	4	<b>8.5</b> $\pm$ 11	
	Raji + rtx (2mg/Kg)	3	<b>2.3</b> $\pm$ 1.3	
	Raji + rtx (2mg/Kg) + ApoCell	6	<b>1</b> $\pm$ 1.5	0.0034 (**)
	Raji + rtx (5 mg/Kg)	7	<b>1.7</b> $\pm$ 1.5	
	Raji + rtx (5 mg/Kg) + ApoCell	6	<b>0.9</b> $\pm$ 0.8	0.0031 (**)
Liver	Raji	6	<b>15.7</b> $\pm$ 15.4	
	Raji + ApoCell	4	<b>1.3</b> $\pm$ 1.3	
	Raji + rtx (2mg/Kg)	3	<b>1.2</b> $\pm$ 0.8	
	Raji + rtx (2mg/Kg) + ApoCell	5	<b>2.5</b> $\pm$ 3.5	
	Raji + rtx (5 mg/Kg)	7	<b>3</b> $\pm$ 2.5	
	Raji + rtx (5 mg/Kg) + ApoCell	7	<b>4.4</b> $\pm$ 9.2	

[00527] **Conclusion:** In summary, the survival plots (Figure 6, Figure 8, and Figure 9) clearly

demonstrate the beneficial effects of ApoCell and Rtx along as well as the synergistic effect of ApoCell and RtX in combination. Of note, when the conventional RtX treatment was combined with ApoCell, survival times increased significantly, regardless of the RtX dose, indicating a potent synergistic effect of the two therapies. A supporting clinical observation was the decrease in the of tumor cell population in the bone marrow and liver (Table 12).

[00528] Surprisingly, ApoCell preparation had a remarkably beneficial effect on disease progression and survival in a leukemic mouse model, independent of any other treatment. 10–20% of mice had prolonged survival in Kaplan-Meier analysis (**Figure 6, Figure 8, and Figure 9**), and the tumor cell burden was reduced in the liver and bone marrow. Furthermore, there was a marked synergistic effect when ApoCell and RtX were administered in combination, further delaying disease onset and progression, and improving survival.

#### ***EXAMPLE 6: Effect of Combined Apoptotic Cell and CAR-T Cell Treatment on a Solid Tumor Model***

[00529] **Objective:** To test the effect of CAR-T cell therapy on a human peritoneal solid tumor model, and evaluate any possible synergistic effect of apoptotic cell infusion on the CAR T-cell therapy anti-cancer action.

#### ***Methods***

[00530] **HeLa-CD19 cell line:** CD19-expressing HeLa cells were purchased from ProMab (ProMab, USA, cat. No. PM-Hela-CD19). In order to follow tumor growth *in vivo*, HeLa-CD19 were stably transduced with pLenti-PGK-V5-Luc-Neo (Addgene, USA, plasmid #21471) and single clones were isolated by flow cytometry cell sorter and cultured with 500 µg/ml G418 (Sigma-Aldrich, USA, cat. no. A1720-1G) as a selective agent. This cell line stably and continuously expresses the firefly *luc* gene under the PGK promoter. Genomic integration was verified by PCR and expression verified by flow cytometry and bioluminescent imaging (BLI) of the positive clones.

[00531] Cells were cultured in RPMI 1640 (Gibco, ThermoFisher Scientific, USA, cat. no. 31870-025) supplemented with 10% FBS (Gibco, ThermoFisher Scientific, South America, cat. no. 12657-029), 2 mM GlutaMAX (Gibco, ThermoFisher Scientific, USA, cat. no. 35050-038), and 100 U/ml Penicillin + 100 U/ml Streptomycin (Gibco, ThermoFisher Scientific, USA, cat. no. 15140-122), referred to as “complete medium”. HeLa-CD19 medium was further supplemented with 1 µg/ml puromycin (Sigma-Aldrich, USA, cat. no. P9620), as the selective antibiotics, during standard culturing.

[00532] For bioluminescent imaging, mice were injected i.p. with 150 mg/kg XenoLight D-

luciferin (PerkinElmer, USA, cat. no. 122799) and anesthetized with 4% isoflurane. Ten minutes after injections, bioluminescence was captured using Caliper IVIS-Kinetics (PerkinElmer, USA) and Living Image software, v4.2 (PerkinElmer, USA).

[00533] **CD19-CAR-T cells:** Fresh mononuclear cells (MNCs) fraction were isolated from the peripheral blood of healthy donors using Ficoll gradient. Cells were then gradually frozen and stored in liquid nitrogen until use. Following thawing, the cells were washed, and introduced with CD28+CD3+ beads (Miltenyi biotech) loaded per manufacturer instructions in a 1:2 bead: cell ratio, respectively. Cells were then incubated for 3 days in the presence of 300U/ml recombinant human IL-2 (rhIL-2, Peprotech). 48 hours prior to MNCs infection, 293 Lenti-X cells (Clontech-Takara, 632180) were transfected with a 3<sup>rd</sup> generation CD19-CAR plasmids (Creative Biolabs) using JetPrime reagent (Polyplus, 114-01) at 2:1 JetPrime: DNA ratio. 24 hours prior to infection, non-treated 24-well plates (SPL, BN30006) were coated with 7.5ug/cm<sup>2</sup> of Retronectin (Takara-Clontech, T100A) according to manufacturer instructions. On the day of infection, virus-containing supernatant collected from the transfected 293 Lenti-X cells was filtered using 0.45um filter (Millipore), transferred to the Retronectin-coated plates (0.75ml of viral supernatant per well), and centrifuged according to manufacturer instructions. Activated T-cells were then added to the plates (0.5x10<sup>6</sup> cells per well) and centrifuged as well at 290g. Plates were then incubated for 60 hours in a humidified incubator. Following incubation, the cells were collected, residual adherent cells were detached using trypsin. Cells were washed twice with Hank's balanced salt solution (HBSS, Biological industries) supplemented with 2.5% Hepes buffer (Lonza). Cells were re-seeded in the presence of 300U/ml rhIL-2, and diluted to a concentration of 1.0x10<sup>6</sup> every 48 hours with fresh media containing 300U/ml rhIL-2. On day 12 following infection, cells were again activated with CD28+CD3+ beads in a 1:2 bead: cell ratio, respectively. Cells were incubated for additional two days, and then injected (in RPMI) to animals on day 14 following infection, a total of 10x10<sup>6</sup> cells per animal. Mock-T cells (Mock-T) were prepared as the CAR-T cells with plasmid lacking the anti-CD19 region and injected as control. PCR and EGFR (Erbix, Merck) expression were used for transduction efficacy. An *in vitro* cytotoxicity assay was used for functional test of CAR T cells.

[00534] **Apoptotic cells:** Enriched mononuclear cell fraction was collected via leukapheresis procedure from healthy, eligible human donors and prepared by as provided herein in Example 1 and gamma irradiated apoptotic cells, as produced herein (2000-6000 rad irradiation). The irradiated apoptotic cells used in this example are considered "over the shelf" (OTS), wherein the donor and recipient would not necessarily be HLA matched. In some embodiments, for methods of use herein, donor and recipient are not HLA matched. In some embodiments, for methods of use herein, donor

and recipient are HLA matched. [Apoptosis and viability of apoptotic cells were determined using Annexin V and PI staining (MBL, MA, USA), as described herein. Lack of proliferation was shown using Carboxyfluorescein succinimidyl ester (CFSE) staining and bead stimulation.

[00535] *CFSE staining*: Cells were brought to final concentration of  $10 \times 10^6$  cells/mL with RPMI1640 and stained with 5  $\mu$ M CFSE for 10 minutes at room temperature (RT) and protected from light with gentle tilting. Following incubation end time, staining reaction stopped with complete FBS for 1 minute. Cells were then washed twice in order to remove excess CFSE dye.

[00536] *Cell seeding*: Cells were brought to concentration of  $1 \times 10^6$  cells/mL with culture media (RPMI1640 and Biotarget, supplemented with 2mM L-Glutamine, 10mM HEPES, 10% Heat inactivated FBS and 100U/mL recombinant human IL-2). Cells were then seeded in 24 wells plates, 1mL per well, either with or without CD3+CD28+ loading beads at 1:3 cell: beads ratio. Plates were incubated in an incubator (Enlivex Equipment number ENX01051) in the presence of 5% CO<sub>2</sub>.

[00537] *Sample analysis*: Every 48 hours, each preparation was sampled, counted and analyzed via flow cytometer in order to access cell number and CFSE staining. Preparations exceeded concentration of  $1.5 \times 10^6$  cells/mL were diluted to  $1 \times 10^6$  cells/mL with culture media. Preparations that did not exceed  $1.5 \times 10^6$  cells/mL were treated with culture media refreshment (0.3mL of media was discarded and fresh culture media was added). Overall 4 testing points were performed throughout 8 days.

[00538] *FACS analysis of subpopulations*: Peritoneal cells were evaluated by flow-cytometry (LSR-II, BD) for the following markers and isotype controls: mMHC-II-PE (12-5321), mCD19-FITC (11-0193), mCD11c-PE-Cy5.5 (35-0114), mF4/80-eFlour450 (48-4801), mCD11b-APC-eFlour780 (47-0112), rIgG2b-PE (12-4031), rIgG2a-FITC (11-4321), Armenian-hamster IgG-PE-Cy5.5 (35-4888), rIgG2a-eFlour450 (48-4801), rIgG2b-APC-eFlour780 (47-4031), hCD19-APC (17-0198) and mIgG1-APC (17-4714) (eBiosciences). Macrophages sub-population characterization was performed according to Ghosn et al. (PNAS 2010) February 9, 2010. 107 (6) 2568-2573 and Casado et al. (PlosOne 2011) published July 22, 2011.

[00539] Briefly, non-CD19, non CD11c peritoneal cells were divided by their CD11b and F4/80 expression to Large Peritoneal Macrophages (LPM) – F4/80<sup>High</sup>CD11b<sup>pos</sup>, Small Peritoneal Macrophages (SPM) – F4/80<sup>low</sup>CD11b<sup>pos</sup>, and Granulocytes (Gra) – F4/80<sup>low</sup>CD11b<sup>neg</sup> (Ghosn et al (2010 *ibid*). Casado et al. (2011 *ibid*) described the same macrophages sub-population slightly differently – non CD19, non CD11c, F4/80 positive cells were divided by their MHC-II and F4/80 expression to LPM – F4/80<sup>high</sup>MHC-II<sup>neg</sup>, SPM- F4/80<sup>low</sup>MHC-II<sup>pos</sup>, Gra- F4/80<sup>low</sup>MHC-II<sup>neg</sup>.

[00540] *Luminex® Cytokine analysis*: Human or mice cytokines were tested by Luminex



cytokine analysis. Custom Multiplex kits were purchased from eBioscience (Vienna, Austria) or from R&D Systems (Minneapolis, USA).

[00541] **For intra-peritoneal solid tumor model**, SCID-Bg mice were injected intra-peritoneally (i.p) with 2 consecutive doses of  $0.25 \times 10^6$  human HeLa-CD19-luciferase cells, on days 1 and 2 of the experiment. Mice also received  $10 \times 10^6$  human apoptotic cells (irradiated as described above, 2000-6000 rad irradiation) or vehicle, on day 9; and  $10 \times 10^6$  CD19-CAR-T (third generation) cells or mock T cells on day 10. Mice were weighted twice a week and monitored daily for clinical signs and peritoneal fluid accumulations. In some experiments, pre-scheduled sacrifices were performed to characterize cell and macrophage sub-population profile. The rest of the mice were kept for survival analysis. Survival endpoint was defined by a score based on severe peritoneal fluid accumulation manifested as enlarged and tense abdomen, and reduced mobility or increased respiratory effort. These clinical findings correlated to large accumulation of HeLa cells in the peritoneum. Survival analysis was performed according to the Kaplan-Meier Log rank statistical test.

### Results

[00542] In this model mice survived about  $30 \pm 5$  days (27-37) and died from the formation of a solid tumor in the peritoneal cavity followed by accumulation of bloody peritoneal fluid and clinical deterioration. Mock treatment showed no significant amelioration of the solid tumor or change of mouse survival ( $34 \pm 4$  days; range 30-38). CAR T cell therapy alone significantly ameliorated mouse survival to  $55 \pm 11$  (range 34-76,  $p < 0.05$ ). However, when mice received co-administration of apoptotic cells and CAR T cells, a further significant increase in survival was seen, with survival reaching  $70 \pm 20$  days (range 48-90,  $P < 0.05$ ) when compared to CAR T cell alone. Furthermore, 2/10 mice were disease free for 150 days (end of experiment). **Figure 12A** (representative of 5 separate experiments) shows survival curves of peritoneal solid tumor Hela-CD19 under control and treatment conditions. **Figure 12B** shows progression of tumor as visualized by an in vivo imaging system (IVIS), representative of the results used for the survival curves of **Figure 12A**. Spread of the tumor can be visualized as early as day 15 (Hela-CD19-Luc) whereas mice treated with CAR do not show any tumor spread until day 43. When mice get apoptotic cells, most mice do not show tumor spread until day 50 and tumor size (see scale for correlation) is clearly smaller as reflected in survival curve (**Figure 12A**).

[00543] As discussed, Chimeric Antigen Receptor (CAR) T cell therapy is a novel and innovative immunotherapy. CAR-T cells are genetically engineered T cells, carrying MHC independent specific antigen receptor and co-stimulatory molecule which can activate an immune response to a cancer specific antigen. This therapy showed great results in hematological malignancies but could not

5 achieve a similar efficacy in solid tumors both hematological and non-hematological. Likely reasons for this failure may be lack of antigens, poor trafficking, and hostile tumor microenvironment. Here, the effect of CAR T cell therapy on human peritoneal solid tumor model in SCID mice was demonstrated, wherein the synergistic effect of apoptotic cell infusion on the anti-cancer action of CAR T-cell therapy was significant.

[00544] While certain features disclosed herein have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those of ordinary skill in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit disclosed herein.

10 [00545] It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.

## CLAIMS

What is claimed is:

1. A method of treating, preventing, inhibiting the growth, delaying disease progression, reducing the tumor load, or reducing the incidence of a lymphoma in a subject, consisting essentially of a step of administering a composition comprising an early apoptotic mononuclear enriched cell population to said subject, wherein said method treats, prevents, delays the disease progression, reduces the tumor load, or reduces the incidence of lymphoma in said subject, or reduces the minimal residual disease, increases remission, increases remission duration, reduces tumor relapse rate, prevents metastasis of said lymphoma, or reduces the rate of metastasis of said lymphoma, or any combination thereof, compared with a subject not administered the early apoptotic cell population.
2. The method of claim 1, wherein the size or the growth rate or a combination thereof, of said lymphoma is reduced, or wherein the survival of said subject is increased or a combination thereof.
3. The method of claim 1 or 2, wherein said early apoptotic cell population comprises
  - a. a mononuclear apoptotic cell population comprising a decreased of non-quiescent non-apoptotic cells, a suppressed cellular activation of any living non-apoptotic cells, or a reduced proliferation of any living non-apoptotic cells, or any combination thereof.
4. The method of any one of claims 1-3, wherein said early apoptotic cell population comprises a pooled population of early apoptotic cells.
5. The method of any one of claims 1-4, wherein said subject is a human subject.
6. The method of any one of claims 1-5, wherein said lymphoma comprises a metastasis of a cancer or tumor.
7. The method of any one of claim 1-6, wherein said lymphoma comprises a Hodgkin lymphoma, or a non-Hodgkin lymphoma.

- 5
8. The method of any one of claims 1-7, wherein said administering comprises a single infusion of said early apoptotic cell population or wherein said administering comprises multiple infusions of said early apoptotic cell population.
- 10
9. Use of a composition consisting essentially of an early apoptotic mononuclear enriched cell population in the manufacture of a medicament for treating, preventing, inhibiting the growth, delaying disease progression, reducing the tumor load, or reducing the incidence of a lymphoma in a subject, wherein administering said medicament to said subject treats, prevents, inhibits the growth of, delays the disease progression, reduces the tumor load, or reduces the incidence of the lymphoma in said subject, or reduces the minimal residual disease, increases remission, increases remission duration, reduces tumor relapse rate, prevents metastasis of lymphoma, or reduces the rate of metastasis of said lymphoma, or any combination thereof, compared with a subject not administered with said medicament.
- 15
10. The use of claim 9, wherein the size or the growth rate or a combination thereof, of said lymphoma is reduced, or wherein the survival of said subject is increased or a combination thereof.
- 20
11. The use of claim 9 or claim 10, wherein said early apoptotic cell population comprises a mononuclear apoptotic cell population comprising a decreased of non-quiescent non-apoptotic cells, a suppressed cellular activation of any living non-apoptotic cells, or a reduced proliferation of any living non-apoptotic cells, or any combination thereof.
- 25
12. The use of any one of claims 9-11, wherein said early apoptotic cell population comprises a pooled population of early apoptotic cells.
13. The use of any one of claims 9-12, wherein said subject is a human subject.
- 30
14. The use of any one of claims 9-13, wherein said lymphoma comprises a metastasis of a cancer or tumor.
15. The use of any one of claims 9-14, wherein said lymphoma comprises a Hodgkin

lymphoma or a non-Hodgkin lymphoma.

16. The use of any one of claims 9-15, wherein said medicament comprises a single infusion of said early apoptotic cell population or wherein said medicament comprises multiple infusions of said early apoptotic cell population.




FIGURE 1

Survival Curve: SCID injected with CD19+Raji




FIGURE 2




FIGURE 3A




FIGURE 3B




FIGURE 3C




FIGURE 3D






FIGURE 4A




FIGURE 4B




FIGURE 4C




FIGURE 4D




FIGURE 4E




FIGURE 5A




FIGURE 5B




FIGURE 6




FIGURE 7A

8/14




FIGURE 7B




FIGURE 7C




FIGURE 8




FIGURE 9




FIGURE 10A




FIGURE 10B






FIGURE 11




FIGURE 12A

Testing the tumor expansion by Luciferase signal. IVIS of intraperitoneal HeLaCD19-Luc cells in SCID mice




FIGURE 12B